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Summary 
 
Cancer is a class of diseases in which a group of cells display uncontrolled growth (division beyond 
the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes 
metastasis (spread to other locations in the body via the circulatory system). In addition to tumor 
cell-intrinsic genetic and epigenetic alterations, the tumor stroma, i.e. endothelial cells, pericytes, 
fibroblasts and a diverse immune cell infiltrate, might substantially contribute to tumor progression, 
metastatic potential and resistance to therapy. 
 I therefore investigated the influence of immune cells on the growth of tumors in the 
Rip1Tag2 mouse insulinoma model of multistage carcinogenesis. I detected a strong infiltration of 
myeloid cells, i.e. macrophages and granulocytes, into insulinomas. Functional experiments in vivo 
revealed that depletion of macrophages in tumors led to reduced angiogenesis but did not affect 
tumor growth. 
 During the characterization of the immune cell contribution to tumor growth in the Rip1Tag2 
tumor model, I detected bone marrow-derived cells at unexpected sites. In particular, when I 
analyzed the spatial contribution of GFP-tagged bone marrow cells in tumors of lymphangiogenic 
Rip1Tag2;RipVEGF-C mice, I detected bone marrow-derived cells in lymphatic endothelium 
surrounding the tumors. 
 Detailed analysis of the integrated GFP+-cells revealed the expression of a complete set of 
markers that are characteristic for lymphatic endothelial cells, the cell surface proteins LYVE-1 and 
Podoplanin, as well as the homeo-box transcription factor Prox-1. Depending on the analysis 
technique applied, either confocal microscopy followed by 3D reconstitution or flow cytometry, 
between 3 and 9% of lymphatic endothelial cells in tumors are derived from the bone marrow. 
These studies were expanded to a second tumor model, the subcutaneous growth of TRAMP-C1 
prostate cancer cells in syngenic mice, which confirmed the findings made in Rip1Tag2;  
RipVEGF-C mice, and allowed to further substantiate the suggested ontogeny of the integrated, 
bone marrow-derived cells. 
 Cell sorting and genetic lineage tracing experiments indicated that the bone marrow-derived 
tumor lymphatic endothelial cells were at least partially derived from the myeloid lineage. Tumor 
mice were adoptively transferred with labeled myeloid (progenitor) cells, and subsequent 
integration of these cells into tumor lymphatic endothelium was detected. Cre/Lox technology 
resulting in myeloid-specific marker gene expression was employed to come to similar conclusions 
in a pure genetic experimental system without bone marrow cell-transfer or irradiation. 
 In a loss-of-function approach, macrophages were pharmacologically depleted in 
Rip1Tag2;RipVEGF-C mice. Peritumoral lymphatic vessel coverage was found to be reduced in 
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macrophage-depleted mice as compared to control mice. Expression level analysis of the 
lymphangiogenic factors VEGF-C and VEGF-D by tumor-infiltrating macrophages indicated that 
their contribution to lymphangiogenesis by supplying growth factors is negligible and that the 
reduced lymphangiogenesis might indeed come from the reduced availability of macrophages as 
building blocks of lymphatic endothelia. 
 The same plasticity of myeloid cells I detected in vivo was also observed in vitro, where 
bone marrow-derived macrophages start forming tube like structures and also start expressing 
lymphatic endothelial markers, when cultured under pro-inflammatory and endothelial specific 
conditions. 
 In conclusion, this data indicates a myeloid origin of cells that trans-differentiate into 
lymphatic endothelial cells in an inflammatory tumor environment. 
 
 The increasing use of non-invasive imaging technologies prompted us to evaluate an 
approach resulting in bioluminescent pancreatic insulinoma, principally an improved Rip1Tag2 
tumor model of multistage pancreatic β-cell carcinogenesis. I therefore constructed a bicistronic 
expression cassette in which SV40 early region is followed by an internal ribosomal entry site and 
a firefly luciferase coding sequence, under the transcriptional control of the Rat insulin promoter 1. 
Transgenic expression in mice resulted in β-cell carcinogenesis that could be monitored non-
invasively by in vivo bioluminescence. Numerous tumors of different malignancy stages can be 
detected in individual mice, indicating that this model recapitulates multistage carcinogenesis. In 
addition, in this mouse strain called RL-1 (RipTag-IRES-Luciferase line 1), due to the very stringent 
expression exclusively in the β-cells of Langerhans islets, we could determine micro-metastasis in 
liver via luciferase expression of metastatic cells. This mouse line will be of value to study anti-
tumoral therapeutic approaches in real-time, as well as to define roles for tumor-promoting as well 
as metastasis-related genes when crossed to other transgenic or gene-targeted mice. 
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Zusammenfassung 
 
Krebs umfasst eine Gruppe von Krankheiten, in deren Verlauf Zellen unkontrolliert wachsen, in 
angrenzende Gewebe eindringen, diese eventuell zerstören und die auch Metastasen bilden 
können (Ausbreitung der Krebszellen im Körper mittels des Kreislaufsystems). Nicht nur 
genetische und epigenetische Mutation innerhalb der Tumorzellpopulation, sondern auch das 
Tumorstroma, welches Endothelzellen, Perizyten, Fibroblasten und veschiedene Immunzellen 
umfasst, kann einen grossen Einfluss auf die Tumorentwicklung und das Metastasierungspotential 
bzw. die Therapieresistenz von Tumoren haben. 
 Daher habe ich den Einfluss von Immunzellen auf das Wachstum von Tumoren im 
Rip1Tag2 Insulinom Mausmodell für stufenweise Krebsentwicklung untersucht. Eine substantieller 
Anteil aller in der Tumormasse gefundenen Zellen sind myeloide Zellen, eine Immunzellgruppe, die 
u.a. Makrophagen und Granulozyten umfasst. Experimentelle Depletion von Makrophagen in 
Tumoren führte zu verminderter Blutgefäss-Bildung ohne jedoch einen Einfluss auf das 
Tumorwachstum zu entfalten. 
 Im Verlaufe meiner Studien über den Beitrag von Immunzellen zur Tumorentwicklung im 
Rip1Tag2 Tumor-Modell, habe ich dem Knochenmark entstammende Immunzellen an 
unerwarteter Stelle gefunden. Als ich die räumliche Verteilung von GFP-markierten Knochenmark-
Zellen in lymphangiogenen Rip1Tag2;RipVEGF-C Mäusen analysierte, habe ich markierte Zellen 
im lymphatischen Endothel gefunden, welches die Tumoren umgibt. 
 Analyse der integrierten GFP+-Zellen hat ergeben, dass die wichtigsten Marker, welche zur 
Definition von lymphatischem Endothel gebräuchlich sind, nämlich die Oberflächenmoleküle  
LYVE-1 und Podoplanin sowie der Transkriptionsfaktor Prox-1, auf den GFP+-Zellen ko-exprimiert 
sind. Je nach Analyse-Methode, entweder konfokale Mikroskopie oder Durchflusszytometrie, 
waren 3 – 9% aller Tumor-Lymphendothelzellen dem Knochenmark entstammende Zellen. Diese 
Studien habe ich daraufhin um ein andersartiges Tumormodell erweitert, das subkutane Wachstum 
von der Prostata-Karzinom-Zelllinie TRAMP-C1 in syngenen Mäusen. In diesem Modell bin ich zu 
gleichen Resultaten gekommen, insbesondere hat sich die vermutete Ontogenese der im 
Lymphendothel integrierten Knochenmark-Zellen bestätigt.  
 Zell-Sortierungs- und genetische Markierungs-Experimente deuten darauf hin, dass dem 
Knochenmark entstammende Tumor-Lymphendothelzellen zumindest teilweise von myeloiden 
Zellen abstammen. In Tumormäusen, welche adaptiv mit markierten myeloiden (Vorläufer)-Zellen 
transferiert worden waren, wurde die gleiche Art von Integration in lymphatische Gefässe entdeckt. 
Mit Hilfe der Cre/Lox Technologie konnte ein Marker-Gen spezifisch in myeloiden Zellen und deren 
Abkömmlingen exprimiert werden und so die adoptiven Transfer-Experimente in einem rein 
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genetischen Ansatz bestätigt werden, der ohne Knochenmarks-Transfer und Bestrahlung 
auskommt. 
 In einem Funktionsverlust-Experiment habe ich Makrophagen pharmakologisch in 
Rip1Tag2;RipVEGF-C Mäusen depletiert. Daraufhin bildeten sich weniger Tumor-umgebende 
Lymphgefässe. Expressionsanalysen der lymphangiogenen Faktoren VEGF-C and VEGF-D in 
Tumor-infiltrierenden Makrophagen deuten darauf hin, dass Makrophagen in diesem Modell nicht 
primär Quelle von lymphangiogenen Wachstumsfaktoren sind, sondern eher eine Funktion als 
Bausteine von lymphatischem Endothel einnehmen. 
 Die gleiche Plastizität, die in vivo festgestellt wurde, konnte auch in vitro festgestellt 
werden. Aus dem Knochenmark gewonnene Makrophagen beginnen röhrenförmige Gebilde zu 
formen und lymphatische Marker zu exprimieren, wenn man sie unter inflammatorischen und 
endothel-spezifischen Bedingungen kultiviert. 
 Wir schliessen aus diesen Daten, dass myeloide Zellen in einer inflammatorischen Tumor-
Umgebung zu Lymphendothel-Zellen trans-differenzieren können. 
 
 Der zunehmende Gebrauch von nicht-invasiven Bildgebungsverfahren veranlasste mich, 
einen Ansatz in Richtung biolumineszenter pankreatischer Insulinome zu entwickeln, also eine Art 
erweitertes Rip1Tag2 Modell der mehrstufigen β-Zell-Krebsentwicklung zu schaffen. Zu diesem 
Zweck wurde eine bicistronische Expressionskassette konstruiert, welche unter Kontrolle des Rip 
(“Rat insulin promoter”) Promoters das SV40 grosse T Antigen kodiert, gefolgt von einer internen 
Ribosomen-Eintrittsstelle und der Glühwürmchen-Luziferase kodierenden Sequenz. Transgene 
Expression in Mäusen führte zu Tumorentwicklung, die durch in vivo Biolumineszenz verfolgt 
werden kann. Da verschiedene Tumorgrade in einer Maus beobachtet werden können, ist dieses 
Mausmodell geeignet, um stufenweise Krebsentwicklung zu untersuchen. Zusätzlich detektierten 
wir in dieser Mauslinie, genannt RL-1 (RipTag-IRES-Luciferase line 1), aufgrund der 
hochspezifischen Expression der Luziferase in β-Zellen, Mikrometastasen in der Leber mittels der 
Luziferase-Aktivität der metastasierten Zellen. Diese Maus-Linie wird von Nutzen sein zur Echtzeit-
Analyse von experimentellen Krebstherapieansätzen und zur Untersuchung von Tumor-
beschleunigenden und Metastasen-relevanten Genfunktionen, wenn man die RL-1 Maus mit 
weiteren genetisch veränderten Mauslinien kreuzt. 
 
 
                                                                                                                                                                                TABLE OF CONTENTS 
 5 
SUMMARY........................................................................................................................................................ 1 
ZUSAMMENFASSUNG.................................................................................................................................... 3 
TABLE OF CONTENTS....................................................................................................................................5 
1. INTRODUCTION........................................................................................................................................... 7 
1.1. HALLMARKS OF CANCER............................................................................................................................ 7 
1.2. MOUSE MODELS OF CANCER ................................................................................................................... 11 
1.2.1. Transgenic mouse models of cancer............................................................................................ 12 
1.2.2. The Rip1Tag2 model of insulinoma.............................................................................................. 12 
1.3. VASCULOGENESIS, ANGIOGENESIS AND LYMPHANGIOGENESIS ................................................................... 13 
1.3.1. Hematopoietic vs. endothelial fate specification........................................................................... 13 
1.3.2. Lymphatic vessel development .................................................................................................... 15 
1.3.3. Tumor angiogenesis and lymphangiogenesis .............................................................................. 18 
Tumor angiogenesis and its molecular regulation ...............................................................................................18 
Tumor lymphangiogenesis and its molecular regulation ......................................................................................20 
1.4. INTERACTIONS TUMOR – IMMUNE SYSTEM: ............................................................................................... 23 
ZUMSTEG AND CHRISTOFORI: “CORRUPT POLICEMEN: INFLAMMATORY CELLS PROMOTE TUMOR ANGIOGENESIS” 
CURRENT OPINION IN ONCOLOGY 2009, 21:60–70 
1.4.1. Introduction................................................................................................................................... 23 
1.4.2. Immune cells as critical drivers of tumor angiogenesis ................................................................ 24 
1.4.2.1. Myelomonocytic cells and tumor associated macrophages (TAM) .........................................................24 
1.4.2.2. Myeloid-derived suppressor cells (MDSC)..............................................................................................27 
1.4.2.3. Neutrophils ..............................................................................................................................................28 
1.4.2.4. Mast cells ................................................................................................................................................29 
1.4.3. Myeloid-endothelial plasticity........................................................................................................ 30 
1.4.4. Perspectives for therapy............................................................................................................... 32 
1.4.5. Conclusions .................................................................................................................................. 35 
2. AIM OF THE STUDY .................................................................................................................................. 38 
3. MATERIALS AND METHODS ................................................................................................................... 39 
4. RESULTS ................................................................................................................................................... 41 
4.1. INFILTRATION OF IMMUNE CELLS INTO TUMORS OF RIP1TAG2 MICE ............................................................ 41 
4.2. MYELOID CELLS CONTRIBUTE TO TUMOR LYMPHANGIOGENESIS.................................................................. 43 
4.2.1. Abstract ........................................................................................................................................ 44 
4.2.2. Introduction................................................................................................................................... 44 
4.2.3. Results.......................................................................................................................................... 45 
BMDC integrate into tumor lymphatics.................................................................................................................45 
Integrated BMDC are of myeloid origin ................................................................................................................52 
Depletion of macrophages ...................................................................................................................................56 
                                                                                                                                                                                TABLE OF CONTENTS 
6 
Macrophages form lymphatic-like structures in vitro ............................................................................................58 
4.2.4. Discussion .................................................................................................................................... 61 
4.2.5. Materials and Methods ................................................................................................................. 63 
4.3. DEPLETION OF MACROPHAGES IN RIP1TAG2/ NCAM+/- MICE REDUCES BLOOD VESSEL DENSITY BUT NOT 
LYMPHANGIOGENESIS .................................................................................................................................... 67 
4.4. IMPROVED MOUSE MODEL OF PANCREATIC β-CELL CARCINOGENESIS ......................................................... 70 
4.4.1. Abstract ........................................................................................................................................ 71 
4.4.2. Introduction................................................................................................................................... 71 
4.4.3. Results.......................................................................................................................................... 73 
RipTag-IRES-Luciferase mice develop insulinoma..............................................................................................73 
Luciferase bioluminescence quantification of tumor growth in vivo .....................................................................80 
Insulinomas are hemorrhagic, poorly vascularized and downregulate insulin and E-Cadherin ...........................81 
RL-1 mice develop lymph node and liver but rarely lung metastases..................................................................85 
4.4.4. Discussion .................................................................................................................................... 88 
4.4.5. Materials and Methods ................................................................................................................. 93 
5. REFERENCES............................................................................................................................................ 98 
6. CURRICULUM VITAE .............................................................................................................................. 110 
7. CONFERENCES....................................................................................................................................... 111 
8. WORKSHOPS/ COURSES ...................................................................................................................... 111 
9. PUBLICATIONS ....................................................................................................................................... 112 
10. PATENTS ............................................................................................................................................... 113 
11. PRICES/ AWARDS................................................................................................................................. 113 
12. LECTURES............................................................................................................................................. 113 
13. ACKNOWLEDGEMENTS....................................................................................................................... 114 
 
                                                                                                                                                                                            INTRODUCTION 
7 
1. Introduction 
 
1.1. Hallmarks of cancer 
 
Cancer is a disease in which a group of cells display uncontrolled growth (division beyond the 
normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes 
metastasis (spread to other locations in the body via lymph or blood). These three malignant 
properties of cancers differentiate them from benign tumors, which are self-limited, do not invade 
or metastasize. In developed countries, cancer is presently responsible for about 25% of all 
deaths, and on a yearly basis, 0.5% of the population is diagnosed with cancer. As cancer rates 
increase with age and average life expectancy goes up, cancer is projected to be the major cause 
of death in the developed countries at around 2010. Many cancers are not yet curable, and a more 
detailed understanding of cancers and their resistance to treatment is warranted and might lead to 
novel therapeutic approaches. 
 Murine models of cancer have been used for more than two decades to model human 
cancer in animal experiments, the mouse being an animal amenable to genetic manipulation (see 
section “1.2. Mouse models of cancer”). Combining results from clinical observations and animal 
experiments allowed to define many clinical and genetic parameters with prognostic (overall 
outcome of a certain cancer type) or predictive (likeliness to respond to therapy) value. Predictive 
biomarkers can be targets for therapy. Examples of genes that have proven to be of relevance are 
well-known markers such as estrogen receptor (ER), progesterone receptor (PR) and HER2/neu in 
breast cancer, BCR-ABL fusion protein in chronic myeloid leukemia, c-KIT mutations in gastro-
intestinal stroma tumors (GIST) and EGFR1 mutations in non-small cell lung cancer (NSCLC).  
 In addition to tumor cell intrinsic genetic and epigenetic alterations, the tumor stroma might 
substantially contribute to tumor progression, angiogenesis, metastatic potential and resistance to 
therapy (see “1.4. Interactions tumor – immune system”). 
 Douglas Hanahan and Robert Weinberg have defined six traits – acquired capabilities – 
shared by most types of human cancer (Hanahan and Weinberg, 2000), which are shortly 
summarized in the following paragraphs.  
 
Self-sufficiency in growth signals 
 Normal cells require extrinsic mitogenic growth signals before they can move from a 
quiescent state into an active proliferative state. Such signals are conveyed to the cells by 
diffusible growth factors, cell-cell contacts and extracellular matrix components. Whereas normal 
cells have to be cultured in presence of the appropriate exogenous mitogenic factors and on a 
suitable substratum for correct ligation of integrins, tumor cells show a reduced dependence on 
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exogenous growth stimulation. In order to obtain a self-sufficient mitogenic stimulus, three 
molecular strategies are applied by cancer cells: synthesis of growth factors by the cancer cell, 
mutation/ over-expression of cell surface receptors leading to increased mitogenic stimulation, and 
alterations in components of the downstream cytoplasmic signaling circuitries that receive and 
processes the signals, elicited by the previously mentioned ligands and receptors. A central role 
among these cytoplasmic circuitries assigns to the SOS-Ras-Raf-MAP kinase pathway. Receptor 
tyrosine kinases, HER2/neu for example over-expressed in some breast cancers, principally elicit 
their mitogenic signals through this pathway. In another example, in the case of human colon 
cancer, about half of the tumors have a mutant ras oncogene. 
 
Insensitivity to antigrowth signals 
 Not only the absence of mitogenic stimuli but also anti-proliferative signals, being either 
soluble or mediated by the extra-cellular matrix, are responsible for keeping cells in a quiescent 
state and tissues in a homeostasis. Much of the circuitry that enables normal cells to respond to 
antigrowth signals is associated with proper cell cycle regulation, specifically the components 
governing the transit of the cell through the G1 phase of its growth cycle. Most anti-proliferative 
signals funnel into the retinoblastoma protein family members pRB, p107 and p130. In a hypo-
phosphorylated state, pRb blocks proliferation by sequestering E2F transcription factors that 
control the expression of genes essential for progression from G1 to S phase. pRb has been 
shown to be inactivated by a number of viral oncogenes, including the human papillomavirus E7 
protein, and simian virus 40 large T antigen. In contrast, the soluble transforming growth factor-β 
(TGF-β) has been shown to elicit a very potent anti-proliferative signal, through blocking of c-myc 
expression controlling G1 cell cycle machinery and induction of p15INK4B and p21 proteins 
responsible for blockade of pRb phosphorylation by cyclin:CDK complexes. Members of the TGF-β 
signaling machinery have been shown to be inactivated in cancers, e.g by down-regulation or 
mutation/ inactivation of the TGF-β receptors or by the inactivation of the SMAD4 gene, encoding a 
cytoplasmic mediator of TGF-β signaling. 
 
Apoptosis evasion 
 The machinery for programmed cell death – apoptosis – is present in a latent form in 
virtually all cell types in the body. The p53 tumor suppressor gene product is critical for sensing 
DNA damage and upon activation induces either cell cycle arrest or apoptosis. Consequently, 
more than 50% of human cancers harbor a functional inactivation of the p53 tumor suppressor. 
Uncontrolled cell growth, for example by forced expression of the oncogene c-myc, often induces 
apoptosis. This is due to sensory machinery detecting cellular imbalances, e.g. an improper 
chromosomal segregation. Besides the inactivation of p53, tumor cells have other strategies to 
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circumvent these pro-apoptotic stimuli.  Either anti-apoptotic proteins are up-regulated, including 
the members of the pro-apoptotic Bcl-2 family or activation of the insulin like growth factor (IGF)/ 
IGF-1R system resulting in activation of the AKT survival signaling pathway, or by disruption of the 
FAS death signaling circuit. 
 
 
Figure 1. Main players of the integrated circuit of the cell and molecular players found to be mutated/ deregulated in 
cancers discussed in the previous paragraphs. (From (Hanahan and Weinberg, 2000)) 
 
Limitless replicative potential 
 Most mammalian cells carry an intrinsic, cell-autonomous program that limits their 
multiplication, working independently of the above-mentioned cell-to-cell signaling pathways. The 
cellular counting devices, the chromosomal ends called telomeres are shortened during each 
replicative division by 50-100 nucleotides. Cultured “normal” human cells have the capacity for 60 
– 70 cell doublings, before the shortened chromosomal ends cause a karyotype disarray, resulting 
in a state called crisis, accompanied by massive apoptosis. An estimated 1 in 107 cells emerges 
during crisis and will acquire the ability to multiply without limit, called immortalization. Telomere 
maintenance is evident in most malignant cells and most of them so do so by up-regulating 
telomerase, the enzyme counteracting telomere shortening. However, from a numbers perspective, 
this doubling capacity would easily be sufficient to allow single tumor cell clones to grow to 
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macroscopic size. Clues to resolve this paradox come from animal studies and analysis of human 
tumors, in which it became evident that evolving pre-malignant and malignant cell populations have 
chronic and widespread apoptosis. Emerging tumors therefore result from a slight outbalancing of 
apoptosis by proliferation, and the numbers of cells constituting a tumor greatly under-represents 
the generations required to produce it. Hence, the generational limit of normal somatic cells arises 
as a barrier to cancer. 
 
Sustained angiogenesis 
 Gain- and loss-of-function experiments indicate that neovascularization is a prerequisite to 
the formation of macroscopic tumors. Also, compelling evidence arose that lymphangiogenesis 
promotes tumor metastasis. For further details see “1.3.3. Tumor angiogenesis and 
lymphangiogenesis”. 
 
Tissue invasion and metastasis 
 Sooner or later, most solid tumors leave the primary tumor site and seed to distant organs, 
a process called metastasis. Tissue invasion and metastasis are mechanistically closely related, 
and cellular changes observed in invading tumor cells are often mirrored by the metastasis. 
Several classes of proteins involved in the tethering of cells to their surroundings in a tissue are 
altered in cells possessing invasive or metastatic capabilities. These include cell-cell adhesion 
molecules (CAM) of the immunoglobulin superfamily and the calcium-dependant cadherins, as well 
as integrins, connecting cells with the extracellular matrix. Many tumors derived from epithelial 
tissues, called carcinomas, lose their principal cell-cell contact molecule E-Cadherin. This results in 
reduced cell-cell contact and liberation of β-catenin from the cell membrane, where it binds to the 
E-Cadherin intracellular domain. Stabilized cytoplasmatic β-catenin can, potentiated by Wnt and 
TGF-β signaling pathways, enter the nucleus and induce Tcf/Lef mediated transcription of pro-
migratory and anti-adhesive genes. Apart from expression changes of molecules conferring 
adhesive properties to the cells, increased extracellular proteolytic activity is observed during 
cancer progression. This increased proteolytic activity might facilitate the invasion of cancer cells 
into nearby stroma, across blood vessel walls and through normal epithelial cell layers. 
 
 An additional level of complexity has come from the recent discovery of micro RNAs 
(miRNA), a class of non-protein coding RNA species. miRNAs regulate gene expression on a post-
transcriptional level by modulating messenger RNA (mRNA) stability and translation efficiency 
through the formation of miRNA/ mRNA duplexes. As a single miRNA can target multiple mRNAs, 
the genetic loss of a single miRNA can have a tremendous influence on protein expression levels 
of many genes. For example, miR-34 miRNA family members have been show to be direct 
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transcriptional targets of p53. miR-34 activation can recapitulate elements of p53 activity, including 
induction of cell-cycle arrest and promotion of apoptosis, and loss of miR-34 can impair p53-
mediated cell death (He et al., 2007). 
 
1.2. Mouse models of cancer 
 
Cancer is a disease that hits humans mainly in their post-reproductive period of life. To acquire all 
cellular traits required for carcinogenesis, many decades of life are necessary, time scales that are 
obviously un-suited for laboratory studies. However, also laboratory animals are prone to 
spontaneous carcinogenesis. Inbred rat strains show a higher incidence of cancer as compared to 
mice, e.g. rats can spontaneously develop prostate adenocarcinoma and endometrial tumors. Also 
in rodents, spontaneous cancer incidence correlates with age. With the availability of transgenic 
and gene-targeting strategies in mice, becoming standard laboratory techniques, it is feasible to 
alter the function of central cellular gatekeepers involved in protection of organism from neoplasia, 
the alteration resulting in hereditary and relatively homogenous tumor formation. Combinatorial 
crossing of genetically modified mice has generated a plethora of knowledge about genes 
modifying tumor development and is nowadays the most commonly used way to study cancer 
development in basic research. 
 In addition to genetically engineered mice, chemical and physical carcinogenesis protocols 
have also been established for mice and other animals, generally also producing relatively 
homogenous tumor types. Tumor transplantation has also been widely used to study tumor growth 
in mice. In this kind of tumor studies, primary or cell line-derived tumor cells are transferred into 
mice. This can either happen in a syngenic background, i.e. the tumor cell and recipient are 
genetically matched, or in mice with a restricted immune system allowing engraftment and growth 
of cells derived from a non-matched genetic origin, e.g. when human cancer cells are injected into 
immune-compromised mice. Topologically, tumor cells can be placed in the mouse at the location 
of their origin, e.g. pancreatic adenocarcinoma cells can be injected into the murine pancreas, 
called orthotopic transplantation. On the other hand, many studies are interested in the effects on 
primary growth of the tumor cells and the cells are therefore injected at sites accessible without 
surgery: subcutaneous, intraperitoneal or intravenous. Transplantation studies are convenient to 
study the role of cancer cell intrinsic factors because genetic manipulation of cell lines is much 
faster than of mice. However, the use of already transformed cells hampers their use in the 
investigation of initiating events in cancer and transplantation models also fail to faithfully mirror 
tumor-stroma interactions developing in transgenic mouse models of cancer. 
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1.2.1. Transgenic mouse models of cancer 
 Genetic mouse tumor models short-circuit the multi-hit concept described above, as they 
directly target central genes and proteins involved in preventing cancer. Conceptually, malignant 
transformation can be mediated and catalyzed by the over-expression of a proto-oncogene or by 
the knockout of a tumor suppressor gene. The first transgenic cancer models in mice have been 
established in the 1980ies, using simian virus 40 (SV40) derived T antigen oncoproteins, myc, ras 
and fos, whose expression was driven by tissue specific or viral promoters. This over-expression 
resulted in brain, mammary, bone, pancreatic acinar cell or endocrine tumors and, in the case of 
myc over-expressed in B lymphocytes, in lymphoma (Hanahan et al., 2007). 
 Mouse models for tumorigenesis have been established for the gastrointestinal tract, 
hematopoietic system, lung, liver, mammary gland, nervous system, ovary, prostate, skin and 
pancreas (http://emice.nci.nih.gov/emice/mouse_models). A common strategy is the tissue-specific 
expression of viral oncogenes, which are very potent by their inactivation of central tumor 
suppressors. For example, using transgenic and gene-targeting approaches, several prostate 
cancer mouse models have been established. Prostate specific expression of SV40 large and 
small antigen under either probasin or C3 promoter results in prostate intraepithelial neoplasia 
(PIN) as well as in invasive adenocarcinoma (Greenberg et al., 1995; Maroulakou et al., 1994). 
Over-expression of c-myc, IGF-I, androgen receptor or fibroblast growth factor 7, all of them 
implicated in human prostate carcinogenesis, under the control of prostate specific promoters also 
gave rise to low grade PIN but generally resulted in less aggressive tumor phenotypes. A central 
role of the PI3K/ Akt pathways was confirmed by the prostate-specific knockout of PTEN, which 
resulted in metastatic, invasive adenocarcinoma  (Wang et al., 2003). 
 
1.2.2. The Rip1Tag2 model of insulinoma 
 Using the strategies described above, the Rip1Tag2 transgenic mouse model of β-cell 
carcinogenesis was established more than 20 years ago. In these mice, the early region of SV40 
encoding large T antigen (Tag) is expressed under the control of the rat insulin gene promoter 
(Rip), and thereby targeted to the insulin-producing β-cells of the endocrine pancreas (Hanahan, 
1985). Tag displays direct transforming functions and disrupts cell cycle control by sequestering 
and inactivating the tumor suppressors p53 and pRb (Sachsenmeier and Pipas, 2001). Inactivation 
of these tumor suppressors results in malignant transformation and uncontrolled proliferation of β-
cells triggering the sequential formation of insulinoma over a period of 12-14 weeks. 
 The murine pancreas contains approximately 400 islets of Langerhans, which together 
constitute the endocrine part of the organ. Islets consist of several types of hormone-producing 
cells, including α-, β-, δ- and PP-cells, with β-cells being the most abundant (80%). In Rip1Tag2 
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mice, β-cells start to express the transgene at embryonic day 8.5. Hyperplastic islets begin to 
appear at around 4 weeks of age, and although all islets express Tag, only about 50% of the islets 
become hyperplastic at 10 weeks. The onset of an angiogenic switch in a subset of hyperplastic 
islets triggers the formation of new blood vessels, resulting in the sequential emergence of 
angiogenic islets at 6 weeks and solid tumors at 9 to 10 weeks of age. At 12 to 14 weeks, 2-4% of 
all initial islets have progressed into well-encapsulated, non-invasive benign tumors (adenomas) 
and about 0.5% of islets into malignant, invasive carcinoma, the latter having the potential to 
metastasize. Importantly however, metastases are rarely found in Rip1Tag2 mice because the 
animals succumb already at 12-14 weeks of age due to hyperglycemia caused by the massive 
production of insulin by the tumors. The predictability and reproducibility of Rip1Tag2 
tumorigenesis allows the study of distinct molecular events that may influence tumor growth and 
progression as well as tumor angiogenesis, lymphangiongenesis, metastasis and tumor-stroma 
interactions. 
 
 
Figure 2. Multistep β-cell carcinogenesis in Rip1Tag2 transgenic mice. As indicated, islets (blue) sequentially progress 
into hyperplastic islets (enlarged, blue), angiogenic islets (red), benign adenoma (enlarged, red), and malignant 
carcinoma (magenta). From the time of the angiogenic switch, immune cell infiltration is prominent (black dots). 
Percentages indicate the subset of initial islets that have developed into a specific tumor grade at 12-14 weeks of age. 
The exocrine pancreatic tissue is drawn in brown, the foregut in green. E8.5, embryonic day 8.5. (Modified from 
(Christofori et al., 1995b)) 
 
1.3. Vasculogenesis, angiogenesis and lymphangiogenesis 
 
1.3.1. Hematopoietic vs. endothelial fate specification 
 Developmentally, the endothelial lineage comprising blood and lymphatic vessels, and the 
hematopoietic system are likely to be closest relatives by their ontogeny, and, in the case of the 
extra-embryonic yolk sac (YS), are derived from a common precursor called the hemangioblast 
(reviewed in (Cumano and Godin, 2007; Lugus et al., 2005)). At embryonic day (E) 7.5, primitive 
blood cells are detected in the YS surrounded by cells that evolve to resemble endothelial cells 
morphologically. Cells isolated from this anatomical region were able to give rise to erythroid and 
myeloid compartment when transplanted into Rag-2-/-;γc-/- mice (Cumano et al., 2001). However, 
only after a vascular connection between the YS and the inner embryo (embryo proper) was 
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established, cells isolated from the YS are also able to give rise to lymphoid cells upon 
transplantation. More recent data indicate that the main site of generation of definitive 
hematopoietic stem cells (HSC) is the para-aortic splanchnopleura (P-Sp)/aorta-gonad-
mesonephros (AGM) region. Indeed, cells isolated from this region are able to provide long-term 
multi-lineage reconstitution even before the establishment of embryonic circulation when 
transplanted into Rag-2-/-;γc-/- mice (Cumano et al., 2001). HSC appear in two defined locations 
around the dorsal aorta between E9 and E12, in hematopoietic intra-aortic clusters (HIAC) inserted 
inside the ventral wall of the dorsal aorta or in subaortic patches (SAP). Independent of their origin, 
either YS or P-Sp/AGM region, HSC generated in situ will then populate the fetal liver, the main 
site of embryonic hematopoiesis. 
 The notion that multi-lineage repopulating competent cells isolated from the P-Sp/AGM 
region expressed the endothelial marker CD31, VE-Cadherin, Tie2 and CD34 prompted 
investigators to propose an close ontogenic relationship between hematopoietic and endothelial 
lineage, in the YS as well as in the AGM region. However, experiments in which genetically labeled 
epiblast fragments were orthotopically grafted into normal embryos and then allowed to develop in 
vitro for a few days showed that simultaneous contribution to endothelial and hematopoietic cells 
constitutes a rare event in the YS (Kinder et al., 1999), suggesting a polyclonal origin of the 
lineages. In the embryo proper, the occurrence of vasculature precedes hematopoietic cell 
production. Whereas this renders the existence of a common, bipotent hemangioblastic precursor 
unlikely, the close association of HSC with the dorsal aorta occurring in the embryo proper 
established the concept of hemogenic endothelium (de Bruijn et al., 2002). According to this 
concept, endothelial cells are able to give rise to intra-embryonic HSC through a transient trans-
differentiation process. 
 Knockout and in vivo tracing studies using Cre/Lox technology and in vitro differentiation 
assays, using embryonic bodies, assigned an outstanding role for fetal liver kinase-1 (Flk-1/ 
VEGFR2) and the transcription factor Scl in the generation of cells with endothelial and 
hematopoietic potential from mesoderm (Figure 3). Lineage tracing experiments using Flk-
1+/Cre;Rosa26R-LacZ mice demonstrated that not only endothelial and hematopoietic but also 
cardiac and skeletal muscle as well as smooth muscle cells originate from a Flk-1 expressing 
precursor cell (Motoike et al., 2003). Knockout of Scl blocked the ability of ES cells to differentiate 
into endothelial and hematopoietic cells; rather these cells became smooth muscle cells 
(Yamashita et al., 2000). A recent report, utilizing either Flk-1+/Cre;Rosa26R-EYFP or Flk-
1+/Cre;Rosa26R-LacZ mice, demonstrated that all blood cells within the yolk sac and aorta were of 
Flk-1+ origin. Additionally, nearly all CD45+ cells in bone marrow and circulating blood in adults 
were of Flk-1+ origin, further substantiating that all blood cells, primitive and definitive, in mice are 
derived from Flk-1+ mesodermal cells (Lugus et al., 2008). 
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Figure 3. Embryonic ontogeny of endothelial and hematopoietic lineages. Flk-1 expressing mesoderm establishes the 
circulatory system. Flk-1 is expressed in mesoderm very early during development and Flk-1-/- embryos are unable to 
form blood islands and to generate hemopoietic precursors. Lineage tracing studies showed that Flk-1 is also expressed 
on progenitor cells of smooth muscle cells, skeletal muscle cells and cardiomyocytes. Whether there is a multi-potent 
common precursor (as suggested here) is unknown at present. Expression of the transcription factor Scl (also known as 
Tal1) is indispensable for the generation of endothelial and hematopoietic lineages. In the P-Sp/AGM region of the 
embryo proper, HSC are derived from hemogenic endothelium. ES: embryonic stem cell, HSC: hematopoietic stem cell, 
Blood-P: primitive blood (comprising erythroid and myeloid lineages), Blood-D: definitive blood (comprising all lineages). 
P-Sp/AGM: para-aortic splanchnopleura/aorta-gonad-mesonephros. (Modified from (Lugus et al., 2005)) 
 
1.3.2. Lymphatic vessel development 
 The cardiovascular system is the first organ that develops during embryogenesis. During 
the process called vasculogenesis, the de novo forming angioblasts aggregate in the embryo and 
YS into a primitive network of endothelial tubes, called the primary vascular plexus (Risau and 
Flamme, 1995). Induction by fibroblast growth factors (FGF) of mesoderm during gastrulation leads 
to the generation of angioblasts and hematopoietic cells. Vascular endothelial growth factor 
(VEGF) and its high-affinity receptor tyrosine kinase Flk-1 represent a paracrine signaling system 
crucial for the differentiation of endothelial cells and the development of the vascular system. 
Specific cell adhesion molecules such as VE-Cadherin and CD31, and transcription factors such 
as Ets-1, as well as mechanical forces and vascular regression and remodeling are involved in the 
subsequent events of endothelial cell differentiation, apoptosis, and angiogenesis.  
 The lymphatic system however, develops only after appearance of blood vasculature, which 
was the first indication that lymphatics might have a blood vasculature origin (reviewed in (Oliver, 
2004)). The lymphatic system is composed of a vascular network of blind-ended, thin-walled 
capillaries and larger vessels that drain protein-rich interstitial fluid (lymph) from the extracellular 
spaces within organs into larger collecting ducts. In contrast to blood capillaries, lymphatic 
capillaries lack fenestrations, a continuous basal membrane and pericytes; instead, these vessels 
are lined with a continuous, single layer of overlapping endothelial cells that form loose intercellular 
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junctions. These characteristics make the lymphatic capillaries highly permeable to large 
macromolecules, pathogens and migrating cells. 
 Nowadays, most experimental data support the hypothesis proposed by Florence Sabin in 
1902 that lymphatic endothelial cells arise by sprouting from embryonic veins (Oliver, 2004; Sabin, 
1902). According to this model (Figure 4), cells within the venous compartment of the blood 
vasculature become competent to respond to induction signals towards the lymphatic lineage at 
embryonic day 9.5, morphologically indicated by the expression of LYVE-1 by a few endothelial 
cells lining the anterior cardinal vein of mice. Neither are the signals known that induce this 
competence nor is LYVE-1, a hyaluronan receptor and lymphatic specific marker, required for the 
lymphatic competence (Gale et al., 2007). 
 Following this initial step, polarized expression of the homeobox protein Prox-1 is detected 
in the anterior cardinal vein in a subpopulation of “competent” LYVE-1-expressing venous 
endothelial cells. As development progresses, the number of Prox-1 expressing cells increases 
and is also detected in more caudally located veins. After the initial phase of Prox-1 expression in 
the veins, Prox-1-expressing lymphatic endothelial cells (LEC) progenitors migrate from the veins 
and form the primitive lymph sacs, scattered along the anteroposterior axis (Wigle and Oliver, 
1999). In parallel, VEGFR3 becomes expressed and activated by its cognate ligand VEGF-C, 
uniformly produced by the mesenchyme surrounding the cardinal veins. Even though uniformly 
expressed, VEGF-C and its receptor constitute at least one of the mechanisms required for the 
polarized budding of Prox-1 expressing LEC, as evidenced by the inability of Prox-1+ LEC 
progenitor to leave the embryonic veins in VEGF-C deficient mice (Karkkainen et al., 2004). At 
around E14.5, the lymphatic vasculature has spread throughout the developing embryo by budding 
and sprouting from the primary lymph sacs, and the immature LEC are in the process of terminal 
differentiation. 
 Late embryonic and postnatal remodeling of the lymphatic vasculature includes sprouting of 
lymphatic capillaries from the primary lymphatic plexus, whereas bigger lymphatic vessels recruit 
smooth muscle cells and develop lymphatic valves, thereby acquiring a collecting vessel 
phenotype. These processes critically depend on Neuropilin-2, Angiopoeitin-1 & -2/ Tie2 as well as 
ephrinB2 signaling pathways (Gale et al., 2002; Yuan et al., 2002) and lead to the expression of 
the full panel of lymphatic specific markers, as indicated in Figure 4. 
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Figure 4. Model for generation of the lymphatic vasculature from venous endothelium. See text for details. (Taken from 
(Oliver, 2004)) 
 
 In addition to a strict origin of LEC from venous vasculature, the existence of mesenchymal 
lymphangioblasts was proposed by studies on avian embryos and Xenopus tadpoles (Ny et al., 
2005; Schneider et al., 1999). Similar observations were made very recently in mouse, where 
proliferating cells co-expressing lymphatic and monocytic markers (Prox-1+/ LYVE-1+/ F4/80+) 
located in the mesoderm, immediately adjacent to, and within lymph vessels were detected (Buttler 
et al., 2008). If these cells are derived from lymphangioblasts, by chance phenocopy a mixed 
lymphatic/ hematopoietic marker profile or rather represent a lymphatic differentiation of monocytic 
cells (or vice versa) cannot be decided at this point. However, our experimental data (see “4.2. 
Myeloid cells contribute to tumor lymphangiogenesis”) indicate that at least in the adult, there is a 
trans-differentiation potential of monocytic cells to the lymphatic lineage under inflammatory 
conditions. 
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1.3.3. Tumor angiogenesis and lymphangiogenesis 
 
Tumor angiogenesis and its molecular regulation 
 In normal tissues, oxygen and nutrients are only efficiently delivered to cells residing within 
a 200µm diameter around a blood capillary. To ensure this proximity, growth of parenchyma and 
expansion of the vasculature are carefully coordinated. Once a tissue is formed, the growth of new 
blood vessels, angiogenesis, only occurs transitory and under tight molecular control. For example, 
during wound healing in the skin, dermal endothelial cells first have to be activated in order to 
expand and then reestablish blood vasculature function in the wound area. This happens via a 
coordinated local action of immune cells, coagulation factors, and activation of matrix components 
- all initially triggered by physical stress like oxygen and nutrient deprivation as well as loss of 
matrix integrity. After the tissue components were successfully repaired, the vasculature will re-
enter quiescence and a pre-wound immune cell status will be reestablished. 
 The quiescence phenotype of the vasculature in adults is mediated by the balance of pro- 
and anti-angiogenic factors within a given tissue (Figure 5). Over time it had become clear, that 
organs as well as tumors produce pro- and antiangiogenic factors, and only upon dominance of the 
pro-angiogenic factors, angiogenesis will take place. The existence of a “tumor angiogenesis factor 
(TAF)” was proposed by Judah Folkman in 1971 (Folkman et al., 1971), but it took more than ten 
years to isolate basic fibroblast growth factor (bFGF) and vascular endothelial growth factor A 
(VEGF-A) and to assign a clear pro-angiogenic role to them (Klagsbrun et al., 1986; Leung et al., 
1989; Senger et al., 1983). 
 
 
Figure 5. Abundance of 
pro- and antiangiogenic 
factors defines vascular 
quiescence, regression or 
angiogenic expansion. 
(From (Zetter, 2008)) 
  
 
 Multiple studies have established VEGF-A as a key angiogenic player in cancer (reviewed 
in (Dvorak, 2002)). It is expressed by most tumors and its expression correlates with tumor 
microvessel density and tumor proliferative status, and exerts its function via activation of VEGF 
receptor 2 (VEGFR2) and, eventually, VEGFR1 on endothelial cells. Also tumor and immune cells 
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have been shown to express VEGF receptors to varying degrees, however the significance of 
these potentially stimulatory signaling circuits is poorly understood. VEGF-A action on endothelial 
cells has mitogenic as well as chemotactic effects. One of the earliest factors implicated in 
angiogenesis that is detected in tumor initiating nodules is Angiopoietin-2 (Ang-2) (Holash et al., 
1999). Ang-2 is a ligand for the receptor tyrosine kinase Tie2, and at least in some settings, Ang-2 
acts antagonistically on Tie2, a function implicated in destabilizing the endothelium and rendering it 
susceptible to VEGF-A stimulus (Figure 6) (Yancopoulos et al., 2000). Ang-2 stimulation without 
concomitant VEGFR2 stimulation rather leads to blood vessel regression. Ang-1, another Tie-2 
ligand, is involved in stabilizing blood vessels, as evidenced by larger vessel size and reduced 
vascular permeability in mice over-expressing Ang-1 in the skin (Thurston et al., 1999). 
 
 
Figure 6. Interplay of VEGF and Angiopoietin system in tumor angiogenesis. (A) Tumor initially grows avascular and 
upon hypoxia VEGF-A is induced and host vessels destabilized/ activated by Ang-2 expression. (B) Tumor initiation with 
concomitant co-option of host vessels, expressing Ang-2, results in temporary vessel and tumor regression, only 
secondary to which tumoral VEGF expression and angiogenic sprouting are induced. (Taken from (Yancopoulos et al., 
2000)) 
 
 The molecular proof of the necessity for tumor angiogenesis came with mouse models in 
which angiogenesis and subsequent tumor growth was impaired upon blockade of the VEGF axis 
by anti-VEGF antibody or dominant negative VEGFR2 in xeno-transplantation studies (Kim et al., 
1993; Millauer et al., 1994). Similarly, treating transgenic tumor mice with anti-angiogenic 
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compounds also proved to be effective in limiting angiogenesis and reducing tumor growth 
(Bergers et al., 1999; Sacco et al., 2001) 
 Expression of VEGF can be induced by multiple cellular pathways: Hypoxia leads to 
stabilization of hypoxia inducible factor 1α (HIF1α) that in turn induces VEGF-A expression via 
HIF-responsible elements in the VEGF-A promoter; a different pathway of VEGF induction is 
mediated by pro-inflammatory cytokines such as TNF-α and TGF-β2. Recently, the transcriptional 
co-activator PGC-1α was shown to induce VEGF-A independent of the HIF pathway; PGC-1α is a 
potent metabolic sensor and regulator of mitochondrial function, but its significance for tumor 
angiogenesis is currently not clear (Arany et al., 2008). 
 A series of publications have recently revealed a mechanism that prevents overshooting of 
sprout formation during angiogenesis via the delta-like ligand 4 (Dll4) – Notch1 pathway (reviewed 
in (Thurston et al., 2007)). Even though tumors elicit a kind of aberrant angiogenesis, resulting in 
leaky vessels and intra-tumoral hemorrhage, the Dll4-Notch1 pathway, already essential during 
vasculature development in the embryo, is tightly controlled in tumor blood vessels to allow 
productive angiogenesis. Blockade of Dll4 inhibited tumor growth by promoting non-productive 
angiogenesis. Mechanistically it was found that Dll4 is induced by VEGF-A as a negative regulator 
of angiogenic sprouting. 
 Judah Folkman stated in 1971 "...antiangiogenesis therapy, perhaps by immunization 
against TAF, should provide a powerful adjunct to the control of solid neoplasms". The prediction 
was that control of vascularity within a tumor would facilitate control of the tumor. If, in fact, one 
substitutes VEGF for TAF, then it is clear that Folkman anticipated the clinical use of anti-
angiogenic antibodies such as bevacizumab (Avastin) decades before they were available in the 
clinic. Aspects of clinical interference with tumor angiogenesis are further discussed in section 
“1.4.4. Perspectives for therapy”. 
 
Tumor lymphangiogenesis and its molecular regulation 
 The metastatic spread of tumor cells is the most lethal aspect of cancer and often occurs 
via the lymphatic vasculature (reviewed in (Achen and Stacker, 2008; Das and Skobe, 2008)). 
Cancer cells may also spread via blood vessels or seed directly to body cavities. Experimental 
tumor models as well as human clinicopathologic data indicate that growth of lymphatic vessels – 
lymphangiogenesis – in or around solid tumors is often associated with lymph node metastasis. 
Correlation studies in humans indicate a clear positive correlation between tumor-associated 
lymphangiogenesis and lymph node metastasis in cutaneous melanoma, inflammatory breast 
cancer, non-small cell lung cancer and bladder carcinoma as well as in head & neck cancer. The 
location of the lymphatic vessel might be crucial as animal experiments revealed most intra-
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tumoral lymphatics to be non-functional and therefore rather suggest peri-tumoral lymphatics to be 
the entry points for tumor cells into the vascular bed (Padera et al., 2002). 
 The most specific lymphangiogenic growth factors promoting formation of (tumor) 
lymphatics that have been identified are the secreted glycoproteins vascular endothelial growth 
factors C (VEGF-C) and VEGF-D (Jeltsch et al., 1997; Stacker et al., 2001). Both ligands bind their 
cognate receptor VEGFR3, which is mainly expressed in lymphatic vasculature in adults, but might 
be re-expressed on blood endothelial cells during tumor angiogenesis (Tammela et al., 2008). 
VEGF-C and -D are proteolytically processed and in fully processed form, they also bind and 
activate VEGFR2, which is expressed on blood and lymphatic endothelial cells. These findings 
implicate that over-lapping ligand/ receptor signaling between VEGFR2/ VEGF-A and VEGFR3/ 
VEGF-C & -D is reactivated in tumors similar to the situation during development, stimulating both 
blood and lymphatic endothelial cells. 
 Tumoral expression of VEGF-C emerges as a reliable marker for ongoing tumor 
lymphangiogenesis and increased risk of regional lymph node metastasis in many carcinomas. 
Data for VEGF-D are less consistent, suggesting that its ability to promote metastatic spread via 
lymphatics depends on the investigated tumor type and/ or grade. Expression of VEGF-C is 
stimulated by the inflammatory mediators interleukin-1β, tumor necrosis factor-α, COX-2 and its 
induced prostaglandins (Ristimaki et al., 1998; Su et al., 2004). Induction of VEGF-C mediated 
lymphangiogenesis could counteract inflammation-induced edema, a situation often occurring in 
cancer due to high immune cell infiltration. 
 Experimental mouse models have clearly shown a firm link between expression of VEGF-C/ 
or –D in cancerous tissue and tumor associated lymphangiogenesis and metastasis in 
experimental insulinoma and in xeno-transplantation studies (Mandriota et al., 2001; Skobe et al., 
2001; Stacker et al., 2001). 
 Increasing evidence suggests that lymph node lymphangiogenesis can precede and 
facilitate lymph node metastasis. This was observed in a chemically induced skin cancer model, 
where either transgenically expressed VEGF-A or VEGF-C could induce tumor and draining lymph 
node lymphangiogenesis (Hirakawa et al., 2006; Hirakawa et al., 2005). Amazingly, the expansion 
of lymph node lymphatic vasculature seemed to significantly promote distant metastases. In 
human melanoma, multivariate analysis revealed that tumor lymphangiogenesis was the most 
significant independent prognostic indicator for the presence of sentinel lymph node metastasis 
(Dadras et al., 2005). In retrospective studies, increased melanoma-associated lymphangiogenesis 
was found to be inversely correlated with disease-free and overall survival of melanoma patients 
(Dadras et al., 2003). 
 The identification of a link between tumoral expression of lymphangiogenic factors, 
associated lymphangiogenesis and the correlation of these events with metastatic events 
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suggested that interference with this system might prevent metastasis. Indeed, studies aiming at 
interfering with VEGFR3 signaling by sequestering the ligands VEGF-C and –D using soluble 
VEGFR3 traps or by neutralizing the receptor with anti-VEGFR3 antibodies successfully reduced 
lymph-angiogenesis and lymph node metastases in murine models of breast, prostate, mammary 
cancer and in malignant melanoma (Lin et al., 2005; Roberts et al., 2006). Interestingly, the re-
expression of VEGFR3 on angiogenic tumor blood endothelial cells also allowed blockade of tumor 
angiogenesis via interference with the VEGFR3 axis (Tammela et al., 2008). 
 Over the last few years, many more signaling pathways stimulating lymphangiogenesis in 
certain systems have been identified, including hepatocyte growth factor/ c-Met (Kajiya et al., 
2005), FGF-2 (Chang et al., 2004), platelet-derived growth factors (Cao et al., 2004) and insulin 
like growth factors (IGF) (Bjorndahl et al., 2005). These receptor/ ligand pairs do not exclusively act 
on lymphatic endothelial cells but also on other cells; additionally, some of the actions observed 
might be due to indirect effects on the VEGF-C/-D VEGFR3 axis. For example, it was shown that 
IGF-1R stimulates the expression of VEGF-C in Lewis lung carcinoma cells (Tang et al., 2003). 
 Very recently, the adrenomedullin/RAMP2/Calcrl signaling pathway has been demonstrated 
to be important for the development of balanced blood and lymphatic endothelial systems. Two 
groups have shown by knockout studies that loss of this signaling pathway results in tissue edema 
and embryonic death due to increased blood vasculature permeability and reduced lymphatic 
uptake of interstitial fluid (Fritz-Six et al., 2008; Ichikawa-Shindo et al., 2008). 
 
Figure 7. Signaling pathways involved in lymphangiogenesis. Whereas the VEGF-C/ -D and VEGFR3 system 
specifically promotes lymphangiogenesis, the other signaling pathways depicted here are also employed by blood 
endothelial cells and/ or other cell types. (From (Rinderknecht and Detmar, 2008)) 
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1.4. Interactions tumor – immune system 
Zumsteg and Christofori: “Corrupt policemen: inflammatory cells promote tumor 
angiogenesis” Current Opinion in Oncology 2009, 21:60–70 
 
Purpose of the review 
 The last decade has seen a paradigm change in that tumor stroma contributes to malignant 
tumor progression in a manner comparable to genetic and epigenetic changes within cancer cells. 
This review summarizes recent novel insights into how inflammatory conditions stimulate the 
formation and expansion of blood and lymphatic vessels within tumors and, thus, allow tumors to 
grow, to gain invasive capabilities, and to finally seed metastasis in distant organs. 
 
Recent findings 
 Different cancer types have a highly defined microenvironment, which is composed of 
cancer-associated fibroblasts, blood vessel and lymphatic endothelial cells, pericytes, and a 
heterogeneous infiltrate of cells of the immune system. In addition to the local stimulation of tumor 
angiogenesis and tumor lymphangiogenesis, cytokines released by the primary tumor and by the 
immune cell infiltrate also instruct bone marrow-derived cells to colonize distant organs and to 
prepare these sites for future metastasis.  
 
Summary 
 Inflammatory reactions coinciding with carcinogenesis can be visualized by the presence of 
specific bone marrow-derived, inflammatory cells in patientsʼ peripheral blood. Recent findings 
suggest that such inflammatory fingerprints may better define the inflammatory nature of the 
primary malignancy and, thus, allow the design of therapeutic strategies targeting the pro-
tumorigenic immune cell stroma compartment. 
 
1.4.1. Introduction 
 The notion that angiogenesis is critical for supplying tumors with sufficient oxygen and 
nutrients to grow beyond a certain size is well established. However, only recently it has been 
appreciated that activation, expansion and maintenance of the tumor vascular system extends 
beyond the function of angiogenic factors released by hypoxic tumor cells. A tumor is usually 
composed of many different cell types, and this composition is spatially and temporally highly 
dynamic and, thus, the causal link between a specific modulating factor and tumor progression has 
been rather speculative than direct. In the past few years, transgenic mouse models of cancer 
have served a critical role in unraveling the complex interplay between tumor cells, infiltrating 
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leukocytes, cancer-associated fibroblasts (CAF), and the tumor blood and lymphatic vasculature. 
Major attention has been paid to the contribution of cells of the immune system to tumor 
progression, mainly by employing bone marrow transplantations and the use of genetically 
modified mice. These experiments have revealed that most immune cell lineages exert anti- as 
well as pro-tumorigenic functions and that established tumors often skew immune cells into a pro-
angiogenic and immunosuppressive state (Figure 8). The use of inducible genetic or 
pharmacological ablation strategies may set the stage for future, even more relevant animal 
studies. 
 
1.4.2. Immune cells as critical drivers of tumor angiogenesis 
The critical functions of CAF and pericytes in angiogenesis, extracellular matrix remodeling 
and metastasis have been recently reviewed (Gerhardt and Semb, 2008; Kalluri and Zeisberg, 
2006). Here, we focus on the role of the immune system in tumor progression, with the innate 
immune system playing a more prominent role than the adaptive immune system in most 
experimental settings. The majority of recent studies discussed in this review are summarized in 
Table 1. 
 
1.4.2.1. Myelomonocytic cells and tumor associated macrophages (TAM) 
Tissue macrophages, derived from the peripheral blood monocytic branch of myeloid cells, 
have been found to be present in virtually all solid tumors. High TAM content in human epithelial 
tumors usually links to poor prognosis with few exceptions (Bingle et al., 2002). TAMs are, 
alongside with myeloid-derived suppressor cells (MDSC, see below), mobilized from the bone 
marrow and recruited to the tumor site upon specific tumor-derived stimuli, such as vascular 
endothelial growth factor (VEGF), placental growth factor (PlGF), CC-chemokine ligand 2 (CCL2), 
granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL3), macrophage CSF 
(M-CSF), IL6 or soluble Kit ligand (sKitL). In a tumor microenvironment, macrophages can be 
polarized to a M1 (classically activated) state, eliciting Th1 adaptive immune cell reactions, host 
defense and tissue destruction, mainly by secretion of high levels of IL1β, tumor necrosis factor-α 
(TNFα), and IL6 and the production of reactive nitrogen and oxygen intermediates. Alternatively, 
macrophages can be polarized to a M2 state, suppressing Th1 adaptive immunity and promoting 
wound healing, angiogenesis and tissue remodeling (Allavena et al., 2008). TAM are rather M2 
polarized and confer immunotolerance to a tumor environment. Macrophages themselves have 
been shown to produce various pro-angiogenic factors, including VEGF, TNFα, IL8, and fibroblast 
growth factor-2 (FGF2). Moreover, TAM secrete proteases for the liberation of matrix sequestered 
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growth factors and for the degradation of extracellular matrix and basement membrane, thus 
promoting sprouting and expansion of the vasculature and invasive motility of tumor cells. 
TAM have been shown to promote tumor angiogenesis mainly by secretion of matrix 
metalloproteinase 9 (MMP9) which activates matrix-sequestered latent forms of VEGF-A. In the 
HPV16/E2 transgenic mouse model of cervical carcinogenesis, tumor-infiltrating macrophages 
provide the majority of MMP9 required for the onset of angiogenesis (Giraudo et al., 2004). Yet, the 
targeted reduction of intratumoral macrophage levels in CC chemokine receptor-2 (CCR2)-deficient 
mice is compensated for by the infiltration of MMP9-expressing neutrophils (Pahler et al., 2008). In 
a syngeneic mouse model of glioblastoma, hypoxia inducible factor 1-α (HIF1α) is critical for the 
induction of VEGF expression in tumor cells and the concomitant recruitment of MMP9-expressing 
myelomonocytic cells from the bone marrow (Du et al., 2008). Thereby, the local expression of the 
cytokine stromal derived factor-1 (SDF1 = CXCL12) contributes to the recruitment and positioning 
of bone marrow-derived cells in the glioblastoma model. CXCR4, the cognate receptor of CXCL12 
is expressed on the majority of CD45+ myelomonocytic cells that are mobilized from the bone 
marrow. Myeloid cells and their secretion of MMP9 also play an important role in the growth of 
tumors in pre-irradiated stroma, particularly in supporting vasculogenesis, i.e. the formation of 
blood vessels by circulating endothelial precursor cells (Ahn and Brown, 2008). Importantly, in all 
these models, MMP9 is not exclusively provided by myelomonocytic cells, but also by other tumor-
infiltrating cells, tumor cells themselves, pericytes or fibroblasts, suggesting that myelomonocytic 
cells as the major source of MMP9 can be replaced by other cell types to promote tumor 
angiogenesis and growth. Hence, from a clinical perspective, targeting stroma-derived enzymes 
might be superior to targeting cell types. 
The critical function of TAM has also been documented in the MMTV-PyMT transgenic 
mouse model of breast cancer. Crossing PyMT breast cancer mice with macrophage-deficient 
CSF1op/op mice suppressed tumor angiogenesis, tumor progression and lung metastasis, while 
primary tumor growth remained largely unaffected (Lin et al., 2006; Lin et al., 2001). Transgenic 
expression of VEGF-A in tumor cells of composite CSF1op/op;MMTV-PyMT mice restored the 
angiogenic switch and tumor progression, indicating that the bioavailability of VEGF-A was a 
critical factor for tumor progression and suggesting that VEGF-A was produced by TAM (Lin et al., 
2007). Similarly, ablating TAM using liposome-encapsulated clodronate significantly reduced tumor 
angiogenesis and growth of subcutaneously transplanted cancer cells in mice (Zeisberger et al., 
2006). Moreover, antibody-mediated inhibition of α4β1 integrin in the syngeneic murine Lewis Lung 
Carcinoma (LLC) model lead to decreased myeloid cell recruitment and resulted in impaired 
angiogenesis and tumor growth (Jin et al., 2006). 
Monocytes called TEM, for Tie2-Expressing Monocytes, constitute a minor proportion of 
tumor-infiltrating myeloid CD11b+ cells, yet they seem to be a crucial pro-angiogenic driving force: 
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firstly, co-injection of tumor cells with tumor-derived TEM but not with Tie2-/CD11b+ myeloid cells 
stimulated angiogenesis in growing tumors. Secondly, specific ablation of Tie2-expressing bone 
marrow cells resulted in markedly impaired tumor angiogenesis (De Palma et al., 2005). Tie2+ 
monocytes have also been found in human blood; these cells respond in vitro to hypoxia and 
angiopoietin-2, a pro-angiogenic ligand for Tie2, by the upregulated expression of Tie2 and CXCR4 
and the down-regulation of TNFα and IL12 (Murdoch et al., 2007). This observation supports the 
concept of tumors skewing macrophages into a pro-angiogenic, M2-polarized phenotype. Notably, 
the upregulation of Tie2 on tumor-infiltrating monocytes relative to blood monocytes has also been 
observed in human cancer patients (Venneri et al., 2007). 
VEGFR1, a receptor for VEGF-A and PlGF, is expressed on a subset of mobilized myeloid 
cells, found in blood and tumors of tumor-bearing mice and cancer patients (Kusmartsev et al., 
2008). The abundance of VEGFR1+ cells correlates with tumor size in mice, and they are found at 
high levels in patients with renal cell carcinoma, a cancer with particularly high levels of circulating 
VEGF-A, suggesting a stimulating effect of systemic VEGF-A on VEGFR1-mediated bone marrow 
myelopoiesis. VEGFR1 cells have also been shown to colonize and prepare the “premetastatic 
niche” in lungs prior to the appearance of metastatic tumors cells (Kaplan et al., 2005). 
Presumably, VEGF-A, TNFα, and transforming growth factor-β (TGFβ) released by tumor cells 
induce the expression of the myeloid cell attractant proteins S100A8 and S100A9 in lung 
endothelial cells (Hiratsuka et al., 2006). 
Myeloid cells can also stimulate angiogenesis in a non-tumorigenic environment with high 
expression of VEGF-A. Notably, myeloid cells from organs, to which they were recruited by organ-
specific over-expression of VEGF-A, were even more potent than recombinant VEGF-A in inducing 
endothelial sprouting (Grunewald et al., 2006). The critical role of VEGFR1 tyrosine kinase activity 
in VEGF-A-mediated macrophage recruitment has also been demonstrated by the transplantation 
of VEGFR1 tyrosine kinase deficient (Vegfr1 tk-/-) bone marrow cells into mice over-expressing 
VEGF-A in the ear skin. Macrophage recruitment, lymphangiogenesis, as well as angiogenesis, 
were significantly decreased, when bone marrow cells from Vegfr1 tk-/- -mice were transplanted as 
compared from wild-type mice (Murakami et al., 2008). However, in another tumor-free model 
system, mobilization of immature myeloid CD11b+/Gr1+ cells from the bone marrow depended 
rather on VEGFR2 signaling than on VEGFR1 signaling as shown in mice injected with either 
VEGFR1 or VEGFR2-specific VEGF-A mutants (Huang et al., 2007). These results suggest that 
VEGFR2 signaling is more important for mobilization and expansion of BMDC, whereas VEGFR1 
signaling is more important for recruitment to and positioning at angiogenic sites. 
 
 A number of studies have suggested that macrophages are also important for 
lymphangiogenesis. In human cervical cancers, peritumoral lymphatic vessel density correlated 
                                                                                 INTRODUCTION: INFLAMMATORY CELLS PROMOTE TUMOR ANGIOGENESIS 
27 
with the abundance of TAM that expressed VEGF-C and VEGF-D, the main mitogenic growth 
factors for lymphatic endothelial cells (Schoppmann et al., 2002). In a model of carcinomatous 
peritonitis, TAM were found to produce VEGF-C and VEGF-D, thus stimulating the expansion of 
lymphatic vessels in the diaphragm after intraperitoneal injection of tumor cells into mice. The 
lymphangiogenic phenotype was attenuated by treatment with the Cox2 inhibitor Etodolac, 
presumably via reduced VEGF-C expression in TAM (Iwata et al., 2007). A similar expression of 
VEGFs by CD11b+/LYVE-1+ macrophages has been observed in a model of non-productive 
dysfunctional lymphangiogenesis in the diaphragm (Jeon et al., 2008). In a corneal vascularization 
model, VEGF-A and PlGF stimulated lymphangiogenesis via recruitment of macrophages, and this 
recruitment was impaired, concomitantly with lymphangiogenesis, when VEGF-A and PlGF were 
neutralized by soluble VEGF receptor (Cursiefen et al., 2004). 
The lymphangiogenic factor VEGF-C is often provided by tumor-recruited macrophages, 
and macrophage mobilization and homing might result from VEGFR1 activation by its ligands 
VEGF-A and PlGF. Consistent with this notion, strategies targeting VEGFR1, the common receptor 
for VEGF-A and PlGF, have been proven successful in reducing tumor angiogenesis and 
lymphangiogenesis in different pre-clinical cancer models (Fischer et al., 2007). However, a formal 
proof for the specific delivery of various VEGF family members by tumor infiltrating cells, for 
example by cell type-specific ablation of these growth factors, is still lacking. 
 
1.4.2.2. Myeloid-derived suppressor cells (MDSC) 
MDSC are cells closely related to TAM, however they show an incomplete differentiation 
along the myeloid axis and cannot be definitely attributed to either the monocytic or the 
granulocytic lineage. In mice, MDSC are characterized by simultaneous expression of Gr1 (a 
granulocyte marker) and CD11b (a myeloid cell marker), and their abundance can increase in 
spleen and peripheral blood in tumor-bearing animals. Importantly, MDSC have the ability to 
suppress T cell activation in vitro and they may overlap functionally (and from their ontogeny) with 
TAM once recruited to the tumor site (Sica and Bronte, 2007). Subcutaneous co-injection of 
syngenic tumor cells and isolated MDSC (from spleen of tumor bearing animals) into mice revealed 
that MDSC directly promoted tumor angiogenesis and tumor growth (Yang et al., 2004). 
Interestingly, MDSC isolated from tumor-free mice rather repressed than supported tumor growth 
in these studies, indicating that myeloid cells were already partially polarized before entering the 
tumor site. Again, MMP9 expression by MDSC was shown to be a critical feature, and one might 
speculate whether MDSC become bona fide TAM upon entering the tumor microenvironment. 
Reducing the levels of MDSC by either treatment of mice with the chemotherapeutic gemcitabine 
or by interfering with the (tumor-produced) Kit ligand/c-Kit receptor axis reversed the immune 
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tolerance of advanced tumors and impaired tumor growth and angiogenesis (Pan et al., 2008; 
Suzuki et al., 2005). MDSC were found in vitro to promote an IL12low M2 state of macrophages 
and, conversely, were stimulated by macrophages to express high levels of IL10. High levels of 
IL10 induced immunotolerance by blocking dendritic cell (DC) maturation, and reduced levels of 
IL12 were insufficient to activate natural killer cells. Similarly, gemcitabine treatment of mice 
transplanted with metastatic 4T1 breast cancer cells lowered peripheral MDSC levels and slightly 
increased animal survival (Sinha et al., 2007). When 4T1 cells were transplanted into IL4Rα-/- mice, 
in which macrophages can hardly be skewed into a M2 state by IL4 or IL13, gemcitabine treatment 
resulted in steady-state levels of MDSC and tumor rejection in almost all treated animals. 
 
 An important signaling pathway involved in establishing an immune-privileged, pro-
angiogenic tumor microenvironment involves signal transducer and activator of transcription 3 
(STAT3) signaling. Many tumor types display constitutively activated STAT3 in tumor and stroma 
cells. In tumor cells, activated STAT3 promotes tumor cell survival but also represses expression 
of Th1 immuno-stimulatory molecules, such as IL12 and interferons. On the other hand, STAT3 
induces expression of immuno-suppressive factors like IL10, VEGF and IL23 (Kortylewski and Yu, 
2008). IL10 itself is a canonical activator of STAT3 signaling, implying a positive feedback loop, 
and VEGF is one of the most potent pro-angiogenic growth factors. Tumor transplantation studies 
employing deletion of STAT3 in the hematopoietic system resulted in highly activated dendritic 
cells, lower levels of regulatory T cells but higher levels of cytotoxic intratumoral T cells. Moreover 
an enhanced anti-tumor activity of natural killer cells and Gr1+/CD11b+ neutrophils has been 
observed, the latter being reminiscent of MDSC (Kortylewski et al., 2005). A recent study also 
suggests a crucial role of activated STAT3 in TAM and MDSC for promoting tumor angiogenesis. 
TAM or MDSC isolated out of tumors from STAT3-deficient mice were markedly less potent in 
inducing endothelial tube formation in vitro as compared to STAT3 wildtype cells, concomitant with 
markedly reduced expression levels of the proangiogenic factors VEGF, bFGF, IL1β, MMP9 and 
CCL2 (Kujawski et al., 2008). 
 
1.4.2.3. Neutrophils  
In the simian virus 40 large T antigen-driven transgenic mouse model of insulinoma 
(Rip1Tag2), antibody depletion experiments revealed that neutrophils were critical players for 
initiating the angiogenic switch during tumorigenesis, and loss of neutrophils could not be 
compensated by other inflammatory cells (Nozawa et al., 2006). Consistent with this notion, 
function blocking antibodies against VEGFR1 expressed on tumor infiltrating monocytes and 
MDSC did not affect Rip1Tag2 tumorigenesis, also indicating that neutrophil recruitment is 
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independent of VEGFR1 signaling (Casanovas et al., 2005). Conversely, ablation of MMP9-
producing macrophages in the HPV16/E2 transgenic mouse model of cervical carcinogenesis can 
be compensated by neutrophils (Pahler et al., 2008). Antibody-mediated neutralization of Bv8, a 
neutrophil-derived soluble mediator of tumor angiogenesis and a regulator of myeloid cell 
mobilization, revealed that early inhibition of Bv8 impaired the angiogenic switch in emerging 
tumors but did not have an effect when applied at later stages of tumor growth in the Rip1Tag2 
model (Shojaei et al., 2008; Shojaei et al., 2007b).  
 
1.4.2.4. Mast cells 
In a transgenic mouse model of pancreatic β-cell carcinogenesis, where a Tamoxifen-
inducible version of the oncoprotein c-Myc induces metastatic insulinoma, infiltration of mast cells 
around neoplastic islets of Langerhans has been observed (Soucek et al., 2007). Mast cell function 
was shown to be essential for the later stages of tumor expansion, since ablation of mast cells 
provoked increased tumor cell apoptosis and reduced vascular expansion. The authors speculate 
whether CCL2 and CCL5 could be responsible for mast cell infiltration, as these chemokines are 
immediate targets of induced c-Myc expression. In the HPV16/E2 transgenic mouse model of 
squamous cell carcinoma (SCC) of the skin, mast cells were also important for the initial 
angiogenic switch by providing MMP9 proteolytic activity, and MMP9-deficiency severely impaired 
keratinocyte hyperproliferation and the incidence of invasive tumors (Coussens et al., 1999; 
Coussens et al., 2000). In this model, attraction of mast cells and neutrophils to the pre-neoplastic 
sites was dependent on tumor-specific, B cell-derived immunoglobulin deposits in the epidermis, 
implying humoral factors in promoting tumor angiogenesis (de Visser et al., 2005).  
D6, a scavenger receptor for CC chemokines mainly expressed on lymphatic endothelial 
cells, was shown to modulate mast cell (and T cell) infiltration in a model of chemically induced 
skin carcinogenesis (Nibbs et al., 2007). Tumor growth was accelerated in D6-deficient mice 
concomitant with increased mast cell and T cell infiltration, whereas tumor growth was delayed in 
mice over-expressing D6 in keratinocytes. These results indicate an important role of CC 
chemokines in setting up a pro-inflammatory milieu for the recruitment of pro-angiogenic mast 
cells. 
Endostatin, an anti-angiogenic fragment of Collagen XIII, inhibited lymphangiogenesis by 
reducing infiltration of VEGF-C-expressing mast cells into chemically induced SCC, whereas 
macrophage recruitment was neither impaired nor did macrophages produce VEGF-C in this 
experimental setting (Brideau et al., 2007). 
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Figure 8. Schematic representation of the interplay between cancer cells and inflammatory, bone marrow-derived cells 
and their contribution to tumor angiogenesis, lymphangiogenesis and metastasis. See text for details. 
 
1.4.3. Myeloid-endothelial plasticity 
The idea that vasculogenesis occurs in adults, and not exclusively during embryonic 
development, was prompted by the finding that bone marrow-derived cells could integrate into 
growing blood vessel, cells that were called by their marker profile rather than by their functionality 
Endothelial Progenitor Cells (EPC). The initial descriptions of EPC were based on the phenotypical 
characterization of CD34+ cells isolated from blood and cultured in pro-angiogenic conditions 
(Asahara et al., 1997). Yet, overlapping marker profiles obscure the discrimination between 
haematopoietic and endothelial progenitor cells, and humans and mice seem to have largely 
different pools of endothelial and hematopoietic stem cells, rendering it difficult to interpret results 
obtained from injecting human cells into immune-compromised mice. In addition, different mouse 
strains exhibit highly variable responses to hypoxia and thus varying levels of EPC-like cells (Li et 
al., 2008; Shaked et al., 2005). EPC characteristics are now generally thought to reside within the 
CD14+/CD34low-monocytic fraction of peripheral (human) blood (Romagnani et al., 2005). 
The remarkable plasticity of monocytic cells has been illustrated by the generation of cells 
with mesenchymal marker expression (osteoblasts, skeletal myoblasts, chondrocytes, and 
adipocytes) from CD14+ peripheral blood cells (Kuwana et al., 2003). More important in the context 
of angiogenesis, cells derived from myeloid progenitors have been found to integrate into the portal 
veins of either bone marrow-transplanted or parabiotic mice (Bailey et al., 2006). Moreover, 
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vascular leukocytes carrying a mixed leukocyte/endothelial cell CD45+/VE-Cadherin+ marker profile 
have been isolated from human ovarian tumors (Conejo-Garcia et al., 2005; Coukos et al., 2005). 
They may have a dendritic cell precursor phenotype, however, their functional significance and 
existence beyond ovarian cancer has not been addressed yet.  
Recent reports have investigated the contribution of BMDC to blood vessel formation in 
tumors in vivo, coming to conflicting results, even though similar experimental approaches have 
been used. In one report, up to 30% incorporation of BMDC into tumor neo-vessels was observed, 
particularly during early tumor growth of LLC cells and in the MMTV-PyMT transgenic model of 
breast cancer (Nolan et al., 2007). Such incorporation was subsequently shown to play a critical 
role in promoting the angiogenic switch of lung metastases (Gao et al., 2008). In contrast, other 
recent reports did not find any integration of BMDC into tumor vessels in a variety of orthotopic 
transplantation and transgenic cancer models (De Palma et al., 2005; Purhonen et al., 2008). 
These contradictory results might be explained by differences between the tumor models used and 
by varying times of analysis during tumor progression. For example, whereas LLC cells employed 
infiltrating CD11b+/Gr1+ BMDC to overcome VEGF-A inhibition, B16F1 cells exhibited minimal 
infiltration of CD11b+/Gr1+ cells and were highly sensitive to VEGF-A inhibition (Shojaei et al., 
2007a). 
In contrast to the discrepancies in EPC and myeloid-lineage cells contributing to and 
incorporating into blood endothelia, several reports have documented the potential of inflammatory 
CD11b+ cells to integrate into lymphatic vessels under acute tissue inflammation stress. Myeloid 
cells, present in the murine inflamed conjunctiva, can express the lymphatic endothelial-specific 
marker VEGFR3 and can integrate into lymphatic structures that develop in mouse cornea 
transplants (Hamrah et al., 2003; Maruyama et al., 2005). Another study, employing a cornea 
angiogenesis model and a syngeneic fibrosarcoma transplantation model, have also revealed the 
incorporation of BMDC in newly formed lymphatic vessels (Religa et al., 2005). Notably, decreased 
macrophage numbers resulted in reduced lymphangiogenesis and impaired wound healing in 
diabetic mice (Maruyama et al., 2007). In another inflammatory condition, the rejection of human 
kidney transplants, the increased numbers of lymphatic vessels within the rejected organs contain 
host-derived lymphatic endothelial cells, suggesting the existence of lymphatic endothelial 
progenitor cells (Kerjaschki et al., 2006). However, the contribution of BMDC to tumor 
lymphangiogenesis is also controversial. For example, transplantation of LLC or B16F1 melanoma 
cells in syngeneic mice has not revealed any integration of BMDC into newly formed lymphatic 
vessels (He et al., 2004). 
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1.4.4. Perspectives for therapy 
The tight coupling of inflammation to the development and progression of most cancers, 
especially by promoting angiogenesis, opens attractive therapeutic options for targeting cancer via 
its inflammatory stroma. In recent years, many strategies have aimed at restoring the 
immunological response against tumor antigens or specific tumor stroma antigens, such as surface 
molecules expressed by activated tumor endothelium. These approaches have involved 
overcoming the tumorsʼ immunological anergy, e.g. by decreasing the activity or abundance of 
immunosuppressor cells or by actively targeting T cell responses to tumor cells or the tumor 
vasculature. Another avenue towards this goal is to force TAMs back into a M1 state, thus favoring 
anti-tumor immune responses. Indeed, a preclinical study in mice succeeded in debulking large 
tumors by a combinatorial treatment with CpG (an activator of Toll-like receptors) and with anti–
IL10R antibody, shown to be mediated by an interplay of activated TAM, dendritic cells and 
cytotoxic T cells (Guiducci et al., 2005). 
Several molecular targets which are either expressed by the tumor cells or by the tumor 
stroma and which are known to promote tumor angiogenesis and tumor progression by supporting 
inflammatory reactions include Cox-2, CXCR4, MMP, the angiogenic growth factors VEGF-A and 
PlGF, as well as pro-tumorigenic, M2-type TAM.  
 
Antibodies against VEGF and PlGF 
Bevacizumab is a neutralizing antibody against VEGF-A that is now increasingly used in the 
treatment of a variety of cancer types by directly targeting ongoing tumor angiogenesis. Such 
treatment has also been found to reduce the levels of circulating immature myeloid cells (iMC), 
reminiscent of MDSC, in a short term treatment of colorectal cancer patients (Osada et al., 2008). 
This study suggests that blocking VEGF-A signaling not only blocks tumor angiogenesis but also 
represses VEGF-Aʼs inhibitory effects on dendritic cell maturation and mobilization of iMC. 
However, studies in mouse models, as well as the moderate effect of VEGF inhibition in human 
cancer treatment, suggest that many tumor types activate compensatory angiogenesis programs 
upon VEGF-A depletion, for example by over-expressing other angiogenic factors, such as FGFs, 
angiopoietins and PlGF (Casanovas et al., 2005; Fischer et al., 2007). Ongoing clinical and 
preclinical approaches aimed at targeting the VEGF signaling system include the antibody-
mediated neutralization of the activities of PlGF and of neuropilins, co-receptors for VEGF binding 
and signaling. 
PlGF exerts an important function in attracting cells of the immune system to tumor sites via 
binding to VEGFR1 expressed by the recruited cells. In mouse tumor models, neutralizing 
antibodies against PlGF reduced tumor vascularization with an efficacy comparable to anti-
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VEGFR2 antibodies, an effect that was based on both the direct inhibition of angiogenesis and a 
reduction of macrophage infiltration into tumors (Fischer et al., 2007). Notably, PlGF seemed to be 
required exclusively for pathological angiogenesis and was dispensable for physiological 
angiogenesis and the homeostasis of normal vessels. A phase I clinical trial with the anti-PlGF 
antibody TB-403 has recently been completed without revealing any toxicity in healthy individuals. 
 
CXCR4 inhibitors 
The CXCR4 inhibitor AMD3100 has been successfully employed to augment CD34+ stem 
cell mobilization upon G-CSF treatment in non-Hodgkin's lymphoma, Hodgkin's disease and 
multiple myeloma patients prior to autologous stem cell transplantation (Calandra et al., 2008). 
CXCR4, the bona fide receptor for CXCL12 (SDF1), has been shown to be critical for cancer cell 
migration, angiogenesis and the positioning and recruitment of pro-angiogenic, myelomonocytic 
cells. Clinical trials involving the novel CXCR4 inhibitor MSX-122 for the treatment of solid tumors 
have started only recently. 
 
Trabectedin 
Trabectedin, a small chemical entity originally discovered in a Carribean marine tunicate, is 
a minor groove DNA binder which disrupts cell cycle progression and cell proliferation. It has been 
approved for the treatment of soft tissue sarcomas refractory to standard chemotherapy regimen 
(Grosso et al., 2007). It is also under investigation in phase II clinical studies for ovarian cancer 
and breast cancer (Krasner et al., 2007; Zelek et al., 2006). Intriguingly, human monocytes were 
particularly sensitive to trabectedin-induced apoptosis as compared to lymphocytes, and in treated 
patients monocyte counts were reduced and their ability to differentiate into macrophages was 
impaired. In parallel, freshly isolated TAM or ovarian tumor cells from patient treated with 
trabectedin expressed lower levels of IL6 and CCL2, the latter being one of the most potent 
monocyte-attractant chemokines (Allavena et al., 2005). Based on these observations, it is 
tempting to speculate that trabectedin-treatment not only affects tumor cells but also 
immunomodulatory functions. The lack of efficacy in trabectedin-treated colorectal cancer (CRC) 
patients could originate from the fact that in CRC, unlike in most other cancer types, macrophage 
infiltration usually is a favorable prognostic marker, and trabectedin-treatment might interfere with 
anti-tumoral TAM (Forssell et al., 2007; Paz-Ares et al., 2007). 
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Cox-2 inhibitors 
Meta-analysis of case control or cohort studies showed a slight but significant risk reduction 
for the development of breast cancer for woman regularly taking aspirin or other non-steroidal, anti-
inflammatory drugs (NSAIDs) (Gonzalez-Perez et al., 2003; Harris et al., 2003; Khuder and Mutgi, 
2001). Clinical trials with specific Cox-2 inhibitors documented a significant reduction in adenoma 
formation in patients at high risk for CRC (Baron et al., 2006; Bertagnolli et al., 2006). However, 
other clinical trials failed to show a benefit of including Cox-2 inhibitors to standard chemo- or 
radiotherapeutic regimens, e.g. in advanced pancreatic adenocarcinoma or in cervical cancer 
(Dragovich et al., 2008; Gaffney et al., 2007). In addition, due to an increased risk of 
cardiovascular complications, the clinical trials in colorectal cancer patients had to be terminated 
prematurely. A recent study in which CRC patients have been treated with NSAID three days 
before surgery, showed an increased tumor infiltration of immune cells indicative for an anti-tumor 
T cell response, suggesting that prostaglandins mediated immunological tolerance in CRC 
(Lonnroth et al., 2008). 
 
Inhibitors of matrix metalloproteases (MMP) 
Based on the observation that MMP are involved in many processes underlying the 
regulation of tumor angiogenesis and tumor progression, they might be ideal targets for therapeutic 
intervention (Noel et al., 2008). However, clinical phase III trials with MMP inhibitors (MMPI) have 
failed to demonstrate a beneficial effect in patients with advanced cancers (Coussens et al., 2002; 
Overall and Kleifeld, 2006b). One explanation for such disappointment may be attributable to the 
use of broad-spectrum inhibitors, which not only block pro-tumorigenic MMP but also repress MMP 
whose functions may be anti-tumorigenic. From a scientific perspective, the problems to 
successfully translate preclinical studies to human cancer patients reach beyond species 
differences. Most likely, the early time point of intervention in animal models fundamentally alters 
the response to MMP inhibition as compared to the clinical trials in which late stage tumors have 
been treated. In some clinical trials, patients treated with MMPI fared even worse highlighting the 
need to develop more specific MMPI (Fingleton, 2003; Overall and Kleifeld, 2006a).  
The amino-bisphosphonate zoledronic acid (ZA) inhibits MMP9 activity in preclinicial 
studies in a mouse cervical cancer model (Giraudo et al., 2004) and is already clinically approved 
to treat bone metastasis by blocking osteoclastic activity (Rosen et al., 2003). Direct targeting of 
pro-angiogenic pathways has been recently tested by metronomic (intermittent administration at 
low dosage) treatment with ZA in a clinical phase I study in patients with advanced solid tumors, 
resulting in reduced serum levels of VEGF-A (Santini et al., 2007). Moreover, liposomal delivery of 
the non-amino-bisphosphonate clodronate depleted macrophages in the synovial fluid of 
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rheumatoid arthritis patients and ablated macrophages and repressed tumor angiogenesis in 
mouse tumor transplantation models (Barrera et al., 2000; Zeisberger et al., 2006). However, this 
approach has not been tested in cancer patients yet. 
 
Thalidomide 
 Thalidomide and its derivative lenalidomide belong to a class of immuno-modulatory drugs 
and are now approved for treatment of multiple myeloma in combination with dexamethasone 
(Palumbo et al., 2008). Immuno-modulatory effects include activation of cytotoxic T and NK cells, 
potentially through upregulation of IL2. Thalidomideʼs reported anti-angiogenic activities have also 
set the stage for clinical trials in solid tumors, including prostate cancer and renal cell carcinoma, 
however with moderate success (Amato et al., 2008; Pacheco et al., 2007; Romero et al., 2007). A 
direct anti-angiogenic effect of this class of drugs has been proposed, and a recent report has 
demonstrated inhibitory effects on endothelial sprout formation induced by hypoxia or VEGF (Lu et 
al., 2008). 
 
1.4.5. Conclusions 
Malignant cancers have evolved in a way that they have not only adapted to grow in a 
growth-restraining environment but they also skew their stroma to support their growth and their 
metastatic dissemination in the body. A general theme in the activities of inflammatory stroma cells 
is the enhancement of tumor angiogenesis and the suppression of T cell responses. 
Understanding these events on a cellular and molecular level will allow the design of novel 
therapeutic approaches that a) target the compensatory functions of tumor-infiltrating leukocytes 
under anti-angiogenic treatment regimen and b) support strategies that aim to boost the 
endogenous immune system, for example by re-activating dendritic cell function and adaptive 
immunity. To successfully translate these insights from the bench to the bed-side, more 
experimental work in early-to-intermediate stage tumor models is required, as most of the 
inflammatory events investigated thus far occur mainly in the early phases of tumor progression, 
whereas clinically manifested cancers are treated rather at advanced stages. 
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Table 1. The function of inflammatory cells in mouse models of tumor angiogenesis.  
 
Abbreviations: ↓: reduced, ↑: increased, ↔: unchanged, Ab: antibody, BMC: blood monocyte count, BM: bone marrow, 
BMDC: bone marrow derived cell, BMT: bone marrow transplantation, Ca: carcinoma, cc: chemical carcinogenesis, DC: 
dendritic cell, EC: endothelial cell, IR: irradiation, it: intratumoral, LNM: lymph node metastasis, LVD: lymphatic vessel 
density, Mφ: macrophage, MC: mast cell, MVD: microvessel density, NK: natural killer cell, SCC: squamous cell 
Tumor model Immune 
cells 
Experimental modulation M
V
D
 
T
V
 
T
P
 
Additional parameters 
(change to control/ 
wildtype) 
Ref 
tg: K14-HPV16/E2 SCC Mφ Bisphosphate inhibition of Mφ ↓ ↓ ↓  [1] 
tg: K14-HPV16/E2 SCC Mφ, 
Neutrophils 
Breeding in CCR2-/- mice 
↔ ↔ ↓ itMMP9
+ Mφ ↓, itMMP9+ 
Neutrophils↑ 
[2] 
tt: glioblastoma, BMT BMDC Hif1α-deficient glioblastoma 
cells 
   
itMMP9+ BMDC↓, VEGF-A↓, 
SDF-1↓, perivascular invasion↑ 
[3] 
tt: breast Ca, BMT CD11b+ 
BMDC 
IR of tumors or pre-IR of 
tumor bed, MMP9-deficient 
host and/or bone marrow 
donor 
↓ ↓  
itMMP9+ BMDC↑ (IR vs. non- 
IR); TV↓ MVD↓ in MMP9-/- 
animals, but TV↔ & MVD↔ 
with MMP9+/+ BM 
[4] 
tg: PyMT breast Ca Mφ breeding in Mφ-deficient 
CSF1op/op mice 
 ↔ ↓ 
itMφ↓, Lung metastasis↓; 
rescue by tg MMTV-CSF1 
[5] 
tg: PyMT breast Ca Mφ breeding in Mφ-deficient 
CSF1op/op mice ↓   
correlation of itMφ, malignant 
transition and angiogenic 
switch; rescue by tg MMTV-
VEGF-A 
[6, 
7] 
tt: glioblastoma 
tt: N202, breast Ca 
TEM TEM ablation in transplanted 
BM 
↓ ↓  
TEM but not CD11b+Tie2- 
myeloid cells isolated from 
tumors stimulate angiogenesis 
when co-injected with tumor 
cells 
[8] 
tt: Lewis Lung Ca 
tt: B16 melanoma 
VEGFR1+ 
BMDC 
anti-VEGFR1 Ab, anti-
Integrinα4 Ab, specific 
VEGFR1+ cells vs. VEGFR1- 
BMT 
   
reduced or abolished lung 
metastases  
[9] 
tt: F9 teratocarcinoma 
tt: A673 rhabdomyosarcoma  
Mφ Mφ-ablation by liposome-
encapsulated clodronate  
↓ ↓  
itMφ ↓; MVD correlation with 
itMφ 
[10] 
tt: Lewis Lung Ca Mφ anti-Integrinα4 Ab ↓ ↓  itMφ ↓ [11] 
tt: OCUM2 gastric Ca Mφ Cyclooxygenase-2 inhibition  ↓  LVD↓, LNM↓, VEGF-C↓ [12] 
tt: Panc02 pancreas Ca 
tt: CT26 colon Ca 
Mφ anti-PlGF Ab, liposome-
encapsulated clodronate Mφ 
ablation 
↓ ↓  
BMC↓, EC apoptosis↑; itMφ ↓, 
LNM↓, LVD↓, VEGF-C↓ [13] 
tt: MC26 colon Ca 
tt: Lewis Lung Ca 
MDSC co-injection of MC26 with 
splenic Gr1+CD11b+ MDSC 
from tumor bearing mice ↑ ↑  
hypoxia↓, tumor cell 
apoptosis↓, pericyte 
coverage↑, effects not seen 
with MDSC from non-turmor 
bearing mice 
[14] 
tt: MCA26 colon Ca MDSC sKitL-deficient colon cancer 
cells; anti-cKit Ab  ↓   
blood MDSC↓, tumor T cell 
proliferative capacity↑, 
itMDSC↓ 
[15] 
tt: A673 rhabdomyosarcoma 
tt: HM7 colon Ca 
MDSC anti-Bv8 Ab 
↓ ↓  
blood MDSC↓, itMDSC↓, 
enhancement of anti-VEGF and 
Cisplatin treatment 
[16] 
tg: Rip1Tag2 insulinoma Neutrophils anti-Gr1 Ab 
 ↔ ↓ 
itMMP9+ Neutrophils↓, ligated 
VEGFR2↓ 
[17] 
tg: K14-HPV16 SCC Granulocyt
es, MC, B 
cells 
breeding in Rag1-/- mice (no 
adaptive immunity) 
 ↓ ↓ 
itMC↓, itGranulocytes↓, itMMP2 
and MMP9 activity↓, 
keratinocyte proliferation↓; 
rescue by B cell transfer or 
serum injection isolated from 
K14-HPV-16 wt tumor bearing 
mice 
[18] 
tg: pIns-mycERTAM inducible 
     insulinoma 
MC inhibition of MC degranula-
tion by cromolyn, breeding in 
MC-deficient KitW-sh/W-sh mice 
↓   
tumor cell proliferation↔, EC 
proliferation↓, tumor cell 
apoptosis↑, hypoxia↑ 
[19] 
cc: SCC  MC tg K14-endostatin mice ↓ ↔ ↓ itMC↓, TI↔, LVD↓, LNM↓; 
VEGFR3↓, VEGF-C↓  
[20] 
tt: B16 melanoma 
tt: MB49 bladder Ca 
Neutrophils
, DC, NK, 
TC 
hematopoietic deletion of 
STAT3 in Mx1-
Cre;STAT3loxP/loxP mice, STAT3 
inhibition by CPA7 
 ↓  
DC activation↑, cytolytic 
activity of neutrophils and NK 
cells↑, itTC↑ itTreg↓ 
[21] 
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carcinoma, TEM: Tie2 expressing monocycte, tg: transgenic, TC: T cell, Treg: regulatory T cell, tt: tumor transplantation, 
TP: tumor progression, TV: tumor volume, TI: tumor incidence, wt: wild-type 
 
References: [1]: (Giraudo et al., 2004), [2]: (Pahler et al., 2008), [3]: (Du et al., 2008), [4]: (Ahn and Brown, 2008), 
[5]: (Lin et al., 2001), [6]: (Lin et al., 2007), [7]: (Lin et al., 2006), [8]: (De Palma et al., 2005), [9]: (Kaplan et al., 
2005), [10]: (Zeisberger et al., 2006), [11]: (Jin et al., 2006), [12]: (Iwata et al., 2007), [13]: (Fischer et al., 2007), 
[14]: (Yang et al., 2004), [15]: (Pan et al., 2008), [16]: (Shojaei et al., 2007b), [17]: (Nozawa et al., 2006), [18]: 
(de Visser et al., 2005), [19]: (Soucek et al., 2007), [20]: (Brideau et al., 2007), [21]: (Kortylewski et al., 2005) 
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2. Aim of the study 
  
The critical importance of the tumor stroma during carcinogenesis has only been appreciated 
during the last decade. Immune cells, mainly derived from the bone marrow, are an important 
component of the tumor stroma and immune cell infiltration into tumors is often indicative for pro-
tumorigenic inflammation. 
 The objective of the studies presented here was to define the functional role of bone 
marrow-derived cells in the processes of angiogenesis and lymphangiogenesis in the Rip1Tag2 
carcinogenesis models. I analyzed the spatial and temporal interaction of bone marrow-derived 
cells with the tumor by employing lineage tracing strategies, including bone-marrow transplantation 
and Cre/Lox technology. High-resolution confocal microscopy and flow cytometry allowed me to 
gain insight into the dynamics of the tumor stroma composition and the interactions between tumor 
and stroma cells. 
 
I particular, I set out to investigate the following research aims:  
 
Aim 1: What is the extent and significance of bone marrow-derived immune cell infiltration into 
tumors of Rip1Tag2 mice? 
 
Aim 2: What is the importance of bone-marrow derived cells in supporting the growth of either 
tumor, endothelial or lymphendothelial cells via paracrine actions using loss-of-function 
approaches? 
 
Aim 3: What is the range of non-hematopoietic phenotypes that bone marrow-derived cells can 
acquire in tumors? 
  
A better understanding of tumor – stroma interactions holds strong promise to funnel into the 
development of novel strategies for the treatment of cancer. Bone marrow-derived cells as crucial 
components of growing cancers might be an attractive target of intervention in order to prevent 
metastasis and resistance to therapy. 
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3. Materials and Methods 
 
Specific Materials and Methods are described in the chapters “4.2. Myeloid cells contribute to 
tumor lymphangiogenesis” and “4.4. Improved mouse model of pancreatic β-cell carcinogenesis.” 
 
Chemicals  
 General chemicals used were all purchased from SIGMA-ALDRICH (Buchs, Switzerland) 
unless otherwise stated. 
 
Laboratory mice/ mouse strains 
 Animals were fed regular laboratory chow (M/R Extrudat 3436EX.F12, Kliba Navag) and 
water ad libitum and were housed in a 12 h day and night cycle. Animals were kept under specified 
pathogen-free conditions and regularly checked for pathogens. All animal experiments described 
were approved by the Cantonal Veterinary office Basel-Stadt and covered by the licenses 1878 
(organ biopsies), 1907 (tumor transplantation), 1908 (pharmacological treatments including 
ClodroLip and Luciferin injections), 2137 (bone marrow transplantations). 
  
Tissue processing for histology  
 For organ biopsies, mice were euthanized by cervical dislocation and organs quickly 
removed. Organs were either fixed at 4° C in 4% phosphate buffered paraformaldehyde (PFA) for 
12 hours and then embedded in paraffin after ethanol/xylene dehydration; alternatively organs 
were fixed at 4°C in 4% PFA for 2h, and cryo-preserved for 10 hours in 20% sucrose in PBS prior 
to embedding in OCT freezing matrix. Occasionally, organs were frozen without prior fixation in 
OCT freezing matrix. Paraffin slides were cut 5µm thick and rehydrated according to standard 
protocols. For immunohistochemical (IHC) stainings of PFA fixed, paraffin embedded specimens, 
antigen epitopes were retrieved by boiling slides in 10mM Na-Citrate buffer (pH6.0) for 10ʼ in a 
microwave oven, endogenous peroxidase was quenched by treatment with 3% H2O2 for 10 
minutes. Cryosections were cut 7µm thick, postfixed for 5ʼ in either 4% PFA or 70% ethanol and 
dried for 30ʼ prior to rehydration in PBS. 
 
Toluidine blue staining for Mast cells 
 Deparaffinize and rehydrate PFA fixed/ paraffin embedded organ sections. Stain Toluidene 
Blue working solution (0.1% (w/v) Toluidine Blue O, 0.9% (w/v) NaCl, 7% ethanol (v/v)) for 2 
minutes, rinse in ddH20 3x, dehydrate quickly thought 95% and absolute ethanol, clear in xylene. 
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Mast cells should stain red-purple (metachromatic staining) and the background stain blue 
(orthochromatic staining). 
Antibodies 
 Antibodies used are specified under the respective manuscripts. 
 
Fluorescence activated cell sorting (FACS) 
 All FACS analyses were performed on a Becton Dickinson FACSCanto II Flow Cytometer 
using FACS DIVA software (Becton Dickinson, Allschwil, Switzerland). 
  
Oligonucleotides 
 Oligonucleotides used for cloning and/ or quantitative real-time PCR (qPCR) are described 
in the respective manuscripts. qPCR primers were designed using Universal ProbeLibrary Assay 
Design Center (http://www.roche-applied-science.com/sis/rtpcr/upl/acenter.jsp?id=030000) or by 
PrimerExpress 1.5 (Applied Biosystems). 
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4. Results 
 
4.1. Infiltration of immune cells into tumors of Rip1Tag2 mice 
 
In order to assess the infiltration of immune cells into Rip1Tag2 tumors, we set out to quantify the 
infiltration by immune cells using immunofluorescence/ histology and flow cytometry. The following 
markers were used to describe the tumors “infiltrome”. 
 
 CD45: pan leukocyte marker 
 CD3ε: pan T-cell marker 
 CD19: pan B-cell marker 
 CD11b: marker for all myeloid cells (including macrophages, monocytes and granulocytes) 
 F4/80: phagocytic macrophage marker 
 Gr-1: granulocyte marker 
 Toluidine blue staining: mast cell 
 
 As can be seen in Figure 9, a robust infiltration of immune cells is evident in tumors of 
Rip1Tag2 mice. CD45+ cells constitute about 9.8% of the tumors total cell number. Myeloid cells 
(CD11b+) constitute 5.8% of the cells in the tumors and are the largest sub-type of infiltrating 
immune cells. T-cells (CD3) contribute 3.4% of cells. B cells were hardly found in Rip1Tag2 
tumors, indicating that blood (which contains 5-10% B cells) is not a major contaminant of tumor 
cell preparations for FACS analysis. The myeloid cells further split into monocytes/ macrophages 
(CD11b+/F4/80+) and granulocytes (CD11b+/Gr-1+), which each constitute 1-2% of cells as 
analyzed by FACS. 
 In contrast to histological analyses, where small tumor foci (< 1mm) can be analyzed, FACS 
analyses can only be done with macroscopic tumors (> 1.5mm). Therefore, one cannot directly 
compare the results obtained by histology and by FACS. Amazingly, whereas in FACS CD11b 
gave an excellent signal for cell preparations from tumors, in histology CD11b was hardly detected 
at intra-tumoral locations (but clearly extratumoral). In contrast, cells positive for F4/80, a marker 
for differentiated phagocytic macrophages, were much more abundant in histology than when 
analyzed by FACS. This could be due to the different processing techniques, which unfold different 
epitopes recognized by the respective antibodies.  
 Even though T cells were quite abundant in macroscopic tumors when analyzed by FACS, 
similarly to CD11b, we could not detect CD3ε positive cells in tumors by histology, whereas in 
lymph nodes of the very same section, CD3ε positive cells were clearly detectable. It has 
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previously been shown that the adaptive immune system does not play a major role in 
tumorigenesis of Rip1Tag2 mice, as crossing of Rip1Tag2 mice with Rag1-/- mice, lacking adaptive 
immunity, did not impair tumorigenesis markedly (Casanovas et al., 2005). 
 Mast cells, identified via a red-purple staining after Toluidine blue stain, were never 
detected by histology within tumors and were only rarely found in connective tissue (inset in Figure 
9). Mast cell infiltration has been identified as an important determinant in the establishment of 
tumor vasculature in a c-Myc induced insulinoma model (Soucek et al., 2007). Fundamental 
differences in the cytokines produced by the neoplastic lesions might be one reason for the 
differential infiltration by mast cells between Rip1Tag2 and c-Myc induced insulinomas. 
 As myeloid cells represent the most abundant immune cell compartment in Rip1Tag2 
tumors, we set out to characterize in further detail the contribution of this immune cell compartment 
to tumorigenesis in Rip1Tag2 mice. 
 
Figure 9. The immune cell infiltration into tumors of Rip1Tag2 was studied by histology and/ or flow cytometry. 
Pancreata of 12-13 week old tumor mice were either analyzed via immuno-fluorescent staining of tissue sections or 
tumor single cell preparations (obtained as described under 4.2.5.) were analyzed by FACS. CD11b+ myeloid cells 
constitute the most abundant immune cell type found in Rip1Tag2 tumors. Mast cells, identified by toluidine blue staining, 
were not found in tumors but only in connective tissue (inset). Arrows in FACS dot plot indicate the marker used in the 
respective axis. Numbers shown are the mean +/- standard deviation of 6 tumors analyzed (from 3 different mice), as 
found in the green shaded area. T: tumor. Scale bar: 100µm. 
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4.2.1. Abstract 
 The formation of new blood vessels (angiogenesis) and lymphatic vessels 
(lymphangiogenesis) promotes tumor outgrowth and metastasis. Previously, it has been 
demonstrated that bone marrow-derived cells (BMDC) can contribute to tumor 
angiogenesis. However, the role of BMDC in lymphangiogenesis has largely remained 
elusive. Here, we demonstrate by bone marrow transplantation/reconstitution and genetic 
lineage tracing experiments that BMDC integrate into tumor-associated lymphatic vessels 
in the Rip1Tag2 mouse model of insulinoma and in the TRAMP-C1 prostate cancer cell 
transplantation model. The results indicate that bone marrow-derived, integrated cells 
originate from the myelomonocytic lineage. Conversely, pharmacological depletion of 
tumor-associated macrophages reduces lymphangiogenesis. No cell fusion events are 
detected by genetic tracing experiments. Rather, the phenotypic transition of myeloid cells 
into lymphatic endothelial cells is recapitulated in an in vitro tube formation assay. The 
data indicate that myeloid cells can trans-differentiate into lymphatic endothelial cells and 
thus contribute to tumor lymphangiogenesis. 
 
4.2.2. Introduction 
 In the adult, the vascular network is usually expanded and remodeled by sprouting and 
proliferation of endothelial cells from pre-existing blood and lymphatic vessels, processes called 
angiogenesis and lymphangiogenesis, respectively. In addition to tissue resident cell types, several 
studies have demonstrated that BMDC are recruited to angiogenic sites to support the 
establishment of new vessels (De Palma et al., 2005; Grunewald et al., 2006; Lyden et al., 2001). 
BMDC are typically sub-classified into haematopoietic progenitor cells (HPC) and endothelial 
progenitors cells (EPC). In various tumor models, HPC have been shown to contribute to blood 
vessel angiogenesis by secreting angiogenic factors and proteases required for the activation of 
latent forms of angiogenic factors (Coussens et al., 2000; Cursiefen et al., 2004). HPC have also 
been implicated in the preparation of a pre-metastatic niche in organs that are colonized by 
disseminating cancer cells (Kaplan et al., 2005). EPC on the other hand have been shown to 
directly integrate into growing blood vessel walls, however, to varying extents, ranging from 0 to 
50% and thus raising questions about their functional contribution to blood vessel angiogenesis in 
various physiological and pathological conditions (De Palma et al., 2005; Garcia-Barros et al., 
2003). Recently, it has been reported that also cells of the myeloid lineage are able to differentiate 
into bona fide blood endothelial cells (Bailey et al., 2006). 
 Only few studies have addressed the role of BMDC in lymphangiogenesis. Haematopoietic 
stem cells have recently been shown to contribute to normal lymphatic endothelium in liver, 
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stomach and intestine under physiological conditions (Jiang et al., 2008). More specifically, 
myeloid cells present in the murine inflamed conjunctiva have been found to express the lymphatic 
endothelial specific marker VEGFR3 and to integrate into lymphatic structures that develop in 
mouse cornea transplants (Hamrah et al., 2003; Maruyama et al., 2005). During the rejection of 
human kidney transplants, another inflammatory process, lymphatic vessels within the rejected 
organs contained host-derived lymphatic endothelial cells, suggesting the existence of lymphatic 
endothelial progenitor cells (Kerjaschki et al., 2006). Experiments employing a cornea 
angiogenesis model and a syngeneic fibrosarcoma transplantation model have also revealed the 
incorporation of BMDC in newly formed lymphatic vessels (Religa et al., 2005). Finally, decreased 
macrophage numbers appear to cause reduced lymphangiogenesis and impaired wound healing in 
diabetic mice (Maruyama et al., 2007). However, the contribution of BMDC to tumor 
lymphangiogenesis is controversial. Transplantation of Lewis Lung Carcinoma or B16-F1 
melanoma cells in syngeneic mice has not revealed any integration of BMDC into newly formed 
lymphatic vessels (He et al., 2004). In contrast, employing two different murine tumor models and 
an in vitro differentiation assay, we demonstrate here that cells derived from the myeloid lineage 
physically contribute to tumor lymphvasculogenesis.   
 
4.2.3. Results 
BMDC integrate into tumor lymphatics 
We have employed the Rip1Tag2 (RT2) mouse model of multistage pancreatic β-cell 
carcinogenesis to investigate the contribution of BMDC to tumor angiogenesis and 
lymphangiogenesis (Hanahan, 1985). RT2 transgenic mice recapitulate hallmarks of tumor 
progression, including the regulated onset of tumor angiogenesis, the functional contribution of 
tumor-infiltrating immune cells to a pro-angiogenic tumor microenvironment, and the transition from 
adenoma to carcinoma (Bergers et al., 2000; Nozawa et al., 2006; Perl et al., 1998). When crossed 
to Rip1VEGF-C (VC) or Rip1VEGF-A (VA) mice, double-transgenic RT2;VC mice develop tumors 
with high peritumoral lymphangiogenesis and lymph node metastasis (Mandriota et al., 2001), 
whereas double-transgenic RT2;VA mice exhibit an earlier onset of tumor angiogenesis and 
accelerated tumor growth in the absence of any lymphangiogenesis and metastasis (Gannon et al., 
2002). 
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Figure 10. Bone marrow transplantation strategies. (A) For total bone marrow transplantations, 5 x 106 T cell-depleted 
total bone marrow cells from donor mice were injected i.v. into lethally irradiated (2 x 550 cGy) mice, as indicated. Semi-
lethally irradiated (450 cGy) mice were injected with FACS-sorted 4 x 105 CD11b+ myeloid cells, 4 x 105 CD19b+ B-cells 
or 4 x 104 common myeloid progenitors (CMP) cells. 4 x 105 CD11b+ myeloid cells were also transferred into non-
irradiated mice. After 3-8 weeks mice were sacrificed, engraftment of transplanted bone marrow was evaluated by FACS 
and pancreata were analyzed by histology for the presence of bone marrow-derived cells at the tumor site. (B) 
Schematic illustration of syngeneic TRAMP-C1 tumor experiments. 5x105 TRAMP-C1 cells were injected into the flank of 
either C57BL/6 previously reconstituted with bone marrow of b-actin-GFP transgenic mice or bone marrow of double-
transgenic CD11b-Cre;Z/EG mice, and tumors were allowed to grow for 3 to 4 weeks. FACS analysis was used to 
assess bone marrow reconstitution or Cre recombinase-mediated GFP expression, respectively. Histological sections 
from TRAMP-C1 tumors were analyzed by immunofluorescence for the presence of GFP+ cells. (C-E) Flow cytometry-
based strategy for cell sorting. (C) Within a scatter gate excluding lymphocytes, CD11bhigh/ GFPhigh cells were isolated by 
FACS. (D) CD19+ was used as marker for the isolation of B lymphocytes. (E) CMP cells were sorted as lin-/ Sca-1-/ 
IL7Ra-/ cKit+ as described in Methods. 
 
 To investigate whether BMDC integrate into tumor blood and lymphatic vasculature in the 
RT2 model, lethally irradiated RT2, RT2;VA and RT2;VC mice were transplanted with bone marrow 
isolated from actin-GFP transgenic mice (Figure 10A). FACS analysis of peripheral blood (PB) 
showed efficient hematopoietic reconstitution with more than 90% chimerism (data not shown). 
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Immunofluorescence analysis of tumor sections revealed that the proportion of GFP+ tumor-
infiltrating BMDC was invariant in the range of 3.5% of total cellularity, independent of the 
transplantation of single transgenic RT2 mice or double-transgenic mice expressing either VEGF-A 
or C (Figure 11). Increased serum levels of these growth factors are thought to mediate 
mobilization and recruitment of BMDC to sites of neo-angiogenesis as shown for VEGF-A 
(Grunewald et al., 2006; Hattori et al., 2001). Yet, despite the high expression of the angiogenic 
factors by tumor cells of double-transgenic RT2;VA and RT2;VC mice, specific ELISA analysis did 
not reveal any of these growth factors in the serum of these mice, suggesting that they are locally 
sequestered and are not affecting the recruitment of BMDC (data not shown). From the GFP+ 
BMDC within the tumors, approximately 80% were F4/80+ macrophages (Figure 11). 
Immunofluorescence co-staining for F4/80 and the hyualuronan receptor LYVE-1 identified LYVE-
1+ macrophages in the tumor periphery with relatively large size compared to intra-tumoral 
macrophages (data not shown) (Cho et al., 2007; Schledzewski et al., 2006). In contrast, 
Podoplanin or Prox-1 were not expressed by tumor-associated macrophages (TAM). These 
observations instructed us to carefully differentiate between tumor lymphatic endothelium, defined 
as a continuous LYVE-1+/Prox-1+/Podoplanin+ and CD31+ vessel lining, and isolated, peritumoral 
LYVE-1+ macrophages. 
 
 
Figure 11. Infiltration of transplanted BMDC in RT2 tumors. Lethally irradiated RT2, RT2;VA and RT2;VC mice were 
transplanted with GFP-labeled bone marrow, as indicated. No significant differences could be observed in tumor 
infiltrating bone marrow-derived cells between the different angiogenic factor-expressing tumors. Approximately 3-3.5% 
of tumor-constituting cells were GFP+ (green) and thus bone marrow-derived, and approximately 80% of GFP+ cells co-
expressed the monocyte/macrophage marker F4/80 (red). White rectangles indicate area of higher magnification shown 
below, with merge picture on the left, F4/80 in the middle, and GFP on the right. F4/80+ macrophages are either donor-
derived (co-expressing GFP, indicated by arrows) or host-derived (no GFP expression, arrowheads). 3 mice per 
genotype with 16-29 tumors each were analyzed. DAPI was used for nuclear counterstaining (blue). Scale bar: 50 µm. 
 
 To assess the potential contribution of BMDC to intra-tumoral blood vessels, confocal 
microscopy and subsequent 3D reconstitution analysis were performed on pancreatic sections of 
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transplanted RT2 and RT2;VA mice stained for the endothelial marker CD31 and for GFP. Bone 
marrow-derived, GFP+ cells were mainly found in close proximity of blood vessels (Figure 12, arrow 
heads). In very rare cases (< 0.4% of blood endothelial cells; Figure 12, arrow), GFP+/CD31+ 
double-positive cells could be observed, indicating that in the Rip1Tag2 model the direct 
incorporation of BMDC into the blood vasculature is negligible. 
 
 
Figure 12. Rare integration of BMDC into blood vessels of RT2 tumors. 20 µm tumor sections of RT2 (3 mice) and 
RT2;VA (2 mice) mice transplanted with GFP-labeled bone marrow were stained for the endothelial marker CD31 (red) 
and GFP (green) and analyzed by confocal microscopy and subsequent 3D reconstitution. Different angles of a 
representative 3D reconstituted tumor section are shown. As indicated by arrowheads, GFP+ cells were mainly found in 
close proximity of blood vessels. As indicated by the arrow, cells co-expressing GFP and CD31 were rarely detected in 
this experimental setting (7 CD31+/GFP+ cells out of 2141 CD31+ cells). Insets represent magnifications of a rare 
GFP/CD31 double-positive cell. DAPI stains nuclei (blue). Scale bar: 20 µm. 
 
 In contrast, BMDC had incorporated into lymphatic vessels surrounding VEGF-C- 
expressing β cell tumors of transplanted RT2;VC mice. Pancreatic sections from these mice were 
stained for the three lymphatic markers Podoplanin, Prox-1 and LYVE-1 and for GFP. Confocal 
imaging revealed that 3% of Podoplanin+ tumor lymphatic endothelial cells (TLEC) as well as 3.5% 
of Prox-1+ or LYVE-1+ TLEC co-expressed GFP, indicating that about 3.3% of tumor-surrounding 
lymphatic endothelial cells are derived from the bone marrow (Figure 13A). Routine laser scanning 
confocal microscopy analysis on 7-20 µm thick sections with subsequent 3D reconstitution enabled 
us to exclude false double-positive cells, as shown in supplemental videos 1 & 2 (on attached CD). 
Furthermore, VE-cadherin, an endothelial-specific adherens junction molecule, reported to connect 
lymphatic endothelial cells in lymphatic vessels (Baluk et al., 2007), was expressed on host as well 
as on bone marrow-derived TLEC, further demonstrating a functional integration of BMDC into 
tumor lymphatic vasculature (Figure 14). Note that in contrast to blood endothelial cells, where VE-
cadherin usually clusters at cell-cell junctions (Figure 14, arrows), VE-cadherin staining on 
lymphatic endothelium is found to be more homogenously distributed throughout the lymphatic 
endothelial cell membranes. 
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Figure 13. BMDC integrate into tumor-associated lymphatic vessels. (A) Lethally irradiated RT2;VC mice (5 mice) were 
reconstituted with GFP-labeled bone marrow. 7-20 µm histological pancreatic sections were stained for the lymphatic 
markers Podoplanin, Prox-1, LYVE-1 and for GFP as indicated and analyzed by confocal microscopy and subsequent 
3D reconstitution. Two representative tumor sections per lymphatic marker are shown. 3% of Podoplanin+ TLEC (7 
Podoplanin+/GFP+ cells out of 227 Podoplanin+ cells) as well as 3.5% of Prox-1+ or LYVE-1+ TLEC (14 Prox-1+/GFP+ 
cells out of 400 Prox-1+ cells and 17 LYVE-1+/GFP+ cells out of 485 LYVE-1+ cells) are bone marrow-derived. (B) 
TRAMP-C1 tumors were subcutaneously implanted in C57BL/6 mice (4 mice) previously reconstituted with GFP-labeled 
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bone marrow. 7µm histological tumor sections were stained as in (A). 4.1% of Podoplanin+ TLEC (14 Podoplanin+/GFP+ 
cells out of 334 Podoplanin+ cells) as well as about 2.8% of LYVE-1+ TLEC (11 LYVE-1+/GFP+ cells out of 395 LYVE-1+ 
cells) are bone marrow-derived. Arrows indicate double-positive cells and arrowheads indicate double-positive cells 
shown in inset magnifications. Insets show merged and individual channels. DAPI stains nuclei (blue). Scale bars: 40 
µm. (C) Tumors of GFP-labeled bone marrow-transplanted RT2;VC mice or TRAMP-C1 tumors grown in GFP-labeled 
bone marrow-transplanted C57BL/6 mice were enzymatically digested (3 mice each). Single cell suspensions were 
stained for the pan-endothelial marker CD31 and the lymphatic endothelial marker Podoplanin and analyzed by FACS 
(left panels). 9.4 +/- 4.1% (RT2;VC) and 10 +/- 4.6% (TRAMP-C1) of CD31+/ Podoplanin+ TLEC were GFP+, indicating 
their bone marrow origin (middle left panels). As control, the anti-Podoplanin antibody was omitted resulting in no 
separation between TLEC and TBEC (middle right panels). Furthermore, similar analysis of tumors grown in non-
transplanted mice showed no GFP+ cells within the TLEC population (right panels).  
 
Figure 14. BMDC 
integrated into tumor 
lymphatics express VE-
cadherin. A representative 
tumor section from RT2;VC 
mice previously 
reconstituted with GFP-
labeled bone marrow was 
stained for the lymphatic 
marker LYVE-1 (purple), for 
the cell junction molecule 
VE-cadherin (red), and for 
GFP (green) and analyzed 
by confocal microscopy and 
subsequent 3D 
reconstitution. As indicated 
by arrowheads and shown 
magnified in insets, VE-
cadherin expression, 
indicative for homophilic 
cell-cell contact, is observed 
between bone marrow-
derived (BMD TLEC) and 
host-derived TLEC (Host 
TLEC). Note the continuous 
VE-cadherin staining 
between lymphatic 
endothelial cells in contrast 
to the cell-cell contact 
restricted staining of blood 
endothelial cells depicted by 
arrows. DAPI was used for 
nuclear counterstaining 
(blue). BV: blood vessel. 
Scale bars: 20 µm. 
 
 To expand the significance of the findings in the RT2 insulinoma model as well as to test 
whether the observed integration of BMDC occurred also in the absence of artificially expressed 
VEGF-C, we employed the TRAMP-C1 murine prostate adenocarcinoma cell line previously shown 
to induce robust tumor lymphangiogenesis upon transplantation into syngeneic C57BL/6 mice 
(Gingrich et al., 1996; Ozerdem, 2006). TRAMP-C1 cells were subcutaneously injected into one 
flank of C57BL/6 mice that had been previously reconstituted with GFP+-labeled bone marrow 
(Figure 13B). In the resulting tumors, the number and morphology of BMDC that had integrated in 
tumor lymphatic vessels were comparable to the results obtained with RT2;VC mice. GFP+ cells 
were detected in lymphatic vessels staining for LYVE-1 and Podoplanin (Figure 13B) and 
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constituted 2.8% of LYVE-1+ and 4.1% of Podoplanin+ cells within lymphatic vessel structures. 
GFP expression was also detected in Prox-1+ TLEC, however to a lower extent as compared to 
LYVE-1 or Podoplanin. This might be explained by the fact that overall only a subset of LYVE-1+ 
TLEC express Prox-1 (data not shown).  
 To validate the results of the confocal microscopical analysis, single cell suspensions of 
tumors obtained from GFP+ bone marrow-transplanted or control non-transplanted mice were 
analyzed by FACS for the presence of GFP+ TLEC (Figure 13C). TLEC were identified by co-
expression of CD31 and Podoplanin (Figure 13C, left panels). Indeed, 9.4 +/- 4.1%  and 10 +/- 
4.6% of TLEC in tumors from RT2;VC and TRAMP-C1 mice , respectively, were GFP+, confirming 
the results obtained by confocal immunofluorescence microscopy analysis. As expected, GFP+ 
TLEC were not observed in non-transplanted mice, documenting the specificity of the FACS 
analysis (Figure 13C, right panels). In order to exclude the detection of false positive signals by cell 
duplets containing GFP+ BMDC and Podoplanin+ TLEC that would appear as 
CD31+/Podoplanin+/GFP+ triple-positive cells, such events were rigidly excluded by forward scatter 
pulse width (data not shown). 
 To investigate whether BMDC integration into newly formed lymphatic structures occurred 
only in a tumor microenvironment, non tumor-bearing, single-transgenic VC mice were 
transplanted with GFP-labeled bone marrow. Notably, no GFP+ cells were found incorporated into 
the lymphatic vessels surrounding normal islets of Langerhans in these mice (Mandriota et al., 
2001) (Figure 15). Increasing the levels of VEGF-A by transgenic expression of VEGF-A in VA;VC 
double transgenic mice also did not provoke an integration of BMDC into the lymphatic vasculature 
surrounding the islets (Figure 15). These results demonstrate the ability of BMDC to incorporate 
into actively growing lymphatic vessels, yet only in a tumor microenvironment. 
Figure 15. BMDC do not integrate into lymphatic vessels 
surrounding normal islets. VC mice (2 mice) or VA;VC (2 
mice) were transplanted with GFP-labeled bone marrow. 
Pancreatic sections of transplanted mice were stained for 
the lymphatic markers LYVE-1 (red) and GFP (green) and 
analyzed by confocal microscopy. Two representative tumor 
sections per experiment are shown. No GFP+ cells were 
found integrated into islet surrounding lymphatic structures, 
indicating that BMDC did not contribute to de novo 
lymphangiogenesis under non-tumorigenic conditions. DAPI 
stains nuclei (blue). Scale bar: 20 µm. 
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Integrated BMDC are of myeloid origin 
 To investigate whether BMDC contributing to tumor lymphangiogenesis express 
macrophage markers, pancreatic sections of transplanted RT2;VC mice were stained for the 
lymphatic marker LYVE-1, the macrophage marker F4/80 and GFP (Figure 16A). Triple-positive 
GFP+/LYVE-1+/F4/80+ cells were readily observed in lymphatic vessels surrounding the tumors. 
Interestingly, not all BMDC that had integrated into the lymphatic vasculature expressed F4/80, 
suggesting that macrophages physically contributed to tumor lymphatics but eventually lost their 
macrophage features upon integration, as previously reported (Maruyama et al., 2007). 
 
Figure 16. Myeloid origin of bone marrow-derived TLEC. 
(A) 20 µm histological pancreatic sections of GFP-labeled 
bone marrow-transplanted RT2;VC mice were stained for 
the lymphatic marker LYVE-1 (purple), for the 
monocyte/macrophage marker F4/80 (red), and for GFP 
(green) as indicated and analyzed by confocal microscopy 
and subsequent 3D reconstitution. Two representative 
tumor sections are shown. Left panel: BMDC that have 
integrated into tumor lymphatics express the macrophage 
marker F4/80. Arrows indicate triple positive cells and the 
arrowhead indicate a triple-positive cell shown in inset 
magnifications. Right panel: not all integrated cells 
express F4/80. The arrowhead indicates an integrated cell 
(LYVE-1+/GFP+) that does not express F4/80. Inset 
magnifications of this double-positive cell are shown. 
Insets show merged and individual channels. (B) 7-20 µm 
histological pancreatic sections of RT2;VC mice 
transplanted with bone marrow isolated from either 
CX3CR1+/GFP (2 mice) or CD11bCre;Z/EG mice (3 mice) 
were stained for the lymphatic markers Podoplanin or 
LYVE-1 (red) as well as for GFP (green) and analyzed by 
confocal microscopy. Two representative tumor sections 
per lymphatic marker are shown. In both transplantation 
settings, myeloid cells were found integrated into the 
lymphatic vasculature surrounding the tumors. 
Arrowheads indicate double-positive cells shown in inset 
magnifications (first inset: merged channels, second and 
third insets: red and green channel, respectively). DAPI 
stains nuclei (blue). Scale bars: 20 µm. (C) Tumors of 
RT2;VC mice were enzymatically digested. Single cell 
suspension was stained for the pan-endothelial marker 
CD31, the lymphatic endothelial marker LYVE-1 and the 
myeloid marker CD11b and analyzed by FACS (left 
panel). 6.2 +/- 4.5% of CD31+/ LYVE-1+ TLEC co-
expressed CD11b (right panel). 
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 To assess whether cells of the myeloid lineage were able to incorporate into tumor 
lymphatic vessels, we performed cell lineage tracing experiments. First, lethally irradiated RT2;VC 
mice were transplanted with bone marrow isolated from either CX3CR1+/GFP knock-in mice or 
CD11b-Cre;Z/EG double-transgenic mice. In CX3CR1+/GFP mice, the coding region for EGFP had 
been inserted in the CX3CR1 gene, a receptor expressed mainly by monocytes and to a minor 
extent by a subset of lymphocytes, resulting in monocyte-specific GFP expression (Jung et al., 
2000) (Figure 17A). The Z/EG transgene contains, under the control of an ubiquitous promoter, a 
lacZ gene/stop cassette flanked by loxP recombination sites and followed by the coding region for 
EGFP (Novak et al., 2000). When crossed to CD11b-Cre mice, expressing Cre recombinase under 
the control of the myeloid specific CD11b promoter, Cre-mediated excision of the lacZ gene/stop 
cassette induced permanent GFP expression exclusively in cells having passed through a CD11b-
expressing, myeloid stage (Ferron and Vacher, 2005). Pancreatic sections of transplanted RT2;VC 
were stained for the lymphatic markers Podoplanin or LYVE-1 and for GFP, and double-positive 
cells were scored. In both transplantation settings, GFP+ cells were found integrated into the tumor 
lymphatic vasculature, demonstrating that cells of the myeloid lineage physically contributed to 
tumor lymphangiogenesis (Figure 16B). In addition, FACS analysis of tumors from non-
transplanted RT2;VC mice revealed that some bona fide CD31+/ LYVE-1+ TLEC express the 
myeloid marker CD11b (Figure 16C), again confirming the microscopical analysis and indicating 
that during active tumor lymphangiogenesis TLEC may express a myeloid marker. 
 To test whether CD11b+ cells indeed integrated into tumor lymphatics without prior bone 
marrow transplantation, TRAMP-C1 cells were transplanted in CD11b-Cre;Z/EG mice (Figure 10B). 
Specific Cre-mediated recombination within the myeloid lineage of these mice was confirmed by 
FACS analysis of peripheral blood cells (Figure 17B). In the resulting tumors, GFP+ cells were 
found incorporated into LYVE-1+ and Podoplanin+ lymphatic vessels (Figure 18A). Triple staining 
for LYVE-1, Prox-1 and GFP further showed that formerly myeloid cells simultaneously expressed 
two lymphatic markers (Figure 18B, arrowhead), demonstrating their differentiation towards a 
lymphatic endothelial phenotype. These experiments also revealed that integration occurred 
independently of prior irradiation, which had been previously reported to increase macrophage 
infiltration in human cancer (McDonnell et al., 2003). No GFP+ cells were found incorporated into 
lymphatic vessels of tumor-free skin or intestine (data not shown), further highlighting the critical 
role of the tumor environment in stimulating integration. 
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Figure 17. FACS analysis of 
the lineage tracing experiments. 
(A) FACS analysis of peripheral 
bood cells from a 
representative RT2;VC mouse 
reconstituted with bone marrow 
isolated from CX3CR1+/GFP 
mice indicates GFP expression 
mainly in CD11b+ cells. A minor 
fraction of CD19+ B-cells and 
CD3+ T-cells also expressed 
GFP. (B) FACS analysis of 
peripheral blood cells from 
CD11b-Cre;Z/EG mice 
transplanted with TRAMP-C1 
tumors indicates effective Cre-
mediated recombination and 
subsequent expression of GFP 
predominantly in F4/80+ 
monocytes and to lesser extent 
in B or T lymphocytes. (C) 
FACS analysis of peripheral 
blood cells from RT2;VC mice 
reconstituted with common 
myeloid progenitor (CMP) cells 
indicates that GFP+ cells are 
present within the 
CD11b+/F4/80+ monocyte 
fraction and the CD11b+/F4/80- 
granulocyte fraction but not in B 
or T lymphocytes. 
 
 
Figure 18. CD11b+ lineage tracing shows myeloid origin TLEC 
in a bone marrow transplantation-independent setting. TRAMP-
C1 tumors were grown subcutaneously in CD11b-Cre;Z/EG 
mice (3 mice). In these mice, cells that have passed through a 
CD11b+ myeloid lineage express GFP. (A) GFP+ cells with 
typical lymphatic extended morphology were identified in 
Podoplanin and LYVE-1-immunoreactive lymphatic vessels. 
Arrowheads indicate double-positive cells shown in inset 
magnifications (first inset: merged channels, second and third 
insets: red and green channel, respectively). (B) Triple stain 
revealed co-expression of LYVE-1 and Prox-1 on myeloid 
derived GFP+ cells integrated into lymphatic vessels 
(arrowhead). The lower panel represents a magnification of the 
relevant region with individual channels combined. Note that 
GFP+ cells not connected to vascular structures do express 
neither LYVE-1 nor Prox-1 (arrow). DAPI stains nuclei (blue). 
Scale bars: 20 µm. 
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 In a second series of lineage tracing experiments, FACS-sorted CD11b+ myeloid cells from 
actin-GFP transgenic mice (Figure 10C) were i.v. injected into semi-lethally RT2;VC mice. 3 weeks 
after injection, adoptively transferred GFP+ cells were observed integrated into tumor lymphatics, 
identified by LYVE-1 or Prox-1 expression. Notably, adoptive transfer of CD11b+/GFP+ cells into 
non-irradiated RT2;VC mice gave similar results (Figure 19A), indicating that reconstitution of the 
haematopoietic system by stem cells is not a prerequisite for BMDC contribution to tumor 
lymphangiogenesis. To assess whether common myeloid progenitor cells (CMP) (Akashi et al., 
2000) provide the cells that incorporate into tumor lymphatics, FACS-sorted CMP cells (lin-/Sca-1-
/IL7Rα-/cKit+/GFP+; Figure 10E) were adoptively transferred into semi-lethally irradiated RT2;VC 
mice. FACS analysis of peripheral blood cells three weeks after transplantation revealed that the 
transferred CMP cells contributed to the generation of CD11b+/F4/80+ monocytes and 
CD11b+/F4/80- granulocytes but not to CD19+ B lymphocytes or CD3+ T lymphocytes (Figure 17C). 
Also here, GFP+ cells were found integrated into tumor-associated lymphatic endothelium, 
detected by LYVE-1 or Podoplanin expression (Figure 19B). In contrast, adoptive transfer of 
FACS-sorted CD19+/GFP+ B cells (Figure 10D) did not result in any incorporation of these cells into 
tumor lymphatic vessels (Figure 20), underscoring the exclusive ability of myeloid cells to 
contribute to tumor lymphangiogenesis and excluding the possibility that minor contaminations of 
haematopoietic stem cells in the FACS-sorted fractions may have contributed to the GFP+ cells that 
incorporated into tumor lymphatics. 
Figure 19. Adoptive transfer of myeloid lineage 
cells. (A) CD11b+ myeloid cells integrate into 
tumor-associated lymphatic vessels. FACS-
sorted CD11b+/GFP+ cells were adoptively 
transferred into non-irradiated RT2;VC mice (3 
mice). 7-20 µm histological pancreatic sections 
of transplanted mice were stained for the 
lymphatic markers LYVE-1 and Prox-1 (red) and 
for GFP (green) and analyzed by confocal 
microscopy. Representative tumor sections are 
shown. Arrows indicate double-positive cells and 
arrowheads indicate double-positive cells shown 
in inset magnifications (first inset: merged 
channels, second and third insets: red and 
green channel, respectively). (B) Common 
myeloid progenitor (CMP) cells integrate into 
tumor-associated lymphatic vessels. FACS-
sorted lin-/Sca-1-/IL7Ra-/cKit+ CMP cells were 
adoptively transferred into semi-lethally 
irradiated RT2;VC mice. Histological sections of 
tumors of the transplanted mice were stained for 
LYVE-1 or Podoplanin (red) and for GFP (green) 
and analyzed as in (A). Arrowheads indicate 
cells double-positive for GFP and LYVE-1 or 
Podoplanin shown in inset magnifications (first 
inset: merged channels, second and third insets: 
red and green channel, respectively). DAPI 
stains nuclei (blue). Scale bar: 20 µm. 
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 In order to assess potential fusion events between bone marrow-derived cells and pre-
existing lymphatic endothelial cells, lethally irradiated triple-transgenic RT2;VC;Z/EG mice were 
transplanted with bone marrow isolated from CD11b-Cre mice. Fusion of CD11b+ BMDC, 
expressing the Cre recombinase, with host (tumor lymphatic endothelial) cells would result in GFP 
expression from the recombined Z/EG locus. Seven weeks after transplantation, no GFP+ cells 
were detected in or around lymphangiogenic insulinomas, indicating that Cre-expressing, bone 
marrow-derived myeloid cells had not fused with RT2;VC;Z/EG lymphatic endothelial cells or any 
other host cell (data not shown). 
 These results demonstrate that cells found integrated into growing tumor lymphatic vessels 
can have a myeloid origin and that bone marrow-derived lymphatic progenitor cells are at least in 
part derived from the already myeloid-committed haematopoietic lineage. 
 
Figure 20. CD19+ B lymphocytes do not integrate into tumor-
associated lymphatics. FACS sorted CD19+/GFP+ cells were 
adoptively transferred into semi-lethally irradiated RT2;VC mice (2 
mice). 3 weeks after transfer, mice were sacrificed and tumor 
sections were stained for the lymphatic marker LYVE-1 (red) and for 
GFP (green) and analyzed by confocal microscopy. No GFP+ cells 
co-expressing LYVE-1 could be observed. DAPI was used for 
nuclear counterstaining (blue).  Scale bar: 20 µm. 
 
 
 
 
Depletion of macrophages 
 To assess the functional contribution of macrophages to tumor lymphangiogenesis, RT2;VC 
mice were treated with liposome-encapsulated Clodronate (ClodroLip) or PBS as vehicle-control 
for four weeks to ablate TAM (Van Rooijen, 1989; Van Rooijen and Sanders, 1994). Successful 
macrophage depletion was achieved as shown by reduced F4/80 immuno-reactivity in ClodroLip 
treated mice (Figure 21A). Peri-tumoral lymphatic vessel density (LVD) was significantly decreased 
in ClodroLip vs. PBS treated mice (Figure 21B; treated: median 70%, mean: 61% vs. control: 
median 90%, mean 74.9%; P < 0.01). In contrast to a recent study where ClodroLip reduced tumor 
growth of xenotransplants in immuno-compromised mice (Zeisberger et al., 2006), average tumor 
volume, tumor incidence and blood vessel density were not significantly reduced in our 
experiments (Figure 22). To evaluate the amount of VEGF-C and VEGF-D provided by TAM, 
CD11b+ cells were isolated from RT2 or RT2;VC tumors and mRNA levels were assessed by 
quantitative PCR and compared to levels in total RT2 tumors. The expression of endogenous 
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murine VEGF-C and D in tumors (not considering the high levels of transgenic human VEGF-C 
expression in RT2;VC mice) was higher than in TAM (Figure 21). From these results we conclude 
that macrophages contribute to tumor lymphangiogenesis in RT2;VC mice by processes other than 
the secretion of the main lymphangiogenic factors. 
 
Figure 21. Depletion of macrophages 
reduces peritumoral lymphatic vessel 
density. (A) RT2;VC mice were treated 
with liposome-encapsulated Clodronate 
(ClodroLip). Pancreatic sections 
representing a total of 5 PBS vehicle 
control-treated mice (97 tumors) and 6 
ClodroLip-treated (132 tumors) mice 
were analyzed. Successful depletion of 
intra- and extra-tumoral macrophages 
in ClodroLip-treated mice is illustrated 
by the reduction of F4/80 
immunoreactivity (red). Co-staining 
with the lymphatic endothelial marker 
LYVE-1 (green) reveals a reduced 
coverage of tumors by lymphatic 
vessels in ClodroLip-treated mice vs. in 
PBS-treated mice. DAPI was used for 
nuclear counterstaining (blue). T: 
tumor. Scale bar: 50 µm. (B) Tumors of 
ClodroLip and control-treated mice 
were analyzed by immunofluorescence 
staining with antibodies against LYVE-
1 for the extent of lymphatic 
vasculature surrounding the perimeter 
of the tumors. Tumors of control-
treated mice were surrounded by 90% 
or more with lymphatic vessels (median 90%, mean 74.9%), whereas tumors of ClodroLip-treated mice had significantly 
lower coverage (median 70%, mean 61.1%; P < 0.01, Mann-Whitney test). (C) Tumor-associated CD11b+ macrophages 
(TAM) were isolated from tumors of RT2 or RT2;VC mice by flow cytometry, and mRNA levels for murine VEGF-C and 
VEGF-D were quantified using real-time PCR and compared to levels in total tumors. Shown is the result of three 
independent TAM isolations. 
 
 
 
Figure 22. Macrophage depletion does not affect tumor growth. RT2;VC mice were treated for 4 weeks either with PBS 
(vehicle control) or with ClodroLip as described in Methods in order to deplete intra- and peritumoral macrophages. 
Tumor volume has been determined as the total volume of tumors per mouse (A), tumor incidence is the number of 
tumors larger than 1mm per mouse (B), and blood vessel density is the % area fraction of CD31 staining, as determined 
using ImageJ image analysis software (C). None of these parameters was significantly altered between ClodroLip- and 
control-treated mice. 
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Macrophages form lymphatic-like structures in vitro  
 We next investigated whether bone marrow-derived macrophages had an intrinsic 
capability to form lymphatic vessel-like structures. Employing a well-established protocol of in vitro 
macrophage differentiation (Gatfield and Pieters, 2000), bone marrow cells were cultured for 7 
days in 30% M-CSF-containing medium to induce the specific differentiation of progenitor cells into 
non-activated macrophages. Flow cytometric analysis confirmed the macrophage identity (CD11b+/ 
F4/80+) of these cells (Figure 23A). The bone marrow-derived-macrophages were then activated 
with LPS and seeded on Matrigel to monitor differentiation and tube formation. After two days in a 
defined endothelial cell-specific medium, macrophages associated in clumps, before forming tube-
like structures with increasing connections between days 3 and 15 (Figure 23A). Confocal 
immunofluorescence microscopy analysis at day 12 revealed that these tube-like structures 
stained positively for the lymphatic marker Podoplanin. Notably, only macrophages that had 
formed tube-like structures and not single isolated cells expressed the lymphatic marker (Figure 
23B). Furthermore, quantitative PCR analysis of mRNA from macrophages isolated either before or 
after the tube formation process revealed a marked up-regulation of the lymphatic markers LYVE-
1, Prox-1, VEGFR3, Foxc2 and Foxc1 as well as a down-regulation of the hematopoietic/monocytic 
markers CD45 and CX3CR1 during tube formation. Exclusion of individual growth factors revealed 
the requirement of FGF-2 for tube formation (Figure 23C), whereas the other supplemental growth 
factors (VEGF-A, IGF-1, EGF, hydrocortisone) were dispensable. Notably, mRNA levels of FGF 
receptors-1 and 2 increased during tube formation (Figure 23C). 
 In order to assess the capacity of myeloid cells to integrate into lymphatic structures in vitro, 
GFP-labeled macrophages were generated as described above from bone marrow of actin-GFP 
transgenic mice and subsequently cultured on Matrigel alone or in combination with SV40 T 
antigen-immortalized murine lymphatic endothelial cells (SV-LEC) (Ando et al., 2005). Five days 
later, the cultures were stained for Podoplanin. Cultured SV-LEC formed tube-like structures 
positive for Podoplanin expression (Figure 23D/1), and cultured in vitro activated macrophages 
were positive for GFP (Figure 23D/2). In mixed cultures, bone marrow-derived macrophages lined 
up with SV-LEC, incorporating into tube-like structures and expressed Podoplanin (Figure 23D/3-
6). Interestingly, GFP+ macrophages were predominantly located at the tips and at branch points of 
growing tube-like structures (Figure 23D/3-6) and seemed to guide SV-LEC to form a new sprout 
as observed by time-lapse video microscopy (Figure 24, supplemental video 3, on CD). These 
results demonstrate that bone marrow-derived macrophages have the ability to form lymphatic 
tube-like structures as well as to incorporate into lymphatic structures in vitro and suggest a role of 
these cells in lymphatic endothelial cell sprouting in vitro. 
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Figure 23. Bone marrow-derived-macrophages form lymphatic-like structures in vitro. (A) In vitro generated 
macrophages showed a specific marker expression profile (CD11b+/ F4/80+) (upper left panel). Tube formation on 
Matrigel was monitored by phase-contrast microscopy. At day 2, macrophages formed clusters. Between days 3 and 15, 
they developed into tube-like structures with numbers of branches increasing over time. Scale bar: 100 µm. (B) 
Immunofluorescence staining against Podoplanin (Pdpn) revealed that macrophages having formed tube like structures 
express Podoplanin whereas single cells do not. Staining of the tubular structures in the absence of any primary antibody 
was used as a control (2ºAb). DAPI stains nuclei (blue). Scale bar: 100 µm. Quantitative PCR analysis revealed that 
upon tube formation, macrophages up-regulate the expression of lymphatic markers (LYVE-1, Prox-1, VEGFR3, Foxc2, 
Foxc1) and down-regulate hematopoietic/myeloid markers (CD45, CX3CR1). ΔΔCT corresponds to the difference 
between the normalized CT values of macrophages forming tubes (day 8) and macrophages not having formed tubes yet 
(day 1). (C) FGF-2 is required for macrophage tube formation as its specific exclusion from culture medium abrogated 
this process (left panel). Furthermore, analysis of mRNA levels revealed up-regulation of FGF receptors -1 and -2 during 
tube formation. (D) Immortalized Podoplanin+ murine lymphatic endothelial cells (SV-LEC) (panel 1), GFP-labeled bone 
marrow-derived-macrophages (panel 2), and mixed cultures of macrophages and SV-LEC (panels 3-6) were seeded in 
Matrigel. At day 5, cells were stained for Podoplanin (red) and analyzed by confocal microscopy. Mixed cultures 
demonstrate that bone marrow-derived macrophages contribute to SV-LEC-mediated tube formation: GFP+ cells (green) 
are found integrated into Podoplanin+ tube-like structures. Note the preferential integration of bone marrow-derived 
macrophages at the tips and branch points of sprouting tube-like structures formed by SV-LEC (magnified in panel 6). 
DAPI stains nuclei (blue). Scale bars: 100 µm (panels 1 and 2) and 50 µm (panels 3 to 6). 
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Figure 24. Macrophages initiate lymphatic 
endothelial cell tube formation in an in vitro co-
culture system. (A) Phase contrast microscopy 
of SV40 large T antigen-immortalized lymphatic 
endothelial cells (SV-LEC) co-cultured with 
GFP+ macrophages in Matrigel. GFP+ 
macrophages are detected by their bright signal 
in phase-contrast microscopy. As an initial step, 
SV-LEC associate into compact cell aggregates 
with concomitant recruitment of macrophages. 
As indicated by an arrowhead, after 1 day, 
GFP+ macrophages could be observed leading 
outgrowing SV-LEC tubes. (B) Immunofluorescence microscopy of a magnification of the same field depicted in (A) 
showing the tube-leading GFP+ macrophage followed by four Hoechst-stained SV-LEC. Scale bars: 10 µm. 
 
Supplemental videos 
 
Supplemental video 1 
 3D reconstitution of a 20µm tissue section of a tumor, derived from a RT2;VC mouse 
transplanted with GFP labeled bone marrow. The arrow indicates a GFP+ cell (green) integrated in 
the Podoplanin+ (red) lymphatic vessel. The arrowhead indicates a GFP+ cell not completely 
integrated (noticeable only at certain angles). Ex: exocrine pancreas, L: lymphatic vessel lumen, T: 
tumor. 
 
Supplemental video 2 
 3D reconstitution of a 7µm tissue section of a TRAMP-C1 tumor, grown in a GFP-labeled 
bone marrow-transplanted C57BL/6 mouse. The arrow indicates a GFP+ cell (green) integrated in 
the Podoplanin+ (red) lymphatic vessel. 
 
Supplemental video 3 
 Macrophages initiate lymphatic endothelial cell tube formation in in vitro co-culture. Time-
lapse video microscopy after 24h co-culture of SV-LEC and GFP+ macrophages on Matrigel. GFP+ 
macrophages were distinguished from SV-LEC by their bright signal in phase-contrast. The movie 
shows a GFP+ macrophage located at the rim of SV-LEC compact structure initiating outgrowth of a 
tube-like structure. As also visible in Figure S7, the SV-LEC follow the tube-leading macrophage in 
the newly forming tube-like structure. 
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4.2.4. Discussion 
 Research on BMDC in patho-physiological processes, such as atherosclerosis, limb/heart 
ischemia and cancer, has in the past mainly focused on the importance of haematopoietic cells in 
promoting or attenuating inflammation, in clearing cancer cells, or in inducing immunological 
tolerance to neoplastic lesions. However, recent findings indicate that the bone marrow is also a 
rich source of progenitor cells with mesenchymal and endothelial potential (Bertolini et al., 2006; 
Gregory et al., 2005). In the case of endothelial progenitor cells, the lineage relationship to the 
haematopoietic system is not clear. While some experiments suggest the existence of an adult 
haemangioblast, a progenitor cell of both haematopoietic and endothelial lineage (Pelosi et al., 
2002), others support a pathway of differentiation of myeloid cells to endothelial cells (Bailey et al., 
2006; Loomans et al., 2006). 
 Here, we have used bone marrow transplantation experiments in two different mouse 
models of carcinogenesis to demonstrate that BMDC significantly contribute to tumor 
lymphangiogenesis, but rarely integrate into tumor blood vessels. About 3% of lymphatic 
endothelial cells in the periphery of lymphangiogenic tumors are of bone marrow origin, a 
contribution comparable to findings in rejected human kidney transplants (Kerjaschki et al., 2006) 
and in liver, stomach and intestine of HSC transplanted mice (Jiang et al., 2008). Moreover, we 
have performed lineage tracing experiments to obtain insights into the ontogeny of bone marrow-
derived TLEC. First, transplantations of FACS-sorted bone marrow fractions representing different 
haematopoietic lineages or of total bone marrow expressing GFP under a myeloid specific 
promoter indicate that integrated BMDC are derived from the myeloid lineage. Second, genetic 
tagging of myeloid cells with GFP confirms this notion; cells that have passed through the myeloid 
linage are found integrated into the lymphatic vasculature surrounding tumors. Third, depletion of 
tissue macrophages using ClodroLip significantly reduces peri-tumoral lymphatic vessel density, 
demonstrating a functional role of macrophages in tumor lymphangiogenesis. In order to directly 
assess whether macrophage depletion would abolish BMDC integration into tumor lymphatic 
vessels, we have combined bone marrow transplantation and ClodroLip treatments, yet due to a 
high mortality rates we had to terminate these experiments. Fourth, the contribution of 
macrophages to lymphatic structures is recapitulated in an experimental in vitro system. 
 Taken together, our results from experiments in vivo and in vitro demonstrate that cells of 
the myeloid lineage physically contribute to tumor lymphangiogenesis. We therefore propose a 
model in which lymphatic vessel growth not only relies on the proliferation, migration and sprouting 
of pre-existing lymphatic endothelial cells but also depends on the trans-differentiation of cells of 
the myeloid lineage into lymphatic endothelial cells. The existence of specific lymphatic progenitor 
cells (LPC), distinct from haematopoietic as well as blood endothelial progenitor cells, has not been 
established. Based on a number of control experiments, such as the transplantation of FACS-
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sorted CD19+ B-cells or the adoptive transfer of CD11b+ myeloid cells into non-irradiated 
recipients, we exclude the possibility that FACS-sorted cell fractions may have contained 
haematopoietic stem cells that also reconstitute potential LPC. Rather, our data indicate a myeloid 
origin of cells that trans-differentiate into lymphatic endothelial cells, thus supporting the notion that 
LPC reside at least partially within an already committed haematopoietic lineage. 
 BMDC integration into newly formed lymphatic vessels has been shown to take place 
mainly under inflammatory or wound healing conditions (Kerjaschki et al., 2006; Maruyama et al., 
2007; Maruyama et al., 2005). Our results support this notion, since transplanted, non-tumor 
bearing mice did not show any BMDC integration into lymphatic vessels. In support, normal tissue 
lymphatics of TRAMP-C1 tumor-bearing CD11b-Cre;Z/EG mice did not show any incorporation of 
myeloid-derived cells. In summary, we demonstrate here that in the inflammatory context of tumor 
growth, cells of the myeloid lineage participate in tumor lymphangiogenesis. Since tumor lymphatic 
vessels provide a route for metastatic dissemination, understanding the functional role of bone 
marrow-derived tumor lymphatic endothelial cells seems warranted. 
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4.2.5. Materials and Methods 
 
Mouse strains 
  Generation and phenotypic characterization of Rip1Tag2, Rip1VEGF-A and Rip1VEGF-C 
mice have been described previously (Gannon et al., 2002; Hanahan, 1985; Mandriota et al., 
2001). C57BL/6-Tg(ACTB-EGFP)mice (Okabe et al., 1997) and Z/EG mice (Novak et al., 2000) 
were provided by K. Hafen  (University of Basel). CD11b-Cre mice (Ferron and Vacher, 2005) and 
CX3CR1+/GFP mice (Jung et al., 2000) were obtained from J. Vacher (University of Montreal) and C. 
Rüegg (CePO Lausanne), respectively. All experiments involving mice were performed in 
accordance with the guidelines of the Swiss Federal Veterinary Office (SFVO) and the regulations 
of the Cantonal Veterinary Office of Basel-Stadt. 
 
Total bone marrow transplantations 
 Bone marrow cells were extracted under sterile conditions from femurs and tibiae from 
donor mice indicated in Figure 1. After T cell depletion (Benard et al., 2006), 5 x 106 cells were 
injected in the tail vein of lethally irradiated (2 x 550 cGy) 6 week old mice which were sacrificed for 
further analysis 5 to 7 weeks after transplantation. 
 
TRAMP-C1 subcutanous tumor model 
 5x105 TRAMP-C1 cells (Foster et al., 1997) (provided by N. Greenberg, FHCRC, Seattle) 
were injected into the flank of either GFP-labeled bone marrow transplanted C57BL/6 mice (4 
weeks after transplantation) or CD11b-Cre;Z/EG mice and grown for 3 to 4 weeks. 
 
Flow cytometric analysis 
 Cells were washed in PBS supplemented with 5% FBS, Fc-blocked with a monoclonal 
antibody against mouse CD16/CD32 (Clone 2.4G2, Pharmingen), and stained with directly-labeled 
monoclonal antibodies against mouse CD19 (Clone MB19-1, eBioscience), CD3 (Clone 145-2C11, 
eBioscience), CD11b (Clone M1/70.15, CALTAG), F4/80 (Clone CI:A3-1, Serotec), LYVE-1 (Clone 
ALY7, CliniSciences), CD31 (Clone 390, eBioscience). Podoplanin expression was revealed by 
hamster anti-mouse Podoplanin (Clone 8.1.1), followed by biotinylated anti-hamster-IgG antibody 
and streptavidin-PE (eBioscience). Stained cells were analyzed on a FACSCanto II using DIVA 
software (Becton Dickinson). Dead cells were excluded by a combination of light scatter and PI 
fluorescence. Cell duplets were excluded by forward scatter pulse width. Peripheral blood 
mononuclear cells were isolated by Ficoll–Histopaque (SIGMA) density-gradient centrifugation. 
Bone marrow cells were extracted from mouse femurs and tibiae by flushing. Tumor single cell 
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suspensions were obtained by digestion for 45 minutes at 37° C using the following digestion 
buffers: TRAMP-C1: HEPES buffered saline, 0.1mg/ml DNaseI (Roche), 1mg/ml collagenase I 
(SIGMA); RT2: DMEM, 5% NU serum (Becton Dickinson), 0.2mg/ml DNaseI, 1.2U/ml DispaseII 
(Roche Applied Science). 
 
CD11b+ and CMP cell sorting and adoptive transfer 
 Bone marrow cells were extracted from femurs and tibiae of female C57BL/6-Tg(ACTB-
EGFP) mice, washed in PBS/ 2% BSA, Fc blocked and stained with a phycoerythrin (PE)-
conjugated monoclonal antibody against mouse CD11b (CALTAG) or, for CMP isolation, lineage 
markers, CD3, CD4 (Clone GK1.5), CD8 (Clone 53-6.7), Ter119 (Clone TER-119), B220 (Clone 
RA3-6B2), CD19, Gr-1 (Clone RB6-8C5), Sca-1 (Clone D7), IL7Ra (Clone A7R34) and 
Allophycocyanin-labeled anti-cKit (Clone 2B8) (all from eBioscience). CD11b+ GFP+ or CMP 
(lineage-/ Sca-1-/ IL7Ra-/ cKit+) cells were sorted on a FACSAria (Becton Dickinson) with a purity > 
98%. 4 x 105 CD11b+ or 4 x 104 CMP were injected in the tail vein of semi-lethally (450 cGy) or non 
irradiated 9 week old RT2;VC mice, which were sacrificed 3 weeks after transplantation. 
 
Histological analysis 
  7 or 20 µm cryosections from pancreata or TRAMP-C1 tumors were prepared and stained 
as described (Bailey et al., 2006). When required, PBS/0.2% Triton-X-100 was used for 
permeabilization. The following primary antibodies were used:  rat anti-mouse LYVE-1 (Clone ALY-
7, MBL, Japan), rabbit anti-mouse LYVE-1 (Reliatech, Germany), rabbit anti-mouse Prox-1 (K. 
Alitalo, University of Helsinki), goat anti-human Prox-1 (R&D Systems), rabbit anti-Podoplanin (D. 
Kerjaschki, Medical University Vienna), hamster anti-mouse Podoplanin (Clone 8.1.1), rat anti-
mouse VE-Cadherin hybridoma supernatant (Clone B14, E. Dejana, University of Milano), rat anti-
mouse F4/80 (Clone CI:A3-1, Serotec), rat anti-mouse CD11b (Clone M1/70.15, Serotec) and rat 
anti-mouse CD31 (Clone MEC 13.3, Pharmingen). Alexa Fluor 488-, 568- and 633-labeled 
secondary antibodies (Molecular Probes) were used. Alexa Fluor 488-conjugated rabbit anti-GFP 
antibody (Molecular Probes) was employed for the detection of GFP. DAPI (SIGMA) was used for 
nuclear counterstaining. Sections were analyzed on a Nikon Diaphot 300 immunofluorescence 
microscope (Nikon) using Openlab 3.1.7. software (Improvision) or with a LSM 510 Meta confocal 
microscope using LSM software  for 2D and 3D analysis (Zeiss). Videos were created using Imaris 
6.1.1 software (Bitplane Scientific Solutions, Zurich, Switzerland). 
 
ClodroLip-mediated macrophage depletion 
 Eight week old RT2;VC mice were injected i.p. every 4 days for 4 weeks with 80mg/kg body 
weight (first injection) or 40mg/kg body weight  (following injections) ClodroLip or with an equal 
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volume of PBS as control. 2 days after the last injection, mice were sacrificed, pancreata were 
embedded in OCT and snap frozen in liquid nitrogen. Tumor macrophage depletion and tumor 
lymphatic vessel coverage were determined by immunofluorescence stainings with anti-F4/80 
antibodies and anti-LYVE-1 antibodies, respectively, and ImageJ software 
(http://rsb.info.nih.gov/ij/). Statistical analysis and graphs were performed with GraphPad Prism 
software (GraphPad Software Inc.). Non-parametric Mann-Whitney tests were used to compare 
tumor lymphatic vessel coverage of treated versus control mice. 
 
Isolation of tumor associated macrophages 
 Single cell suspensions of tumors from 13-14 week old RT2 or RT2;VC mice were obtained 
as described above, washed in FACS buffer (PBS/ 2% BSA/ 5mM EDTA) and stained with anti-
CD11b-PE. 20ʼ000 – 50ʼ000 CD11b+ cells were sorted on a FACSAria directly into TRIZOL reagent 
(Invitrogen). 
 
Quantitative real time RT–PCR 
 Total RNA was prepared using TRIZOL, and reverse transcribed with random hexamer 
primers using M-MLV reverse transcriptase (SIGMA). cDNA was quantified on a ABI Prism 7000 
light cycler (Applied Biosystems) using SYBR green PCR MasterMix (Fermentas) using the 
following primers: mVEGFC: fwd: 5ʼ-AGCAGCCACAAACACCTTCTT-3ʼ, rev: 5ʼ-
TCAAACAACGTCTTGCTGAGG-3ʼ; mVEGFD: fwd: 5ʼ-GCACCTCCTACATCTCCAAACAG-3ʼ, rev: 
5ʼ-GGCAAGCACTTACAACCCGTAT-3ʼ; mFGFR1: fwd: 5ʼ-TGTTTGACCGGATCTACACACA-3ʼ, 
rev: 5ʼ-CTCCCACAAGAGCACTCCAA-3ʼ; mFGFR2: fwd: 5ʼ-TCGCATTGGAGGCTATAAGG-3ʼ, rev: 
5ʼ-CGGGACCACACTTTCCATAA-3ʼ; mLYVE-1: fwd: 5ʼ-GGTGTCCTGATTTGGAATGC-3ʼ, rev: 5ʼ- 
AGGAGTTAACCCAGGTGTCG -3ʼ; mProx-1: fwd: 5ʼ-AAGAGAGAGAGAAAGAGAGAGAGTGG-3ʼ, 
rev: 5ʼ-TGGGCACAGCTCAAGAATC-3ʼ; mVEGFR3: fwd: 5ʼ-CGTGTGTGAAGTGCAGGATAGG-3ʼ, 
rev: 5ʼ-TCACTCACGTTCACCAGGAGGT-3ʼ; mFoxC1: fwd: 5ʼ-GCTTTCCTGCTCATTCGTCTT-3ʼ, 
rev: 5ʼ-AAATATCTTACAGGTGAGAGGCAAG-3ʼ; mFoxC2: fwd: 5ʼ-GACCCTAGCTCGCTGACG-3ʼ, 
rev: 5ʼ-CACCAGCCCTTCCGAGT-3ʼ; mCD45: fwd: 5ʼ-CAAAAGCAGATCGTCCGGA-3ʼ, rev: 5ʼ-
TGTCGGCCGGGAGGTT-3ʼ; mCX3CR1: fwd: 5ʼ-AAGTTCCCTTCCCATCTGCT-3ʼ, rev: 5ʼ-
CAAAATTCTCTAGATCCAGTTCAGG-3ʼ; mRPL19: fwd: 5ʼ-ATCCGCAAGCCTGTGACTGT-3ʼ, rev: 
5ʼ-TCGGGCCAGGGTGTTTTT-3ʼ. Ct values were normalized against ribosomal protein L19 
(RPL19). 
 
Tube formation assay using bone marrow-derived-macrophages 
  Bone marrow cells were extracted from femurs and tibiae of C57BL/6 or C57BL/6-
Tg(ACTB-EGFP) mice and cultured on Teflon plates for 7 days in DMEM supplemented with 10% 
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FBS, 2 mM glutamine, 100 units/ml penicillin and 30% L929 cell conditioned media containing M-
CSF. Bone marrow-derived-macrophages were collected with PBS/ 1 mM EDTA. Matrigel (Becton 
Dickinson) was mixed 1:1 with endothelial cell medium (EGM-2 MV, Cambrex) and allowed to 
solidify for 1 hour at 37°C in 8-chamber slides. 2-3 x 105 bone marrow-derived macrophages or 
immortalized lymphatic endothelial cells (SV-LEC) or a mixture of each 1.5 x 105 cells each in 
EGM-2 MV supplemented with 1 µg/ml LPS were seeded on the polymerized matrigel and tube 
formation was monitored up to 20 days. Immunofluorescence staining of tube-like structures was 
performed as described (Debnath et al., 2003). For time-lapse video microscopy, Hoechst labeled 
SV-LEC and GFP+ macrophages were co-cultured as described above and pictures were taken 
every 10 minutes for a period of 12 hours using a Zeiss Axiovert 35M microscope (Zeiss), 
Princeton Instruments CCD camera and Metamorph Imaging software (Universal Imaging 
Corporation). 
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4.3. Depletion of macrophages in Rip1Tag2/ NCAM+/- mice reduces 
blood vessel density but not lymphangiogenesis 
 
Tumors in Rip1Tag2 mice/ NCAM+/- mice have previously been shown to metastasize to regional 
lymph nodes by a “passive” mechanism, by which tumor disaggregation facilitates spreading of 
tumor cells to the pancreatic lymph nodes (Perl et al., 1999). This lympho-genic spreading of tumor 
cell clusters might be supported by ongoing lymphangiogenesis in NCAM-deficient Rip1Tag2 
tumors (Crnic et al., 2004), where tumor cell clusters within lymphatic vessels were detected. In 
order to evaluate the role of macrophages on tumor lymphangiogenesis and angiogenesis, we 
treated Rip1Tag2;NCAM+/- mice using ClodroLip in to deplete the macrophages. Analysis of 
immune cell infiltration by FACS, similar to section 4.1., did not reveal differences in the overall 
infiltration between Rip1Tag2 and Rip1Tag2;NCAM+/- for CD11b+, F4/80+ or Gr-1+ myeloid cells 
(data not shown). This indicates, that NCAM-deficiency does not trigger a differential immune cell 
infiltration. 
 Macrophage depletion was performed with using Clodronate liposomes as described in 
section 4.2.5., starting at ten weeks of age and giving 4 supplementary doses over 3 weeks until 
analysis (Figure 25A). Body weight was monitored and it was detected that ClodroLip treatment 
resulted in body weight loss, which could lead up to 30% body weight loss upon ClodoLip 
treatment (Figure 25B). At analysis, tumor volume but not incidence of ClodroLip-treated mice was 
moderately reduced as compared to PBS treatment (Figure 25C). When we analyzed macrophage 
infiltration by immunofluorescence for F4/80, we detected a highly significant reduction of 
macrophages in tumors (Figure 25D). Interestingly, F4/80/ LYVE-1 double-positive macrophages, 
usually found around the tumor and in the exocrine pancreas (arrowheads in Figure 25D, left 
panel), were completely absent in ClodroLip-treated animals. This suggests a high phagocytotic 
activity of those cells and a good penetration of the ClodroLip into the exocrine pancreas. We then 
analyzed the tumor microvessel and lymphatic vessel density using CD31 and LYVE-1, 
respectively (Figure 26A). CD31 immunoreactivity was measured by either quantifying the number 
of vessels per area or by quantifying the percentage of area occupied by these vessels (Figure 
26B). Using both readouts, a significantly lower number of blood vessels was observed in tumors 
of ClodroLip vs. PBS treated mice. The tumorʼs lymphatic vessel coverage of the mice in this 
experiment was very low, and we could not detect differences in the amount of lymphatic 
structures around the tumors (Figure 26C). To test if the reduced blood vessel density had an 
effect on proliferation of tumor cells, we stained the sections for the mitotic marker Phosopho-
Histone H3, indicative of cell division. No difference in proliferation was detected (Figure 26D).  
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Figure 25. ClodroLip 
treatment reduces 
intratumoral macrophages. 
(A) Mice were treated with 
ClodroLip or PBS by i.p. 
injection starting at 10 
weeks age and given four 
consecutive injections and 
analyzed at 13 weeks. (B) 
ClodroLip treatment induces 
body weight loss up to 30% 
compared to the beginning 
of the experiment. (C) 
Tumor volume but not 
incidence is reduced in 
ClodroLip vs. PBS treated 
mice (N too low for 
statistical evaluation). (D) 
ClodroLip treatment 
efficiently depletes intra- 
and extratumoral 
macrophages, as assessed 
by F4/80 staining. 
Extratumoral LYVE-1/ F4/80 
double positive 
macrophages (arrowheads) 
are completely absent in 
treated mice. Right panel: 
quantification of intratumoral 
macrophages (N: number of 
mice, n: number of tumors). 
Studentʼs unpaired two-
tailed t-test. Scale bar: 
100µm. 
 
 This sectionʼs results contrast with another ClodroLip treatment (presented in “4.2.3. 
Depletion of macrophages”) by the reduced blood vessel density in this experiment, not observed 
in the other study. In the regimen used in this trial, mice were treated at a later timepoint, and this 
seems to negatively influence the effect of ClodroLip on the general health status, as evidenced by 
the reduced body weight. Even though blood vessel density was reduced in tumors of ClodroLip 
treated mice, other tumor parameters were not or not significantly altered. It seems therefore likely 
that macrophage function is not essential for angiogenesis and tumor growth in Rip1Tag2 mice. It 
has been previously shown that neutrophils are important for providing MMP9 and supporting the 
angiogenic switch in Rip1Tag2 tumors (Nozawa et al., 2006). 
 As the lymphangiogenesis phenotype of Rip1Tag2;NCAM+/- is very moderate in this 
experiment, we cannot draw a conclusion on the effects of macrophages on stochastic, 
endogenous lymphangiogenesis. Correlation analysis performed on Rip1Tag2 and 
Rip1Tag2;NCAM+/- mice did not show a correlation between intra-tumoral or peripheral 
macrophage infiltration and either genotype (Rip1Tag2 vs. Rip1Tag2;NCAM+/-) or extent of 
peritumoral lymphangiogenesis (data not shown). 
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Figure 26. ClodroLip treatment reduces 
blood vessel density. (A) Pancreatic 
sections were stained for blood vessel 
marker CD31 and lymphatic vessel 
marker LYVE-1. (B) ClodroLip treatment 
induces a slight but significant reduction 
of blood vessel density (left panel: 
CD31 area fraction, right panel: number 
of vessels). (C) No difference is found in 
the distribution between not (0% 
surrounded by LYVE-1 vessels), slightly 
(1-10% surrounded) or moderately (11-
50% surrounded) lymphangiogenic 
tumors. Numbers above bars indicate 
tumor in category/ total tumors. (D) The 
reduced blood vessel density does not 
cause a reduction in mitotic Phospho-
Histone H3 positive cells between PBS 
and ClodroLip treated mice. N: number 
of mice, n: number of tumors, n.s.: not 
significant. T: tumor, E: exocrine 
pancreas. Studentʼs unpaired two-tailed 
t-test was used in (B) and (D) Scale bar: 
100µm. 
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4.4.1. Abstract 
 By transgenic expression of a bicistronic mRNA in mice under control of the Rat 
insulin promoter 1, encoding for SV40 large T antigen followed by an internal ribosomal 
entry site preceding a firefly luciferase gene, we developed a versatile tool to study β-cell 
carcinogenesis non-invasively by in vivo bioluminescence. Numerous tumors of different 
malignancy stages can be detected in single mice, indicating that this model recapitulates 
multistage carcinogenesis. In addition, in this mouse strain called RL-1 (RipTag-IRES-
Luciferase line 1), due to the very stringent expression exclusively in the β-cells of 
Langerhans islets, we could determine micro-metastasis in liver via luciferase expression 
of metastatic cells. This mouse line will be of value to study tumor-promoting as well as 
metastasis-related genes when crossed to other transgenic or gene-targeted mice. 
 
4.4.2. Introduction 
 The first transgenic cancer models in mice have been established around 1984, using 
simian virus 40 (SV40) derived T antigen oncoproteins, myc, ras and fos, whose expression was 
driven by tissue specific or viral promoters. This over-expression resulted in brain, mammary, 
bone, pancreatic acinar cell or endocrine tumors and, in the case of myc over-expressed in B 
lymphocytes, in lymphoma (Hanahan et al., 2007). In the meantime, a plethora of new murine 
cancer models have been established, and the range of endogenous tumor models (versus 
transplantation models) has been expanded by chemical, physical and hormonal induction 
protocols of cancer. Transgenic and induced cancer models offer the possibility to study 
tumorigenesis in a fully immune-competent background. This is in contrast to xeno-transplantation 
studies, in which human cancer cell lines are grafted into immune-compromised mice. 
 One of the first “oncomice” was the transgenic Rip1Tag2 mouse, recapitulating β-cell 
carcinogenesis of islets of Langerhans, elicited by rat insulin promoter mediated expression of SV 
40 large T antigen (Tag). It has been used widely in cancer research over the last two decades 
(Hanahan, 1985) and, together with others, has substantially contributed to the concept 
summarized as “hallmarks of cancer” (Hanahan and Weinberg, 2000). Particularly, a tumorsʼ 
requirement for angiogenesis, evasion from apoptosis as well as tissue invasion and metastasis 
were demonstrated in the Rip1Tag2 model. The onset of angiogenesis, a prerequisite for the 
growth of macroscopic tumors, is a highly regulated process, which is mainly governed by the 
expression of pro-angiogenic growth factors including vascular endothelial growth factor A (VEGF-
A) and other factors. In models of multi-stage carcinogenesis, angiogenesis is mainly found to 
occur in mid-stage tumor lesions and results from a shift in the balance of pro- and anti-angiogenic 
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factors, an emerging imbalance triggered by hypoxia, nutrient deprivation and activation and 
liberation of matrix sequestered growth factors. Evasion of apoptosis as a critical feature of tumors 
can be acquired by combined inactivation of cellular apoptosis inducers (e.g. p53 or tumor necrosis 
factor (TNF) receptor) and over-expression of anti-apoptotic molecules including members of the 
Bcl-2 family or activation of anti-apoptotic signaling pathways. In the Rip1Tag2 tumor model, over-
expression of insulin like growth factor II, normally down-regulated in rodents after birth throughout 
the body, was shown to be crucial for growth of macroscopic tumors by counteracting apoptosis in 
tumors (Christofori et al., 1994). Sooner or later, most solid tumors leave the primary tumor site 
and seed to distant organs, a process called metastasis. Tissue invasion and metastasis are 
mechanistically closely related, and cellular changes observed in invading tumor cells are often 
mirrored by the metastasis. Rip1Tag2 mice have been instrumental to define a role for cell-cell 
adhesion molecules of the immunoglobulin and calcium-dependant cadherin families as well as the 
role of integrins, which connect cells to the extracellular matrix. Intercrossing Rip1Tag2 mice with 
transgenic mice that maintain E-cadherin expression in tumor cells results in arrest of tumor 
development at the adenoma stage, whereas expression of a dominant-negative form of E-
cadherin induces early invasion and metastasis (Perl et al., 1998). In the same tumor model, mice 
develop lymph node metastases when neural cell adhesion molecule (N-CAM), a member of the 
immunoglobulin CAM, is expressed at reduced levels (Perl et al., 1999). Partial deletion of β1 
integrin in tumor cells in Rip1Tag2 mice leads to increased tumor cell dissemination via the 
lymphatic system (Kren et al., 2007). 
 Another critical feature of cancer development, not appreciated in experimental animal 
studies until the last decade, is the tumorsʼ interaction with the immune system, resulting in 
recruitment of inflammatory cells that promote tumor growth, angiogenesis and invasion and that 
help the tumor to evade immune surveillance (reviewed in (Zumsteg and Christofori, 2009)). 
Rip1Tag2 mice have been used to define critical roles of bone-marrow derived cells by supplying 
matrix metalloproteinase 9, which can activate matrix sequestered VEGF-A (Bergers et al., 2000; 
Nozawa et al., 2006). 
 However, the Rip1Tag2 model has limitations that we thought could be prevented. In 
contrast to skin, breast or subcutaneously transplanted tumors, the islets of Langerhans form a 
part of the pancreas, hence are buried in the mouse body, rendering it impossible to monitor tumor 
growth in longitudinal analyses. Even though many preclinical studies have been undertaken in 
Rip1Tag2 mice (Schomber et al., 2009; Shojaei et al., 2008; Wicki et al., 2007), the necessity to 
set a defined endpoint due to unknown tumor growth diminishes the flexibility of this cancer model. 
Another limitation is the transgene integration site in the Rip1Tag2 mice, which causes aberrant 
expression in cells of gastrointestinal L cells, giving rise to intestinal neuro-endocrine carcinoid 
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tumors in some backgrounds, occasionally hampering the analysis of β-cell tumorigenesis (Dietrich 
et al., 1994; Grant et al., 1991). 
 
 By using the same construct originally used to create the Rip1Tag2 mouse, and expanding 
it by an internal ribosomal entry site (IRES) followed by a luciferase gene, we were able to develop 
a transgenic carcinogenesis model in which tumor growth can be monitored non-invasively by 
bioluminescence. The integration site causes an expression highly restricted to β-cells in islets of 
Langerhans, avoiding secondary tumor development at other sites and allowing immediate 
detection of metastatic events by analysis of organ lysates due to the expression of luciferase 
exclusively in metastatic tumor cells in target organs. The different tumor stages, occasional 
regional lymph node metastasis and the occurrence of distant organ metastasis therefore 
recapitulate multistage carcinogenesis.  
 
4.4.3. Results 
 
RipTag-IRES-Luciferase mice develop insulinoma 
 
Generation of transgenic RipTag-IRES-Luciferase mice 
 We sought to create a transgene cassette driving the expression of simian virus 40 (SV40) 
large T antigen oncoprotein followed by an internal ribosome entry site (IRES) also allowing firefly 
luciferase expression in a bicistronic manner. To specifically have expression in β-cells of 
Langerhans islets, the rat insulin promoter 1 (Rip1), derived from the rat insulin II gene, was used. 
The original pRip1Tag vector (Hanahan, 1985) was modified by introducing an IRES-luciferase 
cassette between the SV40 large T antigen stop codon and the SV40 polyadenylation signal 
(Figure 27A). SV40 early region encoding large T antigen contains an intron, an important feature 
for efficient transgene expression (Le Hir et al., 2003). The construct was transiently transfected 
into the insulinoma cell line βT2 and luciferase activity above background was detected, indicating 
the functionality of the IRES element and activity of the promoter (data not shown). The linearized 
plasmid was used to generate transgenic mice in FVB/N background. White mice were chosen 
because their lack of melanin expression facilitates the detection of bioluminescence in vivo. Three 
founder lines were obtained, termed RL-1, RL-2 and RL-3. For line RL-1, which was finally 
propagated, we determined the transgene integration site by linker-mediated PCR and found it to 
be in the distal H4 region of chromosome 3, 100kb and 500kb away from the next annotated 
genes, respectively (Figure 27B). This allowed us to design a muliplex PCR discriminating between 
wildtype or RL-1 transgenic allele (Figure 27C). Mice homozygous for the RL-1 transgene did not 
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show any abnormalities, indicating negligible distortion of the genomic locus. Nevertheless, all data 
presented in this publication are derived from heterozygous mice. 
 We analyzed transgene copy number by quantitative PCR on genomic DNA and found RL-
1 mice to have about 8 times more transgene copies than Rip1Tag2 mice, which were reported to 
have a heterozygous copy number of 5 (per diploid genome); we therefore assume a copy number 
of around 40 transgene copy numbers (not shown). 
 
Figure 27. Generation of transgenic Rip-Tag-IRES-Luciferase mouse. (A) An IRES-Luciferase cassette was inserted into 
a modified pRIP1-Tag vector between the SV40 large T antigen STOP codon and the SV40 polyadenylation site as 
described in Materials and Methods. Notice the intron between splice donor and acceptor (SD and SA) in SV40 early 
region. NotI linearized pRTIL was used to produce transgenic mice. (B) Linker mediated PCR was used to determine 
transgene integration site in RL-1 mice, which was found to be the distal arm H4 of mouse chromosome 3, about 100kb 
away from the next protein coding gene. (C) Multiplex PCR allowing detection of wt/wt, heterozygous RL-1/wt or 
homozygous RL-1/RL-1 transgene configuration. IRES: internal ribosomal entry site. 
 
Initial characterization of founder lines by in vivo and ex vivo luciferase bioluminescence 
 All three transgenic mouse lines develop potentially fatal insulinoma, but in lines RL-2 and -
3, only males developed tumors within the observation span (40 weeks), even though the 
transgene did not integrate in the Y chromosome in either of these lines (autosomal transmission 
of the transgene). The amount of mRNA coding for large T antigen, isolated out of Langerhans 
islets from non tumor-bearing mice, indicated a 12 – 20 fold lower expression level in RL-2 and RL-
3 mice as compared to RL-1 mice (data not shown). The onset of tumor growth in males from lines 
RL-2 and RL-3 was after 25 weeks. The lengthy and variable kinetic prompted us not to propagate 
these lines. 
 In vivo bioluminescence signals were aberrant in lines RL-2 and -3, whereas in RL-1 line, 
tumors as small as 2 mm could be detected at the expected site located in the higher peritoneal 
region. Figure 28A shows tumor bearing mice from all three founder lines which were subjected to 
in vivo bioluminescence measurement, all three mice having tumors of 3-4 mm diameter. 
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Figure 28. Luciferase expression in organs and tumor lysates. (A) In vivo luciferase bioluminescence of transgenic 
mouse lines RL-1, RL-2 and RL-3 allows non-invasive tumor monitoring. All three mice shown have similar insulinoma 
sizes of 3-4 mm, yet only line RL-1 shows signals restricted to the pancreatic area, located in the higher peritoneal 
region. Line RL-3 shows detectable luciferase signal in skin devoid of fur. (B) Ex vivo luciferase values from organ 
lysates of 6-8 week old tumor free RL mice. Asterisks indicate levels that are at least 3-fold higher than in control organs 
from non-transgenic mice. Minor leakiness is detected in some organs, including brain, fat, preputial gland, skin, testis 
and uterus. (C) Ex vivo luciferase activity of tumor lysates derived from RL-1 or RL-1 composite mice show normalized 
luciferase values 100 - 10ʼ000 fold higher than from organ lysates (B). Tumors derived from composite mice as 
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compared to RL1 single transgenic mice do not have significantly different ex vivo luciferase activity. Lysates from tumor 
cell lines derived from RL-1 tumors have a statistically higher luciferase activity *. Shown are individual values, with 
means +/- SEM. (D) betaRL1-223 cell line is 100% positive for insulin and Tag expression, indicating functionality of the 
insulin promoter and that the normalized luciferase values measured for cell lines in (C) represent the highest range of 
luciferase expression possible in the RL-1 system. (E) Tag is expressed in total pancreas isolated from newborns and in 
tumors. Top panel: qPCR from mRNA isolated either from pancreas of newborn mice or from tumors, normalized to 
newborn Rip1Tag2. Bottom panel: Western blot for large T antigen of insulinomas shows a tendency towards higher Tag 
expression in RL-1 mice. * Unpaired, two-tailed Studentʼs t-test. (m): males, (f): females, scale bar in (D): 20µm. 
 
 One big advantage of the luciferase approach is the possibility to track tumor cell 
dissemination quantitatively by analysis of organ lysates. To evaluate the feasibility of this 
approach for detecting metastatic events, we analyzed baseline levels of luciferase expression in 
organs from 6 - 8 week old RL mice. As the mice are tumor-free at this point and no metastases 
are expected, any detected luciferase activity would be due to leakiness of the rat insulin promoter. 
The indicated organs were homogenized and luciferase activity analyzed in vitro. Generally, 
luciferase levels were very low in most of the organs analyzed (Figure 28B). Asterisks indicate 
organs in which the raw values were more than threefold over the blank control, which was 
considered as aberrant expression. Testes lysates were positive in all mouse lines, indicating 
baseline activity of the Rip promoter in this organ. Preputial gland was positive in lines RL-2 and 
RL-3. Skin showed aberrant luciferase expression in males of line RL-3 (Figure 28A, right panel). 
Fat tissue has aberrant luciferase expression in all founder lines. Brain homogenates showed 
luciferase expression in line RL-1. 
 Tumor lysates from RL-1 tumors were found to have very high luciferase expression (Figure 
28C), about 3-5 log10 units above levels detected in liver and lung, two potential target organs of 
insulinoma metastasis. The normalized luciferase activity in tumor lysates of RL-1 mice was 
relatively variable ranging from 6ʼ000 to 240ʼ000 relative light units (RLU)/ µg lysate with a mean of 
62ʼ000. This variability might reflect different degree of down-regulation of insulin expression 
observed in insulinomas (Figure 32C) as well as different relative proportions of tumor cells 
constituting the tumor mass. 
 We then crossed the RL-1 mice to mice expressing tumor “modifier” genes, which are also 
expressed under the control of rat insulin promoter and had previously been characterized in the 
Rip1Tag2 tumor model. Vascular endothelial growth factor A (VEGF-A) is one of the most potent 
pro-angiogenic growth factors and accelerates tumor growth in Rip1Tag2 mice without affecting 
metastases (Gannon et al., 2002) whereas VEGF-C and VEGF-D promote tumor 
lymphangiogenesis and lymph node metastases (Kopfstein et al., 2007; Mandriota et al., 2001). 
Insulin like growth factor receptor 1 (IGF-1R) over-expression was shown to dramatically 
accelerate tumor growth and progression in Rip1Tag2 mice (Lopez and Hanahan, 2002), whereas 
neural cell adhesion molecule (NCAM) deficiency was shown to promote lymph node metastases 
by decreasing tumor - extracellular matrix adhesion and increasing tumor lymphangiogenesis 
(Crnic et al., 2004; Perl et al., 1999). Tumor lysates derived from these composite mice didnʼt show 
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significantly different luciferase values, indicating that expression of the modifier genes didnʼt lead 
to a drastically changed tumor/ stroma ratio or perturbation of oncogene expression (Figure 28C). 
Lysates prepared from two cell lines derived from tumors of RL-1 mice showed luciferase 
expression in the highest range detected for total tumor lysates, significantly higher than lysates 
derived from primary tumors of all analyzed genotypes. One of these cell lines is 100% positive for 
Tag and insulin expression (Figure 28D), indicating that the luciferase activity measured for this 
cell line denotes the upper limit of luciferase expression in the RL-1 system. 
 When we analyzed the amount of large T antigen mRNA in RL-1 or Rip1Tag2 from either 
total pancreas of newborn mice or in tumors, we found in tumors of RL-1 mice four-fold higher 
transcript levels as compared to Rip1Tag2 mice, findings that were also confirmed by immuno-
blotting (Figure 28E). In contrast, at birth, Rip1Tag2 mice have about two-fold more Tag mRNA as 
RL-1 mice. In addition to T antigen mRNA, lysates from total pancreata from newborn RL-1 mice 
were also positive for luciferase activity in vitro, demonstrating not only transcription but also 
translation of the bicistronic transgene (not shown). 
 
Bigger but fewer tumors allow RL-1 mice to outlive Rip1Tag2 mice 
 
Rip1Tag2 mice have been classically bred in C57BL/6 background, and the average survival time 
of these mice is around 12.6 weeks with mice living up to 16 weeks (Lopez and Hanahan, 2002). 
Average tumor volume of Rip1Tag2 mice at 12 weeks, i.e. shortly prior to average survival time, is 
around 36 mm3. In contrast, RL-1 mice have a median survival of 20.7 weeks, with a sex difference 
showing female RL-1 mice dying earlier than males, with a median survival of 19.4 weeks for 
female and 22.0 weeks for male mice, respectively (Figure 29A). When we analyzed survival of 
RL-1 mice in pure FVB/N background vs. C56BL/6 into FVB/N backcross generations 1 - 4, we did 
not detect differences in survival for single-transgenic RL-1 mice (Figure 29A, right panel). 
Backcross generations 1 - 4 harbor 50% - 93.75% FVB/N genetic background. These mice were 
obtained from crossing in of modifier genes present in C57BL/6 background. Hence it is feasible to 
use the data from composite mice from all backcross generations pooled. When we analyzed 
survival of RL-1;RipVEGF-C, RL-1;RipVEGF-D and RL-1;NCAM+/- composite transgenic mice, no 
difference in survival was found. In contrast, transgenic co-expression of VEGF-A or IGF1R under 
the Rip promoter caused a drastic, highly significant survival reduction in RL-1;RipVEGF-A and RL-
1;RipIGF1R mice (Figure 29B, Table 2). 
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Genotype N Median survival/ weeks log-rank vs. RL-1 
RL-1 173 20.7   
RL-1; RipIGF1R 26 11.4 P<0.0001 *** 
RL-1; NCAM+/- 16 n.d. P=0.13 
RL-1; RipVEGF-A 26 13.0  P<0.0001 *** 
RL-1; RipVEGF-C 15 21.4 P=0.83 
RL-1; RipVEGF-D 28 20.7 P=0.76 
Table 2. Median survival of RL-1 composite mice as shown in Figure 29. N indicates total number of mice. Survival of 
RL-1;RipIGF1R and RL-1;RipVEGF-A mice was significantly (***) reduced compared to RL-1 mice, as analyzed by log-
rank test. n.d.: not determined 
 
 When we analyzed the tumor volumes of RL-1 female vs. male mice, no significant 
differences could be found in the absolute tumor volumes when mice at age 18 – 20 weeks were 
analyzed (Figure 29C), with an average tumor volume of 99 +/- 29 mm3 and 65 +/- 12 mm3 for 
females and males, respectively (mean +/- SEM). However, at age 21 – 22 weeks, average tumor 
size of females dropped to 37 +/- 11 mm3, whereas males could bear much larger tumors of 233 
+/- 33 mm3 (Figure 29C). This indicates that females alive at this age had a delayed tumor 
progression, whereas males could still live under massively higher tumor burden. The distribution 
of tumor burden within mouse groups was not Gaussian, forcing us to use non-parametric Mann-
Whitney U test for assessing significance of tumor volume differences. When we analyzed the 
tumor incidence, i.e. the number of macroscopic tumors per mouse, in average 2.93 +/- 0.21 
macroscopic tumors were detected per mouse, independent of sex and early vs. late analysis time 
span (not shown). As females and males had age-matched similar tumor size at 18 – 20 weeks of 
age, we compared single RL-1 with composite transgenic mice with data from both sexes 
combined, however only include data up to the median survival time. Similarly to the survival data 
and the previously published data on RipVEGF-C, RipVEGF-D and NCAM+/- in Rip1Tag2 mice, no 
significant changes in tumor volume or incidence were seen when RL-1 mice where compared to 
RL-1;RipVEGF-C/ RipVEGF-D/ NCAM+/- composite mice (Figure 29C, Table 3). In contrast RL-
1;RipIGF1R had bigger and twice as many macroscopic tumors than RL-1 mice (Figure 29C. Table 
3), even though they were analyzed at only 9 – 11 weeks of age (vs. 18 – 20 weeks in RL-1 mice), 
highlighting the role of IGF1R as a tumor progression driver. RL-1;RipVEGF-A double transgenic 
mice, analyzed prior to median survival time, had statistically significant smaller tumors than RL-1 
mice. This is in sharp contrast to the reduced median survival time and suggests that VEGF-A 
does not play a role in tumor cell transformation, but rather allows rapid growth once an initial, 
angiogenesis-dependant tumor has formed. In RL-1 mice, the initial formation of angiogenesis-
dependent hyperplastic islets seems to be delayed as compared to Rip1Tag2 mice, which can also 
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be estimated from the reduced tumor incidence, with only 3 macroscopic tumors in RL-1 mice to 
more than 5 tumors in Rip1Tag2 mice at a much earlier age. 
 
Figure 29. Sex and tumor modifier genes but not genetic background influence survival and tumor size. (A) Survival 
curve of male vs. female RL-1 mice, indicating a significantly reduced survival of female vs. male RL-1 mice (median 
survival 19.4 vs. 22 weeks, respectively; left panel). In contrast, single transgenic RL-1 mice from different backcross 
generations from C57BL/6 into FVB/N did not show significantly different survival (right panel). (B) Survival of RL-1; 
RipIGF1R and RL-1;RipVEGF-A composite mice is dramatically reduced as compared to RL-1 single transgenic mice. 
Neither VEGF-C, VEGF-D over-expression in β-cells nor NCAM heterozygosity impacts survival. See Table 2 for median 
survival of composite mice. (C) RL-1 males and females have similar tumor sizes before week 20, but after week 20 only 
male mice can support larger tumors whereas female tumor size drops, indicating that those were escapers (left panel). 
All mice were therefore analyzed prior to their median survival (as determined for both sexes) indicated in Table 3. RL1; 
RipIGF1R mice had more and bigger tumors than RL-1 mice, whereas RL-1; RipVEGF-C/ RipVEGF-D/ NCAM+/- 
composite mice did not exhibit differential tumor sizes or incidence. RL1; RipVEGF-A mice had smaller tumors than RL-1 
mice prior to median survival. Shown are individual values with means +/- SEM.  
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Genotype N 
Analysis 
window/ age 
in weeks 
Mean tumor 
volume/ mm3 +/- 
SEM 
Mean tumor 
incidence +/- 
SEM 
Mann-Whitney 
test: tumor 
volume vs. 
RL-1 
students t-
test: 
incidence vs. 
RL-1 
RL-1 54 18-20 82 +/- 16 2.93 +/-  0.21     
RL-1; 
RipIGF1R 16 9-11 130 +/- 52 5.82 +/- 0.78 P=0.32 P<0.0001*** 
RL-1; 
NCAM+/- 9 18-20 115 +/- 61 2.00 +/- 0.47 P=0.99 P=0.09 
RL-1; 
RipVEGF-A 17 11-13 23 +/- 8 2.29 +/- 0.58 P=0.003** P=0.20 
RL-1; 
RipVEGF-C 6 18-20 50 +/- 18 2.29 +/- 0.75 P=0.81 P=0.31 
RL-1; 
RipVEGF-D 12 18-20 53 +/- 20 2.41 +/- 0.47 P=0.25 P=0.31 
Table 3. Tumor volume and incidence of RL-1 and RL-1 composite mice as shown in Figure 29C. N: number of mice 
analyzed. 
 
Luciferase bioluminescence quantification of tumor growth in vivo 
 As has been observed for tumor lysates, the luciferase activity in tumors has a relatively 
large spread. Bearing this in mind, we analyzed mice over time up to 4 weeks and analyzed in vivo 
bioluminescence once or twice weekly to estimate relative growth. We found that signal intensity 
was maximal about 10 minutes after D-luciferin injection and stayed at plateau levels for 20 - 30 
minutes (data not shown). As tumors can be located very diversely, especially they can be buried 
deeper in the mouse and the light path might be longer, it is not possible to compare tumor sizes 
between mice. However, for individual mice, an increase in luciferase activity can be nicely 
monitored over time (Figure 30). The fact that RL-1 mice have in average only 3 macroscopic 
tumors facilitates discrimination of tumor nodules at image analysis. When we analyzed a large 
cohort of mice, we could nicely detect a threefold increase in average signal intensity over four 
weeks (Figure 30B), but fluctuations for single mice could be quite high, as can be estimated from 
the individual curves shown in the right panel. 
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Figure 30. In vivo bioluminescence can be used to monitor tumor growth in RL-1 mice. (A) Longitudinal analysis of 
luciferase bioluminescence in a RL-1 mouse over 4 weeks shows increasing light emission over time. The same scale 
was used for all 4 images causing signal intensities out of scale at age 17 and 18.7 weeks (white central area inside false 
colored area). Right panel: photon flow quantification of the (false) colored area from left panel. (B) Tumor growth in a 
cohort of 12 mice (average age at first monitoring: 15 weeks) was followed over 25 days by in vivo bioluminescence. The 
signal intensities were normalized for each mouse individually, with 100% representing the geometrical mean of all 
values obtained per mouse during the 25 days observation period. Shown are means of the 12 mice +/- SEM. Right 
panel: individual mice normalized luminescence signals used to generate curve in left panel indicate relatively high 
variability for individual mice. a.u.: arbitrary units. 
 
Insulinomas are hemorrhagic, poorly vascularized and downregulate insulin and E-
Cadherin 
 Hyperplastic and angiogenic islets were detected in RL-1 mice at 7 weeks of age, as 
detected by BrdU incorporation in islets and hemorrhage, but only after 10 weeks of age 
macroscopic tumors could be detected. The low abundance of macroscopic tumors in RL-1 mice 
was also qualitatively confirmed in histology, where only few small to intermediate size lesions 
apart from the macroscopic tumors were found. We subdivided the identified endocrine tumors into 
3 classes: normal/ hyperplastic islets, type 1 and type 2 tumors, with representative pictures shown 
in Figure 31A. Type 1 tumors show an increased nucleus/ cytoplasm ratio as compared to normal 
appearing hyperplastic islets and they were further subdivided into either hemorrhagic or 
microinvasive type, the latter showing at least one locally invasive area. Type 2 tumors, usually 
bigger than 1mm, have dense and irregular nuclei with little cytoplasm, are intercalated with the 
exocrine pancreas, show acute hemorrhage accompanied by distorted vessel morphology and 
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immune cells infiltration is evident. In type 2 tumors, detached tumor cell clusters within the tumor 
were often detected (Figure 31B), and we also detected tumor cell clusters in blood vessels 
located in the exocrine pancreas, indicative of tumor cell disaggregation (Figure 31C). Per 
pancreatic tissue section from mice analyzed at age 18 – 20 weeks, we found in average 5.5 +/- 
1.8 normal/ hyperplasic islets, 5.5 +/- 1.6 type 1 lesions and 1.6 +/- 0.3 type 2 lesions (mean per 
mouse +/- SEM, 6 mice, 76 counted lesions). BrdU injection 2h before sacrifice and staining for 
incorporated BrdU revealed a proliferation rate of 10.1 +/- 0.7% of all tumor-constituting cells 
(mean of microscopic fields +/- SEM; 3 mice, 12 tumors, 27 microscopic fields). TUNEL stain, 
indicative for apoptosis, revealed 1.05 +/- 0.08% apoptotic cells within tumors (mean of 
microscopic fields +/- SEM; 4 mice, 9 tumors, 25 microscopic fields). 
Figure 31.  Representative Hematoxilin and 
Eosin stainings of RL-1 insulinomas found in 
pancreas. (A) Three types of endocrine 
lesions in RL-1 mice are found. Normal 
appearing hyperplasic islets (top left) with a 
maximal diameter of 200µm and have similar 
nucleus to cytoplasm ratio like normal islets. 
Type 1 lesions are markedly bigger and 
additionally show either hemorrhage (top 
right) and/ or microinvasion (bottom left, 
microinvasion indicated by arrowhead) into 
exocrine pancreas. Type 2 tumors have high 
nucleus density, prominent hemorrhage, 
intercalate with the exocrine pancreas and 
might show marked immune cell infiltration. 
(B) Type 2 tumors display internal loose tumor 
cell clusters in hemorrhagic areas. (C) Tumor 
cell clusters can be found in blood vessels 
within the exocrine pancreas as identified by 
the presence of erythrocytes and a clearly 
defined vascular lining. T: tumor, E: exocrine 
pancreas, scale bars: 50µm 
  
By staining with the endothelial cell marker CD31, we found that larger tumors were poorly 
vascularized towards the tumor centre, whereas an outer rim was highly vascularized (Figure 32A).  
NG2, a marker for pericytes, was strictly colocalized to blood vessels in the tumor periphery 
(Figure 32A). In contrast, central tumor regions have few immuno-reactive CD31 positive vessels 
and the proteoglycan NG2 seems to stay behind as remnants of ancient intact vasculature. 
 E-Cadherin, an epithelial marker robustly expressed in β-cells of Langerhans islets, but 
eventually down-regulated in Rip1Tag2 tumors (Perl et al., 1998), was found to be retained in 
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hyperplastic and type 1 lesions (not shown), but was occasionally lost in type 2 lesions, with E-
Cadherin positive and negative regions within the same tumor (Figure 32B). 
 Similar observations were made for insulin, one of the most characteristic β-cell markers. 
Lesions up to type 1 retained insulin expression (data not shown), albeit at reduced levels 
compared to islets, but type 2 tumors eventually down-regulated insulin expression in certain 
areas, as illustrated in Figure 32C. In order to determine major transcriptional changes that could 
be involved in the differential regulation of tumor onset and progression between RL-1 and 
Rip1Tag2 mice, we analyzed gene expression of total tumors by quantitiative PCR. A group of 
genes was analyzed that was shown to be important either for angiogenesis, namely VEGF-A, as 
well as a group of major transcriptional repressors of E-Cadherin expression, including SNAIL, 
SLUG, E47 and SIP1 (Figure 32D). However, none of these factors was differentially expressed. 
 It has previously been shown, that insulin like growth factor II (IGF-II) is an important 
mitogenic and anti-apoptotic factor for the growth of Rip1Tag2 insulinomas, as its expression 
correlates with hyperproliferation (Christofori et al., 1994) and growth of Rip1Tag2 tumors is 
severly impaired in IGF-II knockout mice (Christofori et al., 1995a). mRNA expression analysis 
revealed that RL-1 tumors dramatically up-regulate expression of IGF-II by more than 100-fold as 
compared to islets of Langerhans. In contrast, Insulin receptor (InsR) and IGF-1 receptor, known 
receptors for IGF-II, have unchanged expression levels between islets, Rip1Tag2 and RL-1 tumors 
(Figure 32E). 
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Figure 32. RL-1 tumors are poorly vascularized towards the centre and show heterogenous E-Cadherin and insulin 
expression. (A) Immunofluorescent staining of type 2 RL-1 tumor for endothelial marker CD31 and pericyte marker NG2 
shows thorough coverage of blood vessels by pericytes in the tumor rim whereas central regions are almost devoid of 
CD31 reactive vessels but still are immunoreactive for the proteoglycan NG2 which might be leftovers from previous 
blood vessels. Background in red channel is from hemorrhage. (B) Whereas type 1 tumors keep E-Cadherin expression 
throughout the tumors, type 2 tumors might down-regulate E-Cadherin in some tumor areas. (C) Insulin stain illustrates 
partial down-regulation of insulin expression in regions of type 2 tumors. (D) & (E) Quantitative real-time PCR from 
macroscopic tumors of Rip1TAg2 and RL-1 mice. (D) No significantly different mRNA levels of the angiogenic factor 
VEGF-A or the E-Cadherin transcriptional repressors E47, SNAIL, SLUG or SIP1 were detected (N = 8 individual tumors 
from each genotype for VEGF-A and E47 and N = 3 individual tumors for SNAIL, SLUG and SIP1). (E): Insulinomas 
upregulate IGF-II compared to islets but the receptor levels are unchanged (two individual islet isolations, N = 8 individual 
tumors for Rip1TAg2, N = 4 for RL-1). Shown are means +/- SEM. Scale bars: 50µm. 
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Reduced infiltration by myeloid-derived suppressor cells (MDSC) 
 In addition to tumor cell intrinsic factors, it has been demonstrated in a number of 
experimental systems, that myeloid cells can be critical components in promotion of tumor 
angiogenesis and metastasis as well as in protection from anti-tumoral adaptive immune 
responses (reviewed in (Zumsteg and Christofori, 2009)). In particular, MDSC have been 
demonstrated to suppress activation of dendritic and cytotoxic T cells, and their abundance 
increases in peripheral blood and spleen with increasing tumor size. MDSC are characterized by a 
concomitant expression of CD11b, a myeloid marker, and Gr1, a granulocyte marker. By flow 
cytometry, we detected an increase of CD11b+/ Gr1+ MDSC in peripheral blood and spleen of 
insulinoma bearing mice as compared to their non-tumor bearing inbred strain. FVB/N mice have 
significantly less MDSC in peripheral blood and spleen as compared to C57BL/6 mice. We found a 
significantly reduced infiltration of MDSC into tumors of RL-1 mice as compared to tumors from 
Rip1Tag2 mice (Figure 33, left panel), a difference that was also detected in spleen and peripheral 
blood (Figure 33, middle and right panel). 
 
 
Figure 33. Reduced immune cell infiltration. RL-1 mice have significantly less CD11b+/ Gr1+ myeloid-derived suppressor 
cells in spleen, peripheral blood and tumors than Rip1Tag2 mice. This is also seen in the respective non tumor-bearing 
FVB/N vs. C57BL/6 strains. P values from unpaired two-tailed Studentʼs t-test. Shown are means +/- SEM. 
 
RL-1 mice develop lymph node and liver but rarely lung metastases  
 When we analyzed pancreatic lymph nodes for the presence of metastasis, we found 3 
lymph node metastases in 3 out of 13 mice with totally 23 lymph nodes analyzed (Figure 34). 
 As normal mammalian cells do not express luciferase, the luciferase system offers a highly 
sensitive method to detect luciferase labeled cells in a luciferase negative environment, for 
example liver and lung in RL-1 mice (Figure 28). Insulinomas have been shown to metastasize to 
these organs in either man (Weber et al., 1995) or mice (Kopfstein et al., 2007). Out of 66 analyzed 
RL-1 single transgenic mice analyzed between 18 and 20 weeks of age, we detected luciferase 
activity at least threefold above background in liver from 19 mice (29%). When we correlated 
primary tumor size with normalized luciferase activity from the liver, a highly significant correlation 
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of tumor size and extent of hepatic metastasis was found (Figure 34B), with mice carrying primary 
tumors above 150 mm3 having a 67% likelihood for liver metastases (Table 4). We confirmed the 
occurrence of metastases in liver by histology, and found structures strongly resembling pancreatic 
islets of Langerhans from cell shape and heamatoxylin/ eosin stain (Figure 34D, left panel). The β-
cell origin of those cells was confirmed by immunohistochemical detection of insulin (Figure 34D, 
right panel), an antibody not labeling any particular structure in livers of wild-type mice. These 
metastases never reached macroscopic size and insulin+ structures up to 150 µm diameter were 
identified. Using insulin staining, we identified in one particular mouse up to 20 insulin positive 
structures in one section, most often in the rim region and only rarely in central regions. When we 
divided insulin+ area by the total section area, a ratio of 1/ 5800 was obtained. The normalized liver 
RLU (RLU/ µg lysate) in this mouse was 64, which is more than 30 fold above the detection level, 
suggesting that a 1/ 100ʼ000 to 1/ 150ʼ000 area fraction, corresponding to mass fraction could be 
detected by assessing ex vivo luciferase activity. 
 From the ratio of liver metastasis we obtained in single transgenic RL-1 mice, it seems 
obvious that a large cohort of mice carrying small to large lesions must be analyzed in order to 
faithfully determine the effect of modifier genes on metastasis probability. Nevertheless, liver 
metastasis were detected using ex vivo luciferase assays in RL-1;RipIGF1R, RL-1;NCAM+/- and 
RL-1;RipVEGF-C composite mice, as indicated in Figure 34C and Table 4, and also confirmed by 
insulin stain of liver sections (not shown). RL-1;RipIGF1R mice develop metastasis to a higher 
extent than single transgenic mice, but the number of mice is too small to yield statistically 
significant differences using Fisherʼs Exact test. 
 Detailed analysis of hepatic metastatic clusters revealed that most of them were partially or 
completely surrounded by CD31 and LYVE-1 positive vessels (Figure 34E). In contrast to many 
other organs, in which LYVE-1 is a marker for lymphatic vessels (Jackson et al., 2001) or a certain 
subset of macrophages (Schledzewski et al., 2006), hepatic sinusoidal endothelial cells express 
LYVE-1 (Mouta Carreira et al., 2001). The blood endothelial character of the vessels surrounding 
the metastatic nodules is highlighted by the erythrocytes present in the vessels (H & E stain, Figure 
34D). Most metastatic nodules we detected were negative for the epithelial marker E-Cadherin, 
which is occasionally lost in type 2 primary tumors (Figure 32B). This indicates that these 
metastatic clusters had undergone an epithelial to mesenchymal transition. Surprisingly, within 
larger metastatic clusters, we found small patches of cells expressing E-Cadherin (Figure 34E). 
The proliferative nature of the metastatic nodules was confirmed by staining for Phospho-Histone-
H3, a marker for mitosis (Figure 34E).  
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Figure 34. RL-1 tumors metastasize to the lymph node and liver. (A) RL-1 mice show lymph node metastasis in 3/13 
mice (23%), as indicated by H & E and insulin staining of pancreatic lymph node showing metastasis. (B) Livers from 18 
– 20 week old RL-1 mice were homogenized and assayed for in vitro/ ex vivo luciferase activity. Normalized luciferase 
activity in liver significantly correlates with primary tumor volume and is indicative of liver metastasis. Dashed line 
indicates the threshold defined as luciferase value 3 fold above background level (obtained with young RL-1 mice livers 
without primary tumors). (C) Composite mice also develop liver metastasis. No increase can be seen in lymphangiogenic 
tumor carrying RL1;RipVEGF-C or RL1;RipVEGF-D mice. Rather, as only a small number of composite mice had been 
analyzed, the lack of mice carrying large tumors makes it impossible to accurately compare the genotypes. 
RL1;RipIGF1R mice develop liver metastasis at a higher frequency but when categorized into different primary tumor 
size groups, fail to give significance (Fisherʼs exact test). (D) H & E stain (left panel) of liver histology shows insulin 
positive (right panel) metastasis (serial section), arrowhead in H & E indicates erythrocyte filled blood vessel (inset). (E): 
Metastatic nodules in the liver are surrounded by sinusoidal endothelial venules as indicated by LYVE-1 and CD31 stain 
(left panel); most metastatic cells lose E-Cadherin expression but some re-express this epithelial marker (arrowhead, 
right panel, inset). P-Histone-H3 staining shows proliferation of metastasis. Scale bars: (A): 200µm, (D) & (E): 50µm. 
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    Primary tumor size/ mm
3   
Genotype N  < 50 > 50    < 150 > 150 
RL-1 66 4/30 (16.7%) 5/21 (23.8%) 10/15 (66.7%) 
RL-1;RipIGF1R 12 1/4 (25%) 3/6 (50%) 2/2 (100%) 
RL-1;RipVEGF-A 14 0/11 (0%) 0/3 (0%) none 
RL-1;RipVEGF-C 6 1/4 (25%) 0/2 (0%) none 
RL-1;RipVEGF-D 13 0/10 (0%) 0/1 (0%) 0/2 (0%) 
RL-1;NCAM+/- 9 0/4 (0%) 2/4 (50%) 1/1 (100%) 
 
Table 4. Metastasis frequency in liver. Mice are categorized according to primary tumor size and genotype. Numbers 
represent mice of category positive for liver metastasis (either by histology and/ or in vitro luciferase) per total mice 
analyzed in the respective category. N is total number of mice analyzed. 
 
 
  Using the same approach as for livers, we analyzed organ lysates from lungs and 
brains for ex vivo luciferase activity. In lung, we detected positive luciferase signals in RL-1 mice in 
3/ 45, in RL-1;RipVEGF-D in 1/ 14 and in RL-1;RipIGF1R in 2/ 4 lungs analyzed, whereas in RL-
1;RipVEGF-C, RL-1;RipVEGF-A and RL-1;NCAM+/- mice we did not detect positive signals. In 
contrast to liver, we were not able to detect metastases by histology in the controlateral lobe to the 
one that was used for the organ lysate. In brain, we detected luciferase values above background 
levels in a series of mice. Histological analysis of whole brains has never indicated any brain 
metastasis. We conclude that the insulin promoter can be activated in the brain (as previously 
shown in rats (Devaskar et al., 1993)) and as suggest the luciferase leakiness in brain lysates of 
young RL-1 mice) by yet unknown stimulus. 
 
4.4.4. Discussion 
 In an attempt to modify the much-appreciated Rip1Tag2 tumor model, we successfully 
implemented luciferase in vivo imaging technology into a transgenic insulinoma model, driven by 
rat insulin promoter mediated expression of SV40 large T antigen. SV40 large T antigen is known 
to bind and inactivate the tumor suppressors p53 and pRB and is therefore a very potent 
oncoprotein often used to generate murine models of carcinogenesis (Ahuja et al., 2005). The 
Rip1Tag2 tumor model has proven to be extremely instructive in identifying molecules and cell 
types participating in the so-called angiogenic switch, i.e. the capacity of a tumor to ensure its own 
oxygen and nutrient supply by acquiring an extended blood vascular network. Yet, due to the 
location of insulinoma within the pancreas, it was not possible to use the Rip1Tag2 tumor model to 
monitor tumor growth over time. Highly specific expression in β-cells of Langerhans islets of a 
bicistronic mRNA coding for large T antigen and firefly luciferase enabled us to generate a 
transgenic mouse, that offers the possibility to observe tumor growth by bioluminescence over time 
and detect organ metastases with very high sensitivity by in vitro/ ex vivo analysis of organ lysates. 
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The low background of luminescence from normal tissue, the rapid turnover of luciferase enzyme, 
and the nonimmunogenic characteristics of luciferin make this method ideally suited for temporal in 
vivo imaging of gene expression.  As primary tumors cause fatal hypoglycemica before metastases 
reach a macroscopic size, it was not possible to identify metastases by in vivo bioluminescence.  
 
 The rat insulin promoter 1 (from the rat insulin II gene) has been used in numerous 
transgenic mouse models to specifically target trangene expression to β-cells of Langerhans islets. 
In several reports, a small number of founder mice was sufficient to drive specific expression of 
transgenic gene products to the insulin secreting β-cells, indicating a high flexibility of this promoter 
concerning the genomic integration site. Indeed, all three founder mice we obtained expressed the 
transgene in the pancreas and developed insulinoma over time. However, aberrant expression in 
other tissues might be a problem, so using luciferase technology we were able to easily select the 
founder with the lowest levels of aberrant expression in other organs apart from the pancreas, a 
stringency level hard and cumbersome to reach using quantitiative PCR or antibody based protein 
detection methods. The genomic integration site in the H4 region of murine chomosome 3 is 100kb 
away from the next protein coding gene, neuronal growth regulator (Negr1), a gene mainly involved 
in the neural system. This integration site might confer the expression detected in brain lysates of 
RL-1 mice. When we crossed the RL-1 transgene into homozygosity, we did not encounter any 
abnormalities, yet as we did not find obvious differences in tumor development due to possible 
gene dosage effects between homozygous RL-1/RL-1 vs. RL-1/wt heterozygous mice, we 
analyzed mainly heterozygous mice. 
 Another important issue is the onset of transgene expression, which can vary widely 
between different founder lines, ranging from embryonic expression to onset after puberty. As we 
found T antigen mRNA and luciferase protein in total pancreas of newborn RL-1 mice, we assume 
that transgene expression begins before birth. The occurrence of hyperplastic islets at 7 weeks of 
age also suggests early β-cell transformation. However, the first macroscopic tumors are detected 
only after 10 weeks of age, indicating a slow progression from hyperplastic islets to macroscopic 
tumors. Alternatively, hyperplastic islets could be recognized by the murine immune system as 
foreign and lost by auto-immune responses. When we analyzed the proportion of cells that was 
labeled after a 5 day pulse of 5-bromodeoxyuridine, labeling cells during S-phase of the cell cycle, 
we indeed found only about 20% of BrdU+ cells within RL-1 tumors (at 14 weeks) compared to a 
50% labeling efficiency in Rip1Tag2 mice at 8 weeks of age (data not shown). This indicates that 
tumors from RL-1 mice have a slower proliferative rate than Rip1Tag2 mice but hyperplasia occurs 
already at early age. The massive upregulation of IGF-II in macroscopic tumors as compared to 
normal islets and the concomitant unchanged levels of the IGF-II receptors IGF-1R and Insulin 
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receptor strongly suggest an important role of IGF-II in tumorigenesis in RL-1 mice, as described 
for Rip1Tag2 mice. 
 Several lines of evidence point towards an impaired angiogenesis onset of RL-1 mice 
versus Rip1Tag2 mice. First, already small RL-1 tumors of type 1 can show substantial amount of 
hemorrhage, not observed like this in Rip1Tag2 tumors, suggesting growth of very delicate and 
torturous vessels. Even though total mRNA levels of VEGF-A do not differ between RL-1 and 
Rip1Tag2 mice, there might be differences in the bio-availability of angiogenic factors. VEGF-A, in 
particular the splice variant VEGF-A165 can be sequestered to heparan sulfate proteoglycans, in 
this form incapable of signaling to VEGF receptors (Gengrinovitch et al., 1999). Activity of matrix 
metalloproteinases or heparinases have been implicated in the control of VEGF-A release, and in a 
series of tumor models, it has been shown that MMP9 activity is crucial for tumor angiogenesis in 
different murine tumor models (Bergers et al., 2000; Coussens et al., 2000; Giraudo et al., 2004). 
Usually, different sources of MMP-9 exist in a tumor environment: the tumor cells, stromal 
fibroblast or inflammatory cells can be prominent sources of MMP-9. Particularly, myeloid derived-
suppressor cells (MDSC) and tumor-associated macrophage have been shown to contribute 
substantially to support the angiogenic switch (reviewed (Zumsteg and Christofori, 2009)). We 
found that RL-1 tumor mice (in FVB/N background) have significantly less Gr1+/CD11b+ MDSC in 
blood, spleen and tumors as compared to Rip1Tag2 mice (in C57BL/6 background). It is tempting 
to speculate that differential infiltration of myeloid cells is crucial for the difference in tumor onset. 
Double transgenic RL-1;RipVEGF-A mice die at a much younger age than their single transgenic 
RL-1 counterparts, indicating that VEGF-A availability indeed limits tumor growth drastically. The 
smaller tumor volumes in RL-1;RipVEGF-A mice (as compared to RL-1 mice) detected prior to 
median survival age might be due to decreased body weight (just by the younger age) and the 
better vascularization, facilitating the release of insulin into the circulation. Both factors would 
increase the relative insulin burden and promote the finally fatal hypoglycemic state of the mice. 
However, as RL-1;RipIGF1R mice die at even younger age but have many more and bigger tumors 
than RL-1;RipVEGF-A mice, it is unlikely that body weight is a critical factor to explain the earlier 
decease of VEGF-A over-expressing mice. 
 Principally, all composite mice analyzed showed phenotypes similar to the ones already 
described. RL-1;RipVEGF-C and RL-1;RipVEGF-D showed peritumoral lymphangiogenesis, rarely 
detected in RL-1 single transgenic mice (data not shown). However, in contrast to Rip1Tag2 mice, 
we found lymph node metastases in single transgenic RL-1 mice. An exception to the described 
phenotypes is the occurrence of lung metastases that was found in 80% of Rip1Tag2;RipVEGF-D 
mice (Kopfstein et al., 2007). By analyzing lung lysates for luciferase activity, we only detected one 
potential metastasis carrier out of 14 RL-1;RipVEGF-D mice, which we could not confirm by 
histology. In contrast to the Rip1Tag2 insulinoma model, in RL-1 mice the transgenic expression of 
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VEGF-D does not trigger massive lymphocyte infiltration, an inflammatory stimulus that could 
potentially support metastatic events. RL-1;RipIGF1R mice showed massively accelerated tumor 
progression as can be seen by the survival time and the larger tumor burden. We conclude that 
IGF1R signaling co-operates with SV40 large T antigen for efficient oncogenic transformation. 
 Using luciferase in vivo imaging technology, growth of insulinomas could be observed and 
quantified over time, a technique already employed for transgenic mice developing pituitary or 
prostate tumors (Liao et al., 2007; Vooijs et al., 2002). We propose this mouse tumor model to test 
the efficacy of anti-tumor regimens in pre-clinical experiments. Some limitations of RL-1 mice 
include the thickness of subcutaneous fat layer that might increase especially when mice get older 
and gain weight and the inherent fluctuation of luciferase expression levels due to reduced insulin 
promoter activity in bigger tumors. However, by analyzing a large cohort of mice, we could observe 
3 fold increase in average photon flow over a 25 day period, stressing the possibility to utilize this 
tumor model in quantitative manner. 
 Like insulinomas in humans, RL-1 mice develop liver metastasis (Hirshberg et al., 2005), 
and total metastasis burden correlates with primary tumor size. The partial surrounding of 
metastatic nodules by LYVE-1+ sinusoidal endothelial vessels but the absence of intra-metastatic 
blood vessels, as judged by the lack of internal LYVE-1+ or CD31+ structures, indicates that the 
metastases do not yet execute an angiogenic program of their own, at least not sufficiently potent 
to induce intra-metastatic vasculature. That the LYVE-1+ sinusoids do not completely surround the 
metastatic nodules suggests that the detected structures are not just stuck in blood vessels but 
rather start to establish their niche in the target organ. We find about 5% of cells positive for the 
mitosis marker Phospho-Histone H3, indicating the proliferating nature of the metastatic nodules. 
The almost complete loss of E-Cadherin in most metastatic nodules indicates that metastatic cell 
must have undergone at least a partial epithelial to mysenchymal transistion (EMT), a 
phenomenon often observed in tumors of epithelial tissues (carcinomas) (Hugo et al., 2007). 
However, if the occurrence of E-Cadherin positive cell patches means re-expression of E-Cadherin 
or if some metastatic cells have never shut down E-Cadherin expression, cannot be decided at this 
point. 
 The route of metastasis to the liver seems be rather haemogenic (primary intravasation into 
blood vessels) than lymphogenic (through lymphatics) by the following observation: 
lymphangiogenic RL-1;RipVEGF-C and RL-1;RipVEGF-D mice show tumor cell clusters within 
LYVE-1 positive lymphatic vessels (not shown), not observed in RL-1 mice, but do not have a 
higher liver metastasis rate or develop liver metastasis at smaller primary tumor sizes as compared 
to RL-1 mice.  
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 In conclusion, we generated a transgenic mouse which holds promise to become a valuable 
tool to study the efficacy of pre-clinical therapeutic approaches in longitudinal analyses. The highly 
specific luciferase expression will be very valuable to utilize this mouse in studies aiming at 
detecting metastases promoting events. Finally, liver metastasis, the most common metastatic 
event in neuroendocrine tumors, can be studied at an early stage. 
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4.4.5. Materials and Methods 
 
Generation of RipTag-IRES-Luciferase construct 
 The total cassette containing rat insulin promoter 1 regulatory region, SV40 early region and 
polyA signal was excised from pRIP1-Tag vector (Hanahan, 1985) using BamHI and cloned into 
BamHI of pBluescript II KS (Promega) vector in forward orientation, yielding pBS-RipTag-pA. 
 The SV40 polyA signal as well as 90bp of SV40-TAG cDNA was removed from this vector 
using BclI, cutting 90bp upstream of the SV40-TAG stop codon, and SalI, cutting in the pBS II 
multiple cloning site downstream of the insertion site. The removed SV40-TAG cDNA was restored 
by insertion of a BclI/ SalI digested PCR product (primers: “TAg Bcl fw” and “TAg 3ʼ end SalI rv”) 
into the BclI/ SalI opened pBS-RipTag-pA, the PCR fragment starting at the BclI site within the 
SV40-TAG cDNA and ending with the SV40-TAG stop codon with an additional SalI site for 
cloning, yielding pBS-RipTag-MCS. The PCR was performed on the original pRIP1-Tag. 
 A 163bp SV40 poly-adenylation signal was then reintroduced into pBS-RipTag-MCS, by 
ligating a XhoI/ KpnI digested PCR product (primers: “XhoI_TAg_pAsig_fwd” and 
“KpnI_TAg_pAsig_rv”) covering the poly-adenylation site of the SV40-Tag of pRIP1-Tag into the 
XhoI/ KpnI opened pBS-RipTag-MCS, yielding pBS-RipTag-MCS-pA. 
 IRES-Luciferase cassette was constructed by amplifying Luciferase out of pUHC13.3 
(Gossen and Bujard, 1992) using “BamHI_Luc_fw“ and „ XhoI_Luc_rv“ into pcDNA3.1 (Invitrogen) 
using BamHI and XhoI, yielding pcDNA3.1-Luc. IRES was amplified out of pCCALL2-IRES-EGFP 
(kindly provided by Jody Haigh, Toronto, Canada) using “BamHI-XhoI-IRES_fw” and “BamHI-
IRES-rv“ and cloned in forward orientation in pcDNA3.1-Luc using BamHI, yielding pcDNA3.1-
IRES-Luc. IRES-Luc was cloned into pBS-RipTag-MCS-pA in forward orientation using XhoI, 
yielding pRTIL. pRTIL was sequenced and the predicted sequence confirmed. 
 
Generation of transgenic mice 
 pRTIL was cut using NotI and linearized plasmid was purified over ultra-pure agarose gel 
elecrophoresis and extracted using GeneClean (Q-Bio gene). The linearized construct was micro-
injected into pronuclei of fertilized FVB/N eggs according to standard techniques (Taketo et al., 
1991). Embryos that survived microinjection were reimplanted the same day into pseudopregnant 
NMRI females that had been random-mated to vasectomized B6D2F1 males. Genomic PCR 
identified 3 founder lines designated RL-1, RL-2 and RL-3. All animal experiments were approved 
by the “Basler Tierschutzkommission” and are covered by the licenses 1878, 1907 and 1908. 
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Determination of transgene integration site in RL-1 line by linker mediated PCR 
 The transgene integration site was principally determined by a method described for 
detecting transposon integration sites (Dupuy et al., 2005). 5 µg of genomic DNA from RL-1 mice 
isolated from liver was digested using 15U NlaIII and fragments subsequently isolated using 
QIAEX II gel extraction kit (Qiagen). To avoid amplification of concatamers of the trangene, the 
extracted DNA was then digested using SacII, eliminating amplification of transgene junctions and 
then again purified using QIAEX II. NlaIII linker was generated by annealing equimolar amount of 
“NlaIII linker+” and “NlaIII linker-“ in NEB buffer 3 (New England Biolabs) at a concentration of 
5mM. “NlaIII linker-“ was 5ʼ phosphate modified to aid linker ligation and 3ʼ C3 spacer modified to 
avoid priming of Taq polymerase. Annealed NlaIII linker at a final concentration of 0.2mM was then 
ligated to 1/40 of the genomic NlaIII/ SacII double digested DNA using T4 DNA ligase. 1/20 of the 
ligation reaction was then used as template for the 1st PCR, using Taq polymerase and “NlaIII Lnkr 
pri” and RipRv2 primers. RipRv2 primer binds in the transgene and will lead to the preferential 
amplification of fragments containing transgenic DNA. No specific DNA fragments were detected 
after this PCR. Then 1/20 of the PCR product was used as template for a nested PCR using “NlaIII 
Nest lnkr pri” and RipRv3 primers. A specific band was detected and cloned into pGEM-T easy 
(Promega) vector. Sequencing of the construct confirmed integration of the transgene with a 
junction between host DNA and transgene consisting of a destroyed NotI site. Integration was in 
mouse Chromosome 3 as indicated in Figure 27. 
 
Genotyping of transgenic mice 
 With the knowledge of the transgene integration site, a multiplex PCR could be designed 
yielding a 281bp amplicon for a transgene allele and a 501bp fragment of a wild-type allele using 
the primers RipMsChr3, MsCh3_24971617fw and MsCh3_24972117rv. Primer RipMsChr3 is 
spanning the transgene integration site.  
 
Mice 
 All mice described carrying modifier genes have been characterized in the Rip1Tag2 tumor 
model previously  (Gannon et al., 2002; Kopfstein et al., 2007; Lopez and Hanahan, 2002; 
Mandriota et al., 2001; Perl et al., 1999) and were coming from a C57BL/6 background and then 
continuously bred into FVB/N background.  
 
In vivo luciferase bioluminescence 
 Prior to measurement, mice were shaved in the peritoneal region to maximize signal 
intensity from insulinomas. Mice were injected intraperitoneally with D-luciferin potassium salt 
(Gold BioTechnology, St. Louis, MO, U.S.A.) dissolved in sterile PBS at 15 mg/ml with a luciferin 
                                                                                                                                                     RIP-TAG-IRES-LUCIFERASE MOUSE 
 
95 
dose of 150mg/kg body weight. 5 minutes after luciferin injection, mice were anaesthetized by 
inhalation of 3% isoflurane (Provet AG, Lyssach, Switzerland) with medical grade oxygen as carrier 
gas and placed in the dark chamber of the “NightOWL II LB 983” imaging system (Berthold 
Technologies, Bad Wildbad, Germany). For quantification experiments with multiple rounds of 
monitoring, timing of injection, anesthesia, and camera setting were standardized and kept 
constant throughout the experiment. Typical acquisition times were between 1 and 5 minutes with 
maximal binning. For quantification of light intensities in time course experiments, a constant 
analysis gate was defined and individual tumor photon counts were determined by centering the 
gate on the highest signal intensity for each time point.  
 
FACS analysis of MDSC in peripheral blood, spleen and tumors 
 Peripheral blood was drawn directly by heart puncture of CO2 sacrificed mice and transferred 
to EDTA anti-coagulated collection tube (Sarstedt). Staining was done using anti-CD11b-PE (Clone 
M1/70) and anti-Gr1-APC (Clone RB6-8C5) (eBioscience) and erythrocytes lysed prior to analysis 
using BD FACS lysing solution (BD Biosciences). Spleens were minced to single cells in PBS/ 5% 
FCS using 100µm nylon mesh followed by filtration over 40µm nylon mesh. Single cell suspensions 
of tumors from 12-13 week old Rip1Tag2 or 16-19 week old RL-1 mice were obtained by digestion 
for 60 minutes at 37°C in Dulbeccoʼs Modified Eagleʼs Medium (DMEM) supplemented with 5% NU 
serum (Becton Dickinson), 0.2 mg/ml DNaseI, 1.2 U/ml Dispase II (Roche Applied Science).  
 
Quantitative real time RT–PCR  
 Total RNA from tumors or total pancreas was prepared by homogenizing tissue using TRI 
Reagent (SIGMA), and reverse transcribed with random hexamer primers using M-MLV reverse 
transcriptase (SIGMA). cDNA was quantified on a ABI Prism 7000 light cycler  (Applied 
Biosystems) using SYBR green PCR MasterMix (Fermentas) using the primers described in Table 
5. Ct values were normalized against ribosomal protein L19 (RPL19) and fold induction calculated 
as 2ΔΔct. 
 
Ex vivo quantification of organ lysate luciferase activity 
 Organs and tumors were homogenized into ice-cooled Reporter Lysis Buffer (Promega) 
using a Polytron PT1200 homogenizer (Kinematica AG, Switzerland). Samples were then 
centrifuged at 12ʼ000 rcf for 10 minutes and supernatants stored at -20° C until further analysis. 
For quantification, 10µl of lysate were mixed with 50µl of Luciferase Assay Reagent (Promega) 
(either manually or by the sample injector) in white 96 well plates (Berthold Technologies) and 
luminescence measured on a Centro LB 960 luminometer (Berthold Technologies). Liver and lung 
lysates were found to have a high quenching activity and were used in a 1:5 dilution.  
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Tissue processing/ histology/ antibodies 
 For organ biopsies, mice were euthanized by CO2 and organs quickly removed. Organs 
were either fixed at 4° C in 4% phosphate buffered paraformaldehyde (PFA) for 12 hours and then 
embedded in paraffin after ethanol/ xylene dehydration; alternatively organs were fixed at 4°C in 
4% PFA for 2h, and cryo-preserved for 10 hours in 20% sucrose in PBS prior to embedding in OCT 
freezing matrix. Paraffin slides were cut 5 µm thick and rehydrated according to standard protocols. 
For immunohistochemical (IHC) stainings of PFA fixed, paraffin embedded specimens, antigen 
epitopes were retrieved by boiling slides in 10mM Na-Citrate buffer (pH6.0) for 10ʼ in a microwave 
oven, endogenous peroxidase was quenched by treatment with 3% H2O2 for 10 minutes. 
Cryosections were cut 7 µm thick, postfixed for 5ʼ in either 4% PFA or 70% ethanol and dried for 
30ʼ prior to rehydration in PBS. Slides were blocked for 30ʼ in PBS/ 5% normal goat serum and 
then incubated with the primary antibody in blocking buffer at 4° C overnight. Antibodies used: rat 
a-CD31 1:50 (clone MEC13.3, B&D), guinea pig a-Insulin (DAKO) 1:100, rabbit anti-NG2 1:200 
(Transduction Lab), rabbit anti-Phospho-Histone H3 (Upstate Biotechnology) 1:500, rabbit anti-
mLYVE-1 (Reliatech) 1:100, rat anti-E-Cadherin (clone ECCD-2, Zymed) 1:100. IHC stainings were 
revealed by incubation with biotinylated secondary antibodies and ABC Elite detection kit using 
AEC substrate (all from Vector Laboratories) according to manufacturers instructions and 
counterstained using haematoxilin. Immunofluorescent stainings were revealed by incubation with 
Alexa488 or Alexa568 labeled secondary antibodies (Molecular Probes) and nuclei stained with DAPI 
(SIGMA). Western blot for large T antigen was done by lysing tumors in RIPA lysis buffer (25mM 
Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% Sodium deoxycholate, 0.1% SDS), resolving 50 µg 
of cleared lysate by 10% SDS-PAGE and revealed using mouse Anti-SV40 T Antigen (Clone Ab-1; 
Calbiochem). 
 
Statistical evaluations 
 All statistical tests were performed using GraphPad Prism 4.0c for Mac. Data was first 
tested for normality and when normality was fulfilled, unpaired, two-tailed studentʼs t-test was 
applied. For non-gaussian data, Mann-Whitney non-parametric U test was performed. Survival 
data was analyzed by log-rank test. P values below 0.05 were considered to be statistically 
significant. 
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Primer name Sequence 5ʼ -> 3ʼ Comments 
TAg Bcl fw CTGTTCATGATCATAATCAGCCA BclI site: bold 
TAg 3ʼ end SalI rv GAGAGTCGACTTATGTTTCAGGTTCAGGGG SalI site: bold, 
STOP codon: italic 
XhoI_TAg_pAsig_fwd CCTCGAGAATGAATGCAATTGTTGTTGTTAAC Xho site: bold 
KpnI_TAg_pAsig_rv GCGGTACCAGACATGATAAGATACATTGATG KpnI site: bold 
NlaIII linker+ GTAATACGACTCACTATAGGGCTCCGCTTAAGG 
GACCATG 
 
NlaIII linker- Phos-GTCCCTTAAGCGGAG-C3 spacer 5ʼ and 3ʼ modified 
NlaIII Lnkr pri GTAATACGACTCACTATAGGGC  
NlaIII Nest lnkr pri AGGGCTCCGCTTAAGGGAC  
RipRv2 GGTGTATTCTCCTGTAGTATCTTAGATTTGC optimized not to 
bind to murine 
insulin promoter 
RipRv3 GGTCAGCAACTCTCCATAAGAGGTG optimized not to 
bind to murine 
insulin promoter 
RipMsChr3 GTTCTAGAGCGGCCAAGTATT NotI site from 
linearized 
transgene: bold 
BamHI_Luc_fw GATCGGGATCCAATATGCAAGCTTGGCATTCCG BamHI site: bold 
XhoI_Luc_rv GATTAGCTCGAGATCGTTACAATTTGGACTTTCCG XhoI site: bold 
BamHI-XhoI-IRES_fw GAGTCGGATCCCTCGAGAGCGCTTCAGGCC 
CCTCTCCCTCCCCCCCC 
BamHI site: bold 
XhoI site: italic 
BamHI-IRES-rv ATCGACGGATCCTTATCATCGTGTTTTTCAAA BamHI site: bold 
MsCh3_24971617fw CATATGGCAGTGTAAACCAGT Genotyping 
MsCh3_24972117rv AGTTCCCAGCATTCTTCATG Genotyping 
mVEGFA_420fw ACTGGACCCTGGCTTTACTG qPCR mVEGF-A 
mVEGFA_497rv TCTGCTCTCCTTCTGTCGTG qPCR mVEGF-A 
mE47_1671fw GGACATTAACGAGGCCTTCCG qPCR mE47 
mE47_1822rv TGGGGTTCAGGTTGCGTTCT qPCR mE47 
mSNAIL_566fw CTCTGAAGATGCACATCCGAA qPCR mSNAIL 
mSNAIL_683rv GGCTTCTCACCAGTGTGGGT qPCR mSNAIL 
mSLUG_671fw TGTGTCTGCAAGATCTGTGGC qPCR mSLUG 
mSLUG_747rv TCCCCAGTGTGAGTTCTAATGTG qPCR mSLUG 
mSIP1_325fw GGAGGAAAAACGTGGTGAACTAT qPCR mSIP1 
mSIP1_403rv GCAATGTGAAGCTTGTCCTCTT qPCR mSIP1 
mRPL19_fw ATCCGCAAGCCTGTGACTGT qPCR mRPL19 
mRPL19_rv TCGGGCCAGGGTGTTTTT qPCR mRPL19 
mIGF2_1244fw CGCTTCAGTTTGTCTGTTCG qPCR mIGF-2 
mIGF2_1338rv GCAGCACTCTTCCACGATG qPCR mIGF-2 
mIR_2623fw TGCTCATGCCCTAAGACTGAC qPCR mInsR 
mIR_2747rv GATCTTCGCTTTCGGGATG qPCR mInsR 
 
Table 5. Primers used for cloning of pRTIL, integration site extraction using LM-PCR, multplex genotyping PCR and real-
time quantitative PCR (SYBR green). 
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